The Immune Response Corp. (IMNR) - 500 Beiträge pro Seite
eröffnet am 15.08.00 16:07:13 von
neuester Beitrag 10.05.01 12:50:16 von
neuester Beitrag 10.05.01 12:50:16 von
Beiträge: 121
ID: 214.455
ID: 214.455
Aufrufe heute: 0
Gesamt: 11.224
Gesamt: 11.224
Aktive User: 0
ISIN: US5770811025 · WKN: 851704
17,168
EUR
+0,04 %
+0,008 EUR
Letzter Kurs 12:55:45 Lang & Schwarz
Neuigkeiten
25.04.24 · Business Wire (engl.)  |
24.04.24 · dpa-AFX |
23.04.24 · Business Wire (engl.) |
22.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
Werte aus der Branche Konsum
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6100 | +37,85 | |
| 13,870 | +28,66 | |
| 0,7725 | +27,06 | |
| 0,6000 | +19,52 | |
| 1,3500 | +15,38 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6725 | -8,98 | |
| 11,570 | -9,18 | |
| 3,6100 | -9,30 | |
| 13,400 | -9,61 | |
| 11,570 | -25,50 |
Feedback
Immune Response ist ein Biotech-Unternehmen, das Immun-Therapien entwickelt, die spezielle T-Zellen induzieren, um bei Krankheiten wie HIV, Auto-Immunkrankheiten, Gentherapien und Krebs eine Gegenreaktion hervorzurufen.
Analysen:
http://www.juchu.de/biotech/archiv/inmr/imnr.html
http://www.diegaertner.de/Analysen/26-03-2000/IMNR.pdfAchtung! PDF Format
Internet
www.IMNR.com
News:
http://www.nasdaq.com/asp/quotes_news.asp?symbol=IMNR`&selec…
Market Cap:
Anzahl der Aktien = 27.368.000 * aktueller Kurs (7) = 191.576.000
KGV(E)
Wachstumsrate(e)
Aktuelle Quartalsgewinne/Verluste
Produktpipeline
Chart:
News auf Deutsch:
13.12.99
Immune erwirbt T-Zell Rezeptor Technik
Die Immune Response Corporation gab heute bekannt von der Connetics Corporation und XOMA LLC die Rechte am Wissen über T-Zell Rezeptoren (TCR) erworben zu haben.
Im Gegenzug erhalten die beiden Firmen Cash und Lizenzgebühren. Immune besitzt bereits weiteres TCR-bezogenes Know-How und plant mit Hilfe dieser Technologie die Forschung und Entwicklung von pharmazeutischen Produkten zur Behandlung von HIV und autoimmun Krankheiten zu verbessern.
18.01.00
Immune Response erhält Erfolgszahlung
Immune Response Corporation gab heute bekannt eine 5 Millionen Dollar Meilensteinzahlung von Agouron Pharmaceuticals, eine 100%ige Tochter von Warner-Lambert, erhalten zu haben.
Die Zahlung ist die letzte von 6 quartärlichen Zahlungen, die Immune Response für die Entwicklung und Kommerzialisierung von Remune(TM), einer immunbasierten Behandlung von HIV. Der Vertrag beinhaltet bis zu 30 Millionen Dollar an weiteren Meilensteinzahlung für Immune Response. Bei erfolgreicher Markteinführung werden die Gewinne 50/50 aufgeteilt.
11.02.00
Immune Response auf Halten herabgestuft
Analysten von Prudential haben heute Immune Respose von Strong Buy auf Halten herabgestuft.
22.02.00
Immune Response mit erfolgreicher Studie
Die Immune Response Corporation gab heute den erfolgreichen Abschluß einer Vorklinischen Studie mit einem Krebsschutzstoff bekannt.
Die patentierten Gentherapie verwendet genetisch veränderte Tumorzellen mit cytokine GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) auf der Zelloberfläche. In Tiermodellen wurde ein signifikanter Schutz gegen eine aggressive Form von Melanomen (Hautkrebs) festgestellt.
GM-CSF ist ein natürlich auftretendes Protein, das hilft eine Immunreaktion zu stimmulieren. In Vorklinischen und Klinischen Studien konnte bereits gezeigt werden, daß mit GM-CSF die Fähigkeit des Immunsystems zur Erkennung und Zerstörung von Tumorzellen verbessert werden kann.
23.02.00
Remune erhöht Anzahl von T-Zellen
Immune Response gab heute bekannt, das ein Phase II Test mit dem Immunsystem stärkenden Medikament Remune eine Vermehrung der T-Zellen bei HIV-Infizierten Personen gezeigt hat.
Das Primärziel der Studie war es die Anzahl von CD4 Hilfs-T-Zellen zu erhöhen. Diese Immunzellen werden durch HIV systematisch zerstört, eine Vermehrung der Anzahl dieser Zellen ist ein guter Indikator für den Zustand der Infektion. Die in Thailand durchgeführte Studie war ein doppelt blinder Placebo kontrolierter Test, mit Remune als einzigem Medikament, an 297 HIV-1 infizierten Personen.
23.03.00
REMUNE™ wirkt gegen AIDS
Das Medikament REMUNE™ von der Immune Response Corporation (Nasdaq: IMNR) scheint nach neuen klinischen Daten bei der AIDS Bekämpfung wirksam zu sein.
Die Daten lassen auf eine Unterstützung zur Wiederherstellung des Immunsystems schließen. Dieser Effekt tritt sowohl bei alleiniger Verabreichung von REMUNE, als auch in Kombination mit Antiviralmedikamenten ein. Die Daten stammen aus einer doppelt-blinden, Placebo kontrollierten Studie an 297 HIV-1 infizierten Patienten in Thailand.
13.04.00
Remune™ aktiviert T-Zellen gegen HIV
Die Immune Response Corporation (Nasdaq: IMNR) hat heute Daten vorgestellt, die zeigen das Remune™, eine potentielle Immun-basierte Therapie zur Behandlung von HIV-Infektionen, scheinbar CD4 Hilfs-T-Zellen aktiviert.
Die T-Zellen (bestimmte Zellen des Immunsystems) werden durch das Medikament zur Bekämpfung von HIV bei schon länger infizierten Patienten aktiviert. HIV-spezifische Immunantworten verschwinden typischerweise im Verlaufe der Erkrankung trotz Behandlung mit antiviralen Medikamenten. Eine Verlängerung der Immunreaktion gegen HIV bietet eine Behandlungsmethode zur Verzögerung des AIDS Ausbruchs.
10.05.00
Immune Response testet HIV-Medikament
Die Immune Response Corporation (Nasdaq: IMNR) und Agouron Pharmaceuticals, Inc. gaben bekannt, dass mit Studien begonnen wurde, die die Sicherheit und die Wirksamkeit von REMUNE™ (HIV-1 Immunogen) untersuchen sollen.
REMUNE™ soll dabei die Zeitspanne, in der die HIV-Viren vom Körper unterdrückt werden, weiter vergrößern. Die Untersuchungen werden dabei von der Adult AIDS Clinical Trial Group (AACTG) geleitet. Die AACTG ist mit zahlreichen klinischen Erprobungen potentieller AIDS-Medikamente beschäftigt.
Agouron Pharmaceuticals, Inc., ist eine Tochtergesellschaft der Warner-Lambert Company, die sich auf die Entwicklung und Vermarktung innovativer Therapien spezialisiert hat. Von den 1.200 Mitarbeitern, sind 80 in Forschung und Entwicklung beschäftigt.
21.06.00
Immune mit erfolgreichen Daten
Immune Response (Nasdaq: IMNR; WKN 879428) gab heute seine vorläufigen Daten einer Phase II für das HIV Medikament Remune bekannt.
Die Daten zeigen, dass Remune die Killer T-Zellen des Immunsystems gegen den HIV Virus aktivieren kann. Die Plazebo kontrollierte doppelt blinde Studie wurde an 243 Patienten HIV infizierten Patienten in Spanien durchgeführt.
„Die Daten lassen vermuten, dass eine Behandlung mit REMUNE die Immunsystem Reserven von HIV-spezifischen CTLs erhöht. Dies ist sehr signifikant, da die CTL Immune Reaktion bei HIV infizierten Personen, typischerweise verloren geht, oder sich auf ein sehr geringes Level verringert,“ sagte Professor Eduardo Fernandez-Cruz, der an der Studie beteiligt war.
13.07.00
Immune Response mit positiver Studie
Immune Response (Nasdaq: IMNR; WKN 879428) hat auf der 13. internationalen AIDS Konferenz in Durban, Südafrika, heute die vorläufigen erfolgversprechenden Daten einer laufenden Phase II Studie gegen HIV vorgestellt.
In der Phase II Studie wurde ein Stimmulierung von Killer T-Zellen bei HIV Patienten durch Remune™ in Kombination mit einer Antiviral Therapie festgestellt. Diese Zellen haben nach Angaben von Professor Eduardo Fernandez-Cruz die Fähigkeit Zellen zu töten die ein HIV Antigen aufweisen.
09.08.00
Immune Response erhält Patent.
Immune Response (Nasdaq: IMNR; WKN 879428) gab heute bekannt ein Patent zur Behandlung von rheumatischer Arthritis erhalten zu haben.
Das Patent bezieht sich auf eine Methode im Zusammenhang mit immunbasierten Technologien zur Vorbeugung und Behandlung von rheumatischer Arthritis. Zur Zeit werden Phase 2 Studien von Immune Response basierend auf einer Immuntherapie durchgeführt.
„Dies ist ein Schlüsselpatent, in dem es direkt die Zusammensetzung von IR501 abdeckt, unserem in der Entwicklung befindlichen therapeutischen Impfstoff zur Behandlung von rheumatischer Arthritis,“ sagte der Executive Director von Immune Response Richard Bartholomew.
Wichtiger Hinweis!
Die Informationen dienen nur zur allgemeinen Information und nicht zur Beratung des Lesers und stellen keine Aufforderung zum Kauf oder Verkauf von Wertpapieren jeglicher Art dar!
Für die Korrektheit der Daten übernehme ich keine Gewähr!
Die Verwendung der Inhalte erfolgt ausschließlich auf eigene Gefahr!
Es obliegt dem Leser, sich vor der Verwendung einer hier gefundenen Information über die Risiken des Wertpapierhandels ausführlich und umfassen zu informieren!
Quellenangaben:
www.Nasdaq.com
www.IMNR.com
www.Bigcharts.com
www.finance-online.de
www.juchu.de
www.diegaertner.de
mfG
RCZ
Tolle zusammenstellung.
Ps:Hab auch ein paar
Pyscho
Ps:Hab auch ein paar
Pyscho
Schöne Zusammenfassung.
Ich habe mir vor einiger Zeit auch ein paar ins Depot gelegt und bin eigentlich auch immer noch von dem Wert überzeugt.
Allerdings frage ich mich, warum der Wert immer noch auf so niedrigem Niveau vor sich hin krepelt, wo das Unternehmen so ein aussichtsreiches Medikament in der Pipeline hat, welches dazu in Thailand kurz vor der Zulassung steht.
So ganz allmählich fange ich allerdings an zu zweifeln, ob da noch alles in Ordnung ist.
Hoffe mit Euch auf steigende Kurse!
Edgar
Ich habe mir vor einiger Zeit auch ein paar ins Depot gelegt und bin eigentlich auch immer noch von dem Wert überzeugt.
Allerdings frage ich mich, warum der Wert immer noch auf so niedrigem Niveau vor sich hin krepelt, wo das Unternehmen so ein aussichtsreiches Medikament in der Pipeline hat, welches dazu in Thailand kurz vor der Zulassung steht.
So ganz allmählich fange ich allerdings an zu zweifeln, ob da noch alles in Ordnung ist.
Hoffe mit Euch auf steigende Kurse!
Edgar
Schaut euch mal den Bericht an
CARLSBAD, Calif., Aug 16, 2000 /PRNewswire via COMTEX/ -- The Immune Response
Corporation, (Nasdaq: IMNR), announced today that the underwriters in the
Company`s recently completed public offering of Common Stock have exercised in
full their over-allotment option.
As a result, The Immune Response Corporation will sell an additional 360,000
shares at the original offering price of $6.00 per share, bringing the total
proceeds of the offering, before underwriting discounts and expenses, to
$16,560,000. The option was granted in connection with the Company`s public
offering of 2,400,000 shares of its Common Stock which was completed on August
11, 2000.
First Security Van Kasper and Gruntal & Co., L.L.C. are the underwriters of the
offering.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology for
gene therapy, which is designed to enable the delivery of genes directly to the
liver via intravenous injection.
This news release contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results to vary materially from those
expected due to a variety of risk factors, including whether the over-allotment
option will be successfully completed and those risks set forth from time to
time in The Immune Response Corporation`s SEC filings, including but not limited
to its report on Form 10-K for the year ended December 31, 1999. The Company
undertakes no obligation to publicly release the result of any revisions to
these forward-looking statements, which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
SOURCE The Immune Response Corporation
CARLSBAD, Calif., Aug 16, 2000 /PRNewswire via COMTEX/ -- The Immune Response
Corporation, (Nasdaq: IMNR), announced today that the underwriters in the
Company`s recently completed public offering of Common Stock have exercised in
full their over-allotment option.
As a result, The Immune Response Corporation will sell an additional 360,000
shares at the original offering price of $6.00 per share, bringing the total
proceeds of the offering, before underwriting discounts and expenses, to
$16,560,000. The option was granted in connection with the Company`s public
offering of 2,400,000 shares of its Common Stock which was completed on August
11, 2000.
First Security Van Kasper and Gruntal & Co., L.L.C. are the underwriters of the
offering.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology for
gene therapy, which is designed to enable the delivery of genes directly to the
liver via intravenous injection.
This news release contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results to vary materially from those
expected due to a variety of risk factors, including whether the over-allotment
option will be successfully completed and those risks set forth from time to
time in The Immune Response Corporation`s SEC filings, including but not limited
to its report on Form 10-K for the year ended December 31, 1999. The Company
undertakes no obligation to publicly release the result of any revisions to
these forward-looking statements, which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
SOURCE The Immune Response Corporation
da kommt frisches Geld in die Kasse!
Trading Spotlight
Weis jemand warum der Kurs so anzieht? Bis 9.30 Uhr wurden 1500 Stck umgesetzt
Wer kann mir näheres über diesen Wert berichten?
Ich weiß nur daß jeden Tag mit der Zulassung des HIV-Mittels gerechnet wird.
Sehr interessante Beiträge !!
Mich würde interessieren wie die Chancen
für eine Zulassung stehen und was sich daraus für
den Kurs ergibt ????
MfG Mr.Keating
Mich würde interessieren wie die Chancen
für eine Zulassung stehen und was sich daraus für
den Kurs ergibt ????
MfG Mr.Keating
@Edgar69
die Frage ist berechtigt,
aber wir sind nicht die einzigen, die an IMNR glauben
siehe Meldung vom 18.1.00
Immune Response Corporation gab heute bekannt eine 5 Millionen Dollar Meilensteinzahlung von Agouron Pharmaceuticals, eine 100%ige Tochter von Warner-Lambert, erhalten zu haben.
Die Zahlung ist die letzte von 6 quartärlichen Zahlungen, die Immune Response für die Entwicklung und Kommerzialisierung von Remune(TM), einer immunbasierten Behandlung von HIV. Der Vertrag beinhaltet bis zu 30 Millionen Dollar an weiteren Meilensteinzahlung für Immune Response. Bei erfolgreicher Markteinführung werden die Gewinne 50/50 aufgeteilt.
@Prosalis
was willst du wissen?
schau doch unter www.IMNR.com
@BergundTal
Remmune ist kein Mittel gegen HIV sondern zur stärkung des Immunsystems, welches dann ein Ausbrechen der Krankheit verhindern soll.
Das Gute daran ist, daß Remmune nicht nur gegen Aids sondern auch gegen andere Immunschwächekrankheiten eingesezt werden könnte. (das ist aber noch weit in die Zukunft geblickt.)
@Mr.Keating
das weiß wohl nur die Zulassungsbehörde in Thailand
in Thailand gibt es über 1,4 Mill. Infizierte, die Regierung benötigt dringend Medikamente gegen Aids, so daß eine Zulassung, wenn die Nebenwirkungen nicht zu groß sind wahrscheilich sein könnte.
Der Kurs bietet bei der geringen Marktkapitalisierung enormes Potenzial.
Mit Remmune wird man in ein paar Jahren mehrere 100 Millionen Dollar Umsätzen können.
Die Biotechs werden meistens mit dem 10 - 20 fachen der Umsätze bewertet.
Kurzfristig scheint der Abwertstrend gebrochen
die Frage ist berechtigt,
aber wir sind nicht die einzigen, die an IMNR glauben
siehe Meldung vom 18.1.00
Immune Response Corporation gab heute bekannt eine 5 Millionen Dollar Meilensteinzahlung von Agouron Pharmaceuticals, eine 100%ige Tochter von Warner-Lambert, erhalten zu haben.
Die Zahlung ist die letzte von 6 quartärlichen Zahlungen, die Immune Response für die Entwicklung und Kommerzialisierung von Remune(TM), einer immunbasierten Behandlung von HIV. Der Vertrag beinhaltet bis zu 30 Millionen Dollar an weiteren Meilensteinzahlung für Immune Response. Bei erfolgreicher Markteinführung werden die Gewinne 50/50 aufgeteilt.
@Prosalis
was willst du wissen?
schau doch unter www.IMNR.com
@BergundTal
Remmune ist kein Mittel gegen HIV sondern zur stärkung des Immunsystems, welches dann ein Ausbrechen der Krankheit verhindern soll.
Das Gute daran ist, daß Remmune nicht nur gegen Aids sondern auch gegen andere Immunschwächekrankheiten eingesezt werden könnte. (das ist aber noch weit in die Zukunft geblickt.)
@Mr.Keating
das weiß wohl nur die Zulassungsbehörde in Thailand
in Thailand gibt es über 1,4 Mill. Infizierte, die Regierung benötigt dringend Medikamente gegen Aids, so daß eine Zulassung, wenn die Nebenwirkungen nicht zu groß sind wahrscheilich sein könnte.
Der Kurs bietet bei der geringen Marktkapitalisierung enormes Potenzial.
Mit Remmune wird man in ein paar Jahren mehrere 100 Millionen Dollar Umsätzen können.
Die Biotechs werden meistens mit dem 10 - 20 fachen der Umsätze bewertet.
Kurzfristig scheint der Abwertstrend gebrochen
Danke RCZ für die schöne Informationssammlung. War vor ein paar
Monaten schon man an IMNR interessiert - hab mich damals aber für
Vertex entschieden, was ja nicht gerade falsch war.
Gestern nun bin ich für 8 € eingestiegen. Ich denke die Zeit ist reif für IMNR.
Positiv überrascht hat mich gestern, dass 2 Orders über je ca. 40000 Stück
den Kurs in US hochgezogen haben. Der kurs ist zwar danach wieder abge-
bröckelt, hat sich zum Schluss bei allgemein steigenden Kursen ja aber
wieder stabilisiert. Vieleicht hatte hier ja ein Fonds die Finger im Spiel -
wär zumindest wünschenswert, dass institutionelle Anleger den Wert auch
langsam entdecken.
Monaten schon man an IMNR interessiert - hab mich damals aber für
Vertex entschieden, was ja nicht gerade falsch war.
Gestern nun bin ich für 8 € eingestiegen. Ich denke die Zeit ist reif für IMNR.
Positiv überrascht hat mich gestern, dass 2 Orders über je ca. 40000 Stück
den Kurs in US hochgezogen haben. Der kurs ist zwar danach wieder abge-
bröckelt, hat sich zum Schluss bei allgemein steigenden Kursen ja aber
wieder stabilisiert. Vieleicht hatte hier ja ein Fonds die Finger im Spiel -
wär zumindest wünschenswert, dass institutionelle Anleger den Wert auch
langsam entdecken.
Habe ich heute direkt von der Homepage von imnr
Corporate Highlights
August 2000: Granted U.S. patent (#6,090,387) for targeting and vaccinating with T cell receptor peptides. Patent covers combination of key protein sequences (Vbetas 3, 14 and 17) in the Company’s investigational immune-based product for the treatment of rheumatoid arthritis (IR501).
August 2000: Announced a public offering of 2,400,000 shares of its common stock at a price of $6.00 per share. The shares are being offered through First Security Van Kasper and Gruntal & Co., L.L.C. The underwriters have been granted an over-allotment option to purchase up to an additional 360,000 shares.
sieht doch ganz gut aus
Corporate Highlights
August 2000: Granted U.S. patent (#6,090,387) for targeting and vaccinating with T cell receptor peptides. Patent covers combination of key protein sequences (Vbetas 3, 14 and 17) in the Company’s investigational immune-based product for the treatment of rheumatoid arthritis (IR501).
August 2000: Announced a public offering of 2,400,000 shares of its common stock at a price of $6.00 per share. The shares are being offered through First Security Van Kasper and Gruntal & Co., L.L.C. The underwriters have been granted an over-allotment option to purchase up to an additional 360,000 shares.
sieht doch ganz gut aus
IMNR bricht gerade charttechnisch aus. Die könnten eine große Zukunft haben!
immer gerne bereit ein fass mit euch von imnr aufzumachen.
aber bei den fakten bleiben. keine news um auszuflippen
und im chart 50 tage linie bei $9.02 und 200 tage linie
bei $ 8.61.
meine meinung: es ist was im busch in der gesamten biotech
aktien-sparte, vielleicht macht man es wie im letzten jahr
und inszeniert eine rally, irgendwelche nachrichten bringen
den rest, aber das ist alles spekulation, also darauf ein-
stellen, jeder sollte vorstellungen von seinen verkaufskursen
haben, denn wie gewohnt kracht das natürlich alles wieder
zusammen.
aber bei den fakten bleiben. keine news um auszuflippen
und im chart 50 tage linie bei $9.02 und 200 tage linie
bei $ 8.61.
meine meinung: es ist was im busch in der gesamten biotech
aktien-sparte, vielleicht macht man es wie im letzten jahr
und inszeniert eine rally, irgendwelche nachrichten bringen
den rest, aber das ist alles spekulation, also darauf ein-
stellen, jeder sollte vorstellungen von seinen verkaufskursen
haben, denn wie gewohnt kracht das natürlich alles wieder
zusammen.
Hallo Dosto,
da gebe ich Dir Recht. 200-Tage Linie wurde heute kurz durchstoßen. Am Schluß wieder sehr starke Gewinnmitnahmen.
Das ganze ist schon ein wildes Gezocke, wo Phantasie eine große Rolle spielt. Wenn der ganze Sektor läuft, laufen halt alle Werte. Das hat mit Verstand nix zu tun.
hast Du auch Biotechs, die Du auch fundamentakl für aussichtsreich hältst, oder kaufst Du nur nach Charts?
Prosalis
da gebe ich Dir Recht. 200-Tage Linie wurde heute kurz durchstoßen. Am Schluß wieder sehr starke Gewinnmitnahmen.
Das ganze ist schon ein wildes Gezocke, wo Phantasie eine große Rolle spielt. Wenn der ganze Sektor läuft, laufen halt alle Werte. Das hat mit Verstand nix zu tun.
hast Du auch Biotechs, die Du auch fundamentakl für aussichtsreich hältst, oder kaufst Du nur nach Charts?
Prosalis
fundamental:
schau dir mal PDLI an
schau dir mal PDLI an
IMNR wird kurzfristig auf die 13 zugehen! hab das so im gefühl 
-->MACD...RSI sieht nicht ganz so positiv aus!
ich blicke bei IMNR aber nicht ganz so durch...hieß es da nicht mal remune-zulassung in thailand oder sowas??
--der falsche captain--
-->MACD...RSI sieht nicht ganz so positiv aus!ich blicke bei IMNR aber nicht ganz so durch...hieß es da nicht mal remune-zulassung in thailand oder sowas??
--der falsche captain--
hallo prosalis
es geht mir genauso wie dir und wahrscheinlich allen anderen.
ich habe keinen einblick in die labors und keinen einblick
in die testphasen, also ich habe keine facts.
das einzige was ich sehe sind bilanzen und die sagen mir
jedesmal die labs brauchen geld und das bekommen sie von
den grossen (AHP, Novartis etc.), natürlich nur gegen
firmenbeteiligung. gleichzeitig gebe ich dir recht, wenn
eine biohausse beginnt ist es wahrscheinlich egal
welchen wert die hast, das ist dann eine frage des geld-
beutels. im januar/februar hatte ich alles wahllos gekauft
was zwischen 5 -20 $ lag. die ersten zwei runden gingen
an mich. die letzte runde habe ich verloren. aber innerhalb 25 tagen
war für mich alles gelaufen. einen wert halte ich als spekulation
ticker symbol SCLN gibt es glaube ich nur in amerika.
es geht mir genauso wie dir und wahrscheinlich allen anderen.
ich habe keinen einblick in die labors und keinen einblick
in die testphasen, also ich habe keine facts.
das einzige was ich sehe sind bilanzen und die sagen mir
jedesmal die labs brauchen geld und das bekommen sie von
den grossen (AHP, Novartis etc.), natürlich nur gegen
firmenbeteiligung. gleichzeitig gebe ich dir recht, wenn
eine biohausse beginnt ist es wahrscheinlich egal
welchen wert die hast, das ist dann eine frage des geld-
beutels. im januar/februar hatte ich alles wahllos gekauft
was zwischen 5 -20 $ lag. die ersten zwei runden gingen
an mich. die letzte runde habe ich verloren. aber innerhalb 25 tagen
war für mich alles gelaufen. einen wert halte ich als spekulation
ticker symbol SCLN gibt es glaube ich nur in amerika.
Bei IMNR bin ich auch dabei! Mein KK war allerdings 14 E !
Ausserdem bin ich kürzlich eingestiegen bei Gene Logic!
Und sehr spekulkativ bei Xenova! Desweiteren hab ich den DWS-Biotechfond, und der ist zur Zeit mein Gewinner mit plus 30 % in 8 Wochen!
Alle diese Werte sind spekulativ! Riesengewinne und Totalverluste sind möglich! Alles hängt von Forschung und Zulassung ab! Ist fast wie auf der Spielbank! (Bis auf den Fond)!
Ausserdem bin ich kürzlich eingestiegen bei Gene Logic!
Und sehr spekulkativ bei Xenova! Desweiteren hab ich den DWS-Biotechfond, und der ist zur Zeit mein Gewinner mit plus 30 % in 8 Wochen!
Alle diese Werte sind spekulativ! Riesengewinne und Totalverluste sind möglich! Alles hängt von Forschung und Zulassung ab! Ist fast wie auf der Spielbank! (Bis auf den Fond)!
Hi IMNRler
Irgendwie habe ich auch das Gefühl im Bauch, daß wir die nächsten Tage noch sehr schöne Kurse sehen werden.
Gruß
guntis
Irgendwie habe ich auch das Gefühl im Bauch, daß wir die nächsten Tage noch sehr schöne Kurse sehen werden.
Gruß
guntis
Meine Meinung guntis 
Gruss Mr.Gröwah
Gruss Mr.Gröwah
Jetzt +7,8 % auf 9,44$ Weiter so !!!
IMNR beginnt endlich zu laufen, was meint ihr?
MACD sieht weiterhin sehr positiv aus aber der RSI macht mir doch sehr zu schaffen!!! eigentlich deutet er auf einen rückgang um bis zu 40 % hin! aber mein gefühl bleibt weiterhin positiv! ich glaube wir werden die 12 kurzzeitig von unten sehen! wenn jedoch news kommen kann dieser anstieg auch noch andauern!!...meine meinung...
--der falsche captain--
--der falsche captain--
12 natürlich von OBEN !!! sorry!
--der falsche captain--
sorry!--der falsche captain--
jaja jungs ihr habt jetzt platz bis 12 1/2
REMUNE™ WKN 879428 wirkt gegen AIDS
Das Medikament REMUNE™ von der Immune Response Corporation (Nasdaq: IMNR) scheint nach neuen klinischen Daten bei der AIDS Bekämpfung wirksam zu sein.
Die Daten lassen auf eine Unterstützung zur Wiederherstellung des Immunsystems schließen. Dieser Effekt tritt sowohl bei alleiniger Verabreichung von REMUNE, als auch in Kombination mit Antiviralmedikamenten ein. Die Daten stammen aus einer doppelt-blinden, Placebo kontrollierten Studie an 297 HIV-1 infizierten Patienten in Thailand.
Das Medikament REMUNE™ von der Immune Response Corporation (Nasdaq: IMNR) scheint nach neuen klinischen Daten bei der AIDS Bekämpfung wirksam zu sein.
Die Daten lassen auf eine Unterstützung zur Wiederherstellung des Immunsystems schließen. Dieser Effekt tritt sowohl bei alleiniger Verabreichung von REMUNE, als auch in Kombination mit Antiviralmedikamenten ein. Die Daten stammen aus einer doppelt-blinden, Placebo kontrollierten Studie an 297 HIV-1 infizierten Patienten in Thailand.
Die Wirksamkeit von Remune steht schon länger fest und ist bereits im Kurs enthalten. Entscheidend ist
wann Remune erstmals zugelassen wird !!!
wann Remune erstmals zugelassen wird !!!
es wird wohl langsam wieder zeit für eine meldung von imnr
letzte auf yahoo am 16. aug.
hoffe das die nächste wohl die zulassung betrifft
das dürfte dann wohl eine mk von 1mrd bedeuten und der kurs müßte sich vervierfachen
meinungen erwünscht
K.
letzte auf yahoo am 16. aug.
hoffe das die nächste wohl die zulassung betrifft
das dürfte dann wohl eine mk von 1mrd bedeuten und der kurs müßte sich vervierfachen
meinungen erwünscht
K.
Tach Kipferl!!
Ich glaube es kann sich nur noch um Jahre handeln! Ha Ha
Nein im Ernst, ich hoffe auch das so langsam mal was Weltbewegendes aus dem Ticker bezüglich Remune kommt! Heute geht´s ja leider wieder in die falsche Richtung !!
Gruss Vadders
Ich glaube es kann sich nur noch um Jahre handeln! Ha Ha
Nein im Ernst, ich hoffe auch das so langsam mal was Weltbewegendes aus dem Ticker bezüglich Remune kommt! Heute geht´s ja leider wieder in die falsche Richtung !!
Gruss Vadders
Hi
Das war ja heute dennoch ein guter Schlußkurs.
IMNR bitte bring mal wieder eine gute News, und wenn es sich nur um die Zulassung von Remune handelt, wären wir ja auch schon dankbar.
Gruß
guntis
Das war ja heute dennoch ein guter Schlußkurs.
IMNR bitte bring mal wieder eine gute News, und wenn es sich nur um die Zulassung von Remune handelt, wären wir ja auch schon dankbar.
Gruß
guntis
7:11 [IMNR-GLX] immune response corp.`s remune to be included in glaxo anti-HIV study
sounds good ;-)
sounds good ;-)
Der Kurs hat auch schon wieder gedreht!
Hoffentlich werden wir für unser warten mal Belohnt !!
Wann seid Ihr eigendlich eingestiegen ?? Bei mir handelt es sich um einen Kurs von 12€ ! Also immer noch im MINUS !!!
IMNR go North!!
Gruss Vadders
Hoffentlich werden wir für unser warten mal Belohnt !!
Wann seid Ihr eigendlich eingestiegen ?? Bei mir handelt es sich um einen Kurs von 12€ ! Also immer noch im MINUS !!!
IMNR go North!!
Gruss Vadders
Hier die Meldung
Tuesday September 19, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces the Addition of
REMUNE(TM), An Investigational Therapeutic Vaccine for the Treatment of
Primary HIV Infection, to the `QUEST` Study
Glaxo Wellcome`s QUEST Study to Test Anti-HIV Strategy of Combining Very Early HAART Intervention and HIV
Vaccination to Maintain Viral Suppression After Treatment Is Stopped
CARLSBAD, Calif., Sept. 19 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that REMUNE(TM) (HIV-1
Immunogen), an investigational therapeutic vaccine for the treatment of HIV infection, will be tested as part of a clinical trial entitled QUEST. Glaxo Wellcome (NYSE:
GLX - news) is the main sponsor of QUEST, an international study designed to evaluate the effectiveness of an anti-HIV strategy that combines highly active
antiretroviral therapy (HAART) and therapeutic HIV vaccination in keeping the virus suppressed after complete treatment cessation. A total of 150 patients have been
recruited for QUEST in Australia, Europe and Canada.
``When QUEST was initiated, leading HIV researchers believed that HIV might be eradicated from an infected individual`s system if a `treat early and treat hard`
strategy was implemented. Since then, however, it has become clear that sanctuaries of HIV-infected cells persist despite early and aggressive intervention with
HAART. The pools of latently infected cells are very problematic because they serve as HIV reservoirs that contribute to viral rebound when HAART is stopped,`` said
Li-Ean Goh, Pharm. D., Project Leader of the QUEST study. ``As such, it is very important to test new strategies, such as investigational therapeutic vaccination, to
augment the anti-HIV effect of currently available drugs.``
The QUEST study involves HIV patients who were infected within the past 2 years and who immediately began HAART quadruple therapy -- Combivir (AZT + 3TC),
Ziagen and Agenerase -- lasting 18 months. In addition to continuing quadruple HAART, patients will receive investigational HIV therapeutic vaccines for 6 months,
after which time all treatment will cease. A 6-month follow-up period will then begin during which viral load (the amount of HIV in the blood) will be monitored.
Treatments considered successful in the context of this trial setting will be those for which viral load is maintained below a pre-determined level for the 6 months in a
significant number of patients or when a new equilibrium between the virus and the host immune response is achieved.
``Results from the first phase of QUEST have shown the merits of early HAART intervention. It is now our hope to prolong the anti-HIV effects of HAART by using
vaccination to boost the body`s natural immune defenses against HIV. Using REMUNE and another investigational vaccine in the QUEST setting, wherein patients
were treated within a month of infection with potent HAART and have low levels of virus at the time of vaccination, we believe that the durability and magnitude of the
immune response may be even more pronounced than previously observed in vaccinated chronically infected patients,`` said Dr. Goh.
REMUNE is an investigational therapeutic vaccine that may bolster the immune system`s helper T cell responses against HIV in chronically infected individuals. In
clinical trials conducted to date with REMUNE, with or without antiviral drug therapy, the most frequently reported side effects include local transient pain, soreness and
redness at the site of injection, muscle aches, fatigue, and headache.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune
responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy,
which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release
made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can
also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not
limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended
December 31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking
statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
REMUNE (TM) is a trademark of The Immune Response Corporation.
SOURCE: The Immune Response Corporation
K.
Tuesday September 19, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces the Addition of
REMUNE(TM), An Investigational Therapeutic Vaccine for the Treatment of
Primary HIV Infection, to the `QUEST` Study
Glaxo Wellcome`s QUEST Study to Test Anti-HIV Strategy of Combining Very Early HAART Intervention and HIV
Vaccination to Maintain Viral Suppression After Treatment Is Stopped
CARLSBAD, Calif., Sept. 19 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that REMUNE(TM) (HIV-1
Immunogen), an investigational therapeutic vaccine for the treatment of HIV infection, will be tested as part of a clinical trial entitled QUEST. Glaxo Wellcome (NYSE:
GLX - news) is the main sponsor of QUEST, an international study designed to evaluate the effectiveness of an anti-HIV strategy that combines highly active
antiretroviral therapy (HAART) and therapeutic HIV vaccination in keeping the virus suppressed after complete treatment cessation. A total of 150 patients have been
recruited for QUEST in Australia, Europe and Canada.
``When QUEST was initiated, leading HIV researchers believed that HIV might be eradicated from an infected individual`s system if a `treat early and treat hard`
strategy was implemented. Since then, however, it has become clear that sanctuaries of HIV-infected cells persist despite early and aggressive intervention with
HAART. The pools of latently infected cells are very problematic because they serve as HIV reservoirs that contribute to viral rebound when HAART is stopped,`` said
Li-Ean Goh, Pharm. D., Project Leader of the QUEST study. ``As such, it is very important to test new strategies, such as investigational therapeutic vaccination, to
augment the anti-HIV effect of currently available drugs.``
The QUEST study involves HIV patients who were infected within the past 2 years and who immediately began HAART quadruple therapy -- Combivir (AZT + 3TC),
Ziagen and Agenerase -- lasting 18 months. In addition to continuing quadruple HAART, patients will receive investigational HIV therapeutic vaccines for 6 months,
after which time all treatment will cease. A 6-month follow-up period will then begin during which viral load (the amount of HIV in the blood) will be monitored.
Treatments considered successful in the context of this trial setting will be those for which viral load is maintained below a pre-determined level for the 6 months in a
significant number of patients or when a new equilibrium between the virus and the host immune response is achieved.
``Results from the first phase of QUEST have shown the merits of early HAART intervention. It is now our hope to prolong the anti-HIV effects of HAART by using
vaccination to boost the body`s natural immune defenses against HIV. Using REMUNE and another investigational vaccine in the QUEST setting, wherein patients
were treated within a month of infection with potent HAART and have low levels of virus at the time of vaccination, we believe that the durability and magnitude of the
immune response may be even more pronounced than previously observed in vaccinated chronically infected patients,`` said Dr. Goh.
REMUNE is an investigational therapeutic vaccine that may bolster the immune system`s helper T cell responses against HIV in chronically infected individuals. In
clinical trials conducted to date with REMUNE, with or without antiviral drug therapy, the most frequently reported side effects include local transient pain, soreness and
redness at the site of injection, muscle aches, fatigue, and headache.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune
responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy,
which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release
made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can
also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not
limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended
December 31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking
statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
REMUNE (TM) is a trademark of The Immune Response Corporation.
SOURCE: The Immune Response Corporation
K.
Hi
Kann mir jemand kurz sagen um was es sich bei der Meldung geht.
Danke
guntis
PS: Mein Einstieg war bei 11,50 Euro
Kann mir jemand kurz sagen um was es sich bei der Meldung geht.
Danke
guntis
PS: Mein Einstieg war bei 11,50 Euro
Vielleicht hilft das dem Kurs mal ein wenig.
Grüsse
VSAT Among 50 Top Growing Companies:
San Diego Technology Companies Recognized in Deloitte & Touche`s Annual Fast 50 Ranking-- ComGlobal Systems, Inc. tops list of fastest growing companies with a 19,094 percent five-year revenue growth --
SAN DIEGO, Sep 26, 2000 (BUSINESS WIRE) -- The fastest growing technology
companies in the region were recognized by Deloitte & Touche at an awards dinner
held September 25 at the Marriott`s Laguna Cliffs Resort at Dana Point. Called
the "2000 Orange County/San Diego Technology Fast 50," the annual awards program
ranks technology companies located in Orange and San Diego counties by revenue
growth over a five-year period.
Of the 50 companies honored this year, 28 were based in San Diego. With an
impressive revenue growth of 19,094 percent, San Diego-based ComGlobal Systems,
Inc. leads this year`s Fast 50. The company`s specialized software, hardware,
and systems engineering development services enable its government and
commercial customers to increase both their effectiveness and their
competitiveness.
Seventy-percent of the 50 companies are public, while 30 percent are private.
The industry segment breakdown is as follows: Software (30%);
Communications/Networking (22%); Medical/Scientific/Technical (14%);
Biotechnology (10%); Computer/Peripherals (10%); Other (10%); and Internet (4%).
The total revenue generated by the 2000 Orange County/San Diego Technology Fast
50 companies in 1999 was $7.6 billion.
"We congratulate all of the Fast 50 companies for their commitment to the
technology industry, and for delivering on the promise of market longevity,"
said James Fazio, partner in Deloitte & Touche`s San Diego Technology and
Communications Group. "Being named a Fast 50 winner is a testament to each
company`s leadership, and its ability to not only have the right solution at the
right moment, but also the vision that contributes to the growth of the business
over five years."
To qualify for the Orange County/San Diego Technology Fast 50, companies must be
in business for a minimum of five years; must not be a subsidiary or division,
unless separately traded and having some public ownership; must have 1995
operating revenues of at least $50,000 and 1999 operating revenues of $1 million
or more; must be considered a technology company which is defined as developing
proprietary technology which contributes to a significant portion of the
company`s operating revenues, manufacturing a technology-related product, or
devoting a high percentage of effort to research and development of technology;
and must be headquartered in Orange or San Diego counties.
The 2000 Orange County/San Diego Technology Fast 50 program is presented by
Deloitte & Touche and sponsored by A. G. Edwards; Bowne of Irvine; Brobeck
Phleger & Harrison LLP; E-Media Corp.; Imperial Bank; Marsh; in association with
the American Electronics Association; and California Manufacturing Technology
Center.
The 2000 Orange County/San Diego Fast 50 company rankings are as follows:
Company Name City Exchange/Ticker 5-Year
Revenue
Growth
1 ComGlobal Systems, Inc. San Diego PRIVATE 19,094%
2 autobytel.com Inc. Irvine NASD:ABTL 14,607%
3 Wireless Facilities, Inc. San Diego NASD:WFII 8,443%
4 Broadcom Corporation Irvine NASD:BRCM 8,249%
5 I/OMagic Corp. Irvine OTC:IOMC 6,266%
6 SRS Labs, Inc. Santa Ana NASD:SRSL 4,141%
7 JABRA Corporation San Diego PRIVATE 3,996%
8 CardioDynamics International
Corp. San Diego NASD:CDIC 2,538%
9 Nanogen, Inc. San Diego NASD:NGEN 2,453%
10 SVI Holdings, Inc. San Diego AMEX:SVI 1,993%
11 Micro Therapeutics, Inc. Irvine NASD:MTIX 1,303%
12 Immune Response Corp. (The) Carlsbad NASD:IMNR 1,230%
13 Sonnet Technologies, Inc. Irvine PRIVATE 1,165%
14 MassHysteria, Inc. San Diego PRIVATE 1,119%
15 iBASEt Lake Forest PRIVATE 990%
16 QUALCOMM, Incorporated San Diego NASD:QCOM 918%
17 Linksys Irvine PRIVATE 907%
18 Trega Biosciences, Inc. San Diego NASD:TRGA 876%
19 Powerwave Technologies, Inc. Irvine NASD:PWAV 713%
20 Quest Software, Inc. Irvine NASD:QSFT 644%
21 Innovative Medical Services El Cajon NASD:PURE 636%
22 DAOU Systems, Inc. San Diego NASDAOU 622%
23 HNC Software Inc. San Diego NASD:HNCS 607%
24 Peregrine Systems, Inc. San Diego NASD:PRGN 603%
25 Marotz, Inc. Jamul PRIVATE 576%
26 Magellan Sofware, Inc. Irvine PRIVATE 508%
27 BIOLASE Technology, Inc. San Clemente NASD:BLTI 508%
28 Dura Pharmaceuticals, Inc. San Diego NASDURA 485%
29 Advanced Remote Communication
Solutions, Inc. San Diego OTC:BTRK 436%
30 Emergent Information
Technologies, Inc. Newport Beach NASD:EITI 414%
31 IDEC Pharmaceuticals Corp. San Diego NASD:IDPH 399%
32 Epicor Software Corporation Irvine NASD:EPIC 360%
33 Vision Solutions Irvine PRIVATE 355%
34 Composite Optics, Inc. San Diego PRIVATE 322%
35 Engineering/Documentation
Systems, Inc. Yorba Linda PRIVATE 308%
36 Captiva Software Corporation San Diego PRIVATE 306%
37 ResMed Corp. San Diego NYSE:RMD 277%
38 Cardiff Software, Inc. Vista PRIVATE 273%
39 Litronic, Inc. Irvine NASD:LTNX 270%
40 AstroTerra Corporation San Diego PRIVATE 269%
41 Laser Diagnostic
Technologies, Inc. San Diego PRIVATE 262%
42 VISTA Information
Solutions, Inc. San Diego NASD:VINF 251%
43 Printrak International, Inc. Anaheim NASD:AFIS 223%
44 MedCom USA, Incorporated Irvine NASD:EMED 222%
45 Vista Medical
Technologies, Inc. Carlsbad NASD:VMTI 221%
46 ViaSat, Inc. Carlsbad NASD:VSAT 220%
47 Meade Instruments Corporation Irvine NASD:MEAD 206%
48 Titan Corporation (The) San Diego NYSE:TTN 203%
49 I-Flow Corporation Lake Forest NASD:IFLO 196%
50 Continuus Software
Corporation Irvine NASD:CNSW 185%
Four additional companies were honored in a special "Rising Star" category,
which seeks to recognize technology companies that have achieved outstanding
growth, and that meet all eligibility requirements but have been in business a
minimum of three years. Those companies were: 1) The TriZetto Group, Inc.
(Newport Beach; 1,207 percent revenue growth since 1997); 2) Silicon Space, Inc.
(San Diego; 1,075 percent revenue growth since 1997); 3) InfoGation Corporation
(San Diego; 756 percent revenue growth since 1997); and 4) Log-On Data
Corporation (Orange; 393 percent revenue growth since 1997).
The program also recognized Orange County and San Diego up-and-coming Internet
technology companies. These companies included: Entrepreneur.com (Irvine);
Go2Systems Inc. (Irvine); LoanTrader, Inc. (Irvine); One Voice Technologies,
Inc. (San Diego); and Websense, Inc. (San Diego).
Deloitte & Touche, one of the nation`s leading professional services firms,
provides assurance and advisory, tax, and management consulting services through
30,000 people in more than 100 U.S. cities. The firm is dedicated to helping our
clients and our people excel. Known as an employer of choice for its innovative
human resources programs, Deloitte & Touche has been recognized as one of the
"100 Best Companies to Work For in America" by Fortune magazine for three
consecutive years. Deloitte & Touche is part of Deloitte Touche Tohmatsu, one of
the world`s leading professional services firms, with more than 90,000 people in
over 130 countries. For additional information, please visit our Fast 50 website
at www.fast50.com.
CONTACT: Deloitte & Touche
Tammy Nelson, 714/436-7244
tnelson@dttus.com
URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2000 Business Wire. All rights reserved.
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: INTERNET
ENTERTAINMENT
ADVERTISING/MARKETING
PUBLISHING
CONSUMER/HOUSEHOLD
Grüsse
VSAT Among 50 Top Growing Companies:
San Diego Technology Companies Recognized in Deloitte & Touche`s Annual Fast 50 Ranking-- ComGlobal Systems, Inc. tops list of fastest growing companies with a 19,094 percent five-year revenue growth --
SAN DIEGO, Sep 26, 2000 (BUSINESS WIRE) -- The fastest growing technology
companies in the region were recognized by Deloitte & Touche at an awards dinner
held September 25 at the Marriott`s Laguna Cliffs Resort at Dana Point. Called
the "2000 Orange County/San Diego Technology Fast 50," the annual awards program
ranks technology companies located in Orange and San Diego counties by revenue
growth over a five-year period.
Of the 50 companies honored this year, 28 were based in San Diego. With an
impressive revenue growth of 19,094 percent, San Diego-based ComGlobal Systems,
Inc. leads this year`s Fast 50. The company`s specialized software, hardware,
and systems engineering development services enable its government and
commercial customers to increase both their effectiveness and their
competitiveness.
Seventy-percent of the 50 companies are public, while 30 percent are private.
The industry segment breakdown is as follows: Software (30%);
Communications/Networking (22%); Medical/Scientific/Technical (14%);
Biotechnology (10%); Computer/Peripherals (10%); Other (10%); and Internet (4%).
The total revenue generated by the 2000 Orange County/San Diego Technology Fast
50 companies in 1999 was $7.6 billion.
"We congratulate all of the Fast 50 companies for their commitment to the
technology industry, and for delivering on the promise of market longevity,"
said James Fazio, partner in Deloitte & Touche`s San Diego Technology and
Communications Group. "Being named a Fast 50 winner is a testament to each
company`s leadership, and its ability to not only have the right solution at the
right moment, but also the vision that contributes to the growth of the business
over five years."
To qualify for the Orange County/San Diego Technology Fast 50, companies must be
in business for a minimum of five years; must not be a subsidiary or division,
unless separately traded and having some public ownership; must have 1995
operating revenues of at least $50,000 and 1999 operating revenues of $1 million
or more; must be considered a technology company which is defined as developing
proprietary technology which contributes to a significant portion of the
company`s operating revenues, manufacturing a technology-related product, or
devoting a high percentage of effort to research and development of technology;
and must be headquartered in Orange or San Diego counties.
The 2000 Orange County/San Diego Technology Fast 50 program is presented by
Deloitte & Touche and sponsored by A. G. Edwards; Bowne of Irvine; Brobeck
Phleger & Harrison LLP; E-Media Corp.; Imperial Bank; Marsh; in association with
the American Electronics Association; and California Manufacturing Technology
Center.
The 2000 Orange County/San Diego Fast 50 company rankings are as follows:
Company Name City Exchange/Ticker 5-Year
Revenue
Growth
1 ComGlobal Systems, Inc. San Diego PRIVATE 19,094%
2 autobytel.com Inc. Irvine NASD:ABTL 14,607%
3 Wireless Facilities, Inc. San Diego NASD:WFII 8,443%
4 Broadcom Corporation Irvine NASD:BRCM 8,249%
5 I/OMagic Corp. Irvine OTC:IOMC 6,266%
6 SRS Labs, Inc. Santa Ana NASD:SRSL 4,141%
7 JABRA Corporation San Diego PRIVATE 3,996%
8 CardioDynamics International
Corp. San Diego NASD:CDIC 2,538%
9 Nanogen, Inc. San Diego NASD:NGEN 2,453%
10 SVI Holdings, Inc. San Diego AMEX:SVI 1,993%
11 Micro Therapeutics, Inc. Irvine NASD:MTIX 1,303%
12 Immune Response Corp. (The) Carlsbad NASD:IMNR 1,230%
13 Sonnet Technologies, Inc. Irvine PRIVATE 1,165%
14 MassHysteria, Inc. San Diego PRIVATE 1,119%
15 iBASEt Lake Forest PRIVATE 990%
16 QUALCOMM, Incorporated San Diego NASD:QCOM 918%
17 Linksys Irvine PRIVATE 907%
18 Trega Biosciences, Inc. San Diego NASD:TRGA 876%
19 Powerwave Technologies, Inc. Irvine NASD:PWAV 713%
20 Quest Software, Inc. Irvine NASD:QSFT 644%
21 Innovative Medical Services El Cajon NASD:PURE 636%
22 DAOU Systems, Inc. San Diego NASD
AOU 622% 23 HNC Software Inc. San Diego NASD:HNCS 607%
24 Peregrine Systems, Inc. San Diego NASD:PRGN 603%
25 Marotz, Inc. Jamul PRIVATE 576%
26 Magellan Sofware, Inc. Irvine PRIVATE 508%
27 BIOLASE Technology, Inc. San Clemente NASD:BLTI 508%
28 Dura Pharmaceuticals, Inc. San Diego NASD
URA 485% 29 Advanced Remote Communication
Solutions, Inc. San Diego OTC:BTRK 436%
30 Emergent Information
Technologies, Inc. Newport Beach NASD:EITI 414%
31 IDEC Pharmaceuticals Corp. San Diego NASD:IDPH 399%
32 Epicor Software Corporation Irvine NASD:EPIC 360%
33 Vision Solutions Irvine PRIVATE 355%
34 Composite Optics, Inc. San Diego PRIVATE 322%
35 Engineering/Documentation
Systems, Inc. Yorba Linda PRIVATE 308%
36 Captiva Software Corporation San Diego PRIVATE 306%
37 ResMed Corp. San Diego NYSE:RMD 277%
38 Cardiff Software, Inc. Vista PRIVATE 273%
39 Litronic, Inc. Irvine NASD:LTNX 270%
40 AstroTerra Corporation San Diego PRIVATE 269%
41 Laser Diagnostic
Technologies, Inc. San Diego PRIVATE 262%
42 VISTA Information
Solutions, Inc. San Diego NASD:VINF 251%
43 Printrak International, Inc. Anaheim NASD:AFIS 223%
44 MedCom USA, Incorporated Irvine NASD:EMED 222%
45 Vista Medical
Technologies, Inc. Carlsbad NASD:VMTI 221%
46 ViaSat, Inc. Carlsbad NASD:VSAT 220%
47 Meade Instruments Corporation Irvine NASD:MEAD 206%
48 Titan Corporation (The) San Diego NYSE:TTN 203%
49 I-Flow Corporation Lake Forest NASD:IFLO 196%
50 Continuus Software
Corporation Irvine NASD:CNSW 185%
Four additional companies were honored in a special "Rising Star" category,
which seeks to recognize technology companies that have achieved outstanding
growth, and that meet all eligibility requirements but have been in business a
minimum of three years. Those companies were: 1) The TriZetto Group, Inc.
(Newport Beach; 1,207 percent revenue growth since 1997); 2) Silicon Space, Inc.
(San Diego; 1,075 percent revenue growth since 1997); 3) InfoGation Corporation
(San Diego; 756 percent revenue growth since 1997); and 4) Log-On Data
Corporation (Orange; 393 percent revenue growth since 1997).
The program also recognized Orange County and San Diego up-and-coming Internet
technology companies. These companies included: Entrepreneur.com (Irvine);
Go2Systems Inc. (Irvine); LoanTrader, Inc. (Irvine); One Voice Technologies,
Inc. (San Diego); and Websense, Inc. (San Diego).
Deloitte & Touche, one of the nation`s leading professional services firms,
provides assurance and advisory, tax, and management consulting services through
30,000 people in more than 100 U.S. cities. The firm is dedicated to helping our
clients and our people excel. Known as an employer of choice for its innovative
human resources programs, Deloitte & Touche has been recognized as one of the
"100 Best Companies to Work For in America" by Fortune magazine for three
consecutive years. Deloitte & Touche is part of Deloitte Touche Tohmatsu, one of
the world`s leading professional services firms, with more than 90,000 people in
over 130 countries. For additional information, please visit our Fast 50 website
at www.fast50.com.
CONTACT: Deloitte & Touche
Tammy Nelson, 714/436-7244
tnelson@dttus.com
URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2000 Business Wire. All rights reserved.
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: INTERNET
ENTERTAINMENT
ADVERTISING/MARKETING
PUBLISHING
CONSUMER/HOUSEHOLD
Die Meldung hat leider nichts bewirkt, IMNR ist gerade wieder einmal um 2% gefallen. Ich glaube langsam, dass solange die Zulassung in Thailand nicht aktuell ist, sich bei IMNR gar nichts relevantes tut.
Beobachte imnr jetzt 1 Jahr objektiv betrachtet ist das für mich
das gleiche wie mit Met(a)Box. Die Meldungen kommen nur von der Fa. selber bewegen kurzfristig den Kurs aber auf eine Zulassung in Thailand kann man noch Dekaden warten . Wenn die Zulassung kommt, und der Kurs 50% nach oben geht ist das bei den meisten Shareholdern noch weit unter Einstand.
das gleiche wie mit Met(a)Box. Die Meldungen kommen nur von der Fa. selber bewegen kurzfristig den Kurs aber auf eine Zulassung in Thailand kann man noch Dekaden warten . Wenn die Zulassung kommt, und der Kurs 50% nach oben geht ist das bei den meisten Shareholdern noch weit unter Einstand.
würde mal imnr nicht mit metabox vergleichen
1.
haben die nicht planzahlen rausgegeben die nicht eingehalten werden
2.
ganz anderer sektor
3.
eine zulassung würde für imnr einen quantensprung bedeuten
4.
eine firma die gerade mal mit 250 mio $ bewertet ist hat ein zugelassenes medikament
dass ist dann doch weit mehr als viele andere bios aufweisen können die mit dem 10 oder noch mehrfachen
bewertet sind
grüsse
K.
1.
haben die nicht planzahlen rausgegeben die nicht eingehalten werden
2.
ganz anderer sektor
3.
eine zulassung würde für imnr einen quantensprung bedeuten
4.
eine firma die gerade mal mit 250 mio $ bewertet ist hat ein zugelassenes medikament
dass ist dann doch weit mehr als viele andere bios aufweisen können die mit dem 10 oder noch mehrfachen
bewertet sind
grüsse
K.
Immune Response heute bei $6. Sollte man jetzt einsteigen?
Trinity Medical Group USA, Inc. Announces Assignment of License Agreement for REMUNE
SAN RAFAEL, Calif., Oct. 9 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC: TMGU) announces that the License and Collaboration agreement for REMUNE(TM) and the Stock Purchase Agreement between Trinity Medical Group Ltd. of Bangkok, Thailand and The Immune Response Corporation of Carlsbad, CA have been assigned to TMGU.
The License and Collaboration Agreement between Trinity Medical Group, Ltd. and The Immune Response Corporation dated Sept. 15, 1995 provided for the sale, distribution, and use of REMUNE in ten South East Asian countries, including Thailand. The Immune Response Corporation approved the assignment.
Subsequent to the assignment, TMGU assigned the sales and marketing rights in Thailand to Trinity Assets Company, Ltd. (TAC), an affiliate of the Company. TAC will formally apply for regulatory approval of REMUNE with Thailand`s FDA and upon approval will conduct local distribution of product.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
For more information on the company, visit the web site at http://www.trinitymg.com
Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is listed on the National Quotation Services Pink Sheets under the symbol TMGU. The Company`s first product in development is an Immune Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further testing in Thailand.
REMUNE is a trademark of The Immune Response Corporation of Carlsbad, CA (Nasdaq: IMNR).
For more information on the Company, contact Investor Relations, Trinity Medical Group USA, Inc., 55 Shaver Street Suite 320, San Rafael, CA 94901 (303) 369-7128, email: IR@trinitymg.com.
/CONTACT: Investor Relations, 303-369-7128, IR@trinitymg.com, or after hours, James Namnath, 415-378-3955, both of Trinity Medical Group USA, Inc./
SAN RAFAEL, Calif., Oct. 9 /PRNewswire/ -- Trinity Medical Group USA, Inc. (OTC: TMGU) announces that the License and Collaboration agreement for REMUNE(TM) and the Stock Purchase Agreement between Trinity Medical Group Ltd. of Bangkok, Thailand and The Immune Response Corporation of Carlsbad, CA have been assigned to TMGU.
The License and Collaboration Agreement between Trinity Medical Group, Ltd. and The Immune Response Corporation dated Sept. 15, 1995 provided for the sale, distribution, and use of REMUNE in ten South East Asian countries, including Thailand. The Immune Response Corporation approved the assignment.
Subsequent to the assignment, TMGU assigned the sales and marketing rights in Thailand to Trinity Assets Company, Ltd. (TAC), an affiliate of the Company. TAC will formally apply for regulatory approval of REMUNE with Thailand`s FDA and upon approval will conduct local distribution of product.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
For more information on the company, visit the web site at http://www.trinitymg.com
Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is listed on the National Quotation Services Pink Sheets under the symbol TMGU. The Company`s first product in development is an Immune Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further testing in Thailand.
REMUNE is a trademark of The Immune Response Corporation of Carlsbad, CA (Nasdaq: IMNR).
For more information on the Company, contact Investor Relations, Trinity Medical Group USA, Inc., 55 Shaver Street Suite 320, San Rafael, CA 94901 (303) 369-7128, email: IR@trinitymg.com.
/CONTACT: Investor Relations, 303-369-7128, IR@trinitymg.com, or after hours, James Namnath, 415-378-3955, both of Trinity Medical Group USA, Inc./
Na Ihr Daueroptimisten. Die Zulassung für Thailand ist da , aber es interessiert keinen. Wo bleibt der Quantensprung?
ist schon traurig, daß jetzt nichts passiert. vielleicht ist es das momentane umfeld, daß einen ausbruch verhindert. die umsätze in usa sind jedenfalls nicht schlecht.
mal sehen wie`s weiter geht
b.s.
mal sehen wie`s weiter geht
b.s.
Hi
Ist nun wirklich die Zulassung durch? Wer von auch weiß mehr?
Gruß
guntis
Ist nun wirklich die Zulassung durch? Wer von auch weiß mehr?
Gruß
guntis
Also mein Englisch ist zwar nicht das Beste aber eine Zulassung ist das nicht. Das ist die `ne Firmencooperationsmeldung
zwischen Immune und Trinity Medical.
zwischen Immune und Trinity Medical.
Hi
Hätte mal nen Vorschlag für alle, die dem Englisch etwas besser bewandert sind, bzw. für solche die englischsprachige Texte hier reinstellen.
Bitte könntet Ihr nicht in ein oder zwei kurzen Sätzen kurz erläutern um was es sich bei der Meldung geht.
Danke
guntis
Hätte mal nen Vorschlag für alle, die dem Englisch etwas besser bewandert sind, bzw. für solche die englischsprachige Texte hier reinstellen.
Bitte könntet Ihr nicht in ein oder zwei kurzen Sätzen kurz erläutern um was es sich bei der Meldung geht.
Danke
guntis
Ich lese den Text auch so, dass es sich um eine Kooperation handelt. Auf alle Fälle steigt der Kurs in den USA
hi
wer kann mir sagen wo ich den aktuellen kurs in den usa abfragen kann??? vielen dank
wer kann mir sagen wo ich den aktuellen kurs in den usa abfragen kann??? vielen dank
@carri
Amerikanische Kurse am besten und www.nasdaq.com abfragen. In den USA sind "Kürzel" zu verwenden. Immune Response = IMNR.
Viel Erfolg
Amerikanische Kurse am besten und www.nasdaq.com abfragen. In den USA sind "Kürzel" zu verwenden. Immune Response = IMNR.
Viel Erfolg
da steht, daß es eine Vereinbarung zwischen TMGU und IMNR gibt, welche besagt, daß TMGU die Verkaufsrechte an Remmune für 10 Süd-Ost-Asiatische Länder hat(inkl. Thailand), und davon auch gebrauch machen wird. Diese Vereinbarung stammt vom 15. Sept. 1995
sale, distribution, and use of REMUNE in ten South East Asian countries, including Thailand. The Immune Response Corporation approved the assignment
@ MUMOMA
Remmune wurde von der FDA noch nicht zugelassen
sale, distribution, and use of REMUNE in ten South East Asian countries, including Thailand. The Immune Response Corporation approved the assignment
@ MUMOMA
Remmune wurde von der FDA noch nicht zugelassen
für Freudensprünge ist es noch zu früh, der Abwertstrend bleibt weiterhin bestehen.
inzwischen sieht der Chart wieder besser aus
ich habe mal bei Yahoo ins Board geschaut und folgendes gefundenhttp://messages.yahoo.com/bbs?.mm=FN&action=m&board=7076930&…(Englisch)
und hier die Lycos.com Übersetzung
Translation
Immune Antwort AG (IMNR-NASDAQ, $5.38, bemessen 1-1) Wir erwarten Immun Antwort, dritte Viertel-Einnahmen von $200,000 gegen $3.8 Million in zu berichten das Jahr-vor Periode. Die vierteljährlichen Variationen entstehen vom Timen von Meilenstein Zahlungen und Forschung-Unterstützung von Pfizer (PFE-NYSE, $43.50, bemessen 1-1) und ist von irgendeiner Gesellschaft-Schwäche nicht anzeigend. Wir erwarten R&D Aufwendungen von $5.3 Million, entlang von $7.7 Million in vor dem Jahr Periode und auf bilden Sie die $5.1 Million, die im zweiten Viertel berichtet wird, in regelmäßiger Folge. Wir setzen Sie fort, zu glauben, daß der Anteil-Preis von Immuner Antwort nicht widerspiegelt, das potentiell von Remune für die Behandlung von HIV, und ignoriert ganz das Gesellschaft Plattform-Impfstoff-Technologien für autoimmune-Krankheit und Onkologie Anwendungen. Wir erwarten das nah-Begriff Katalysator für die Anteile zu sein das Vortrag von virological-Fakten vom europäischen entscheidenden Versuch der wir erwarten Sie, in November vorzukommen. Wir wiederholen unsere 1-1 Klasse auf Immuner Antwort Firma mit Ziel-Preisen von $21 und $24 ins dazwischenliegend-und lang-Begriff beziehungsweise.
und hier der Englische Orginaltext
gruntal report
by: inflammablematerial (34/M/Bethesda, Maryland) 10/17/00 4:19 pm
Msg: 22023 of 22047
Immune Response Corp. (IMNR-NASDAQ, $5.38, rated 1-1) We expect Immune
Response to report third quarter revenues of $200,000 versus $3.8 million in
the year-ago period. The quarterly variations arise from timing of milestone
payments and research support from Pfizer (PFE-NYSE, $43.50, rated 1-1) and
are not indicative of any company weakness. We are anticipating R&D expenses
of $5.3 million, down from $7.7 million in the year ago period and up
sequentially form the $5.1 million reported in the second quarter. We
continue to believe that Immune Response`s share price does not reflect the
potential of Remune for the treatment of HIV, and completely disregard the
company`s platform vaccine technologies for autoimmune disease and oncology
applications. We expect the near-term catalyst for the shares to be the
presentation of virological data from the European pivotal trial which we
expect to occur in November. We reiterate our 1-1 rating on Immune Response
Corporation with target prices of $21 and $24 in the intermediate- and
long-term, respectively.
und hier die Lycos.com Übersetzung
TranslationImmune Antwort AG (IMNR-NASDAQ, $5.38, bemessen 1-1) Wir erwarten Immun Antwort, dritte Viertel-Einnahmen von $200,000 gegen $3.8 Million in zu berichten das Jahr-vor Periode. Die vierteljährlichen Variationen entstehen vom Timen von Meilenstein Zahlungen und Forschung-Unterstützung von Pfizer (PFE-NYSE, $43.50, bemessen 1-1) und ist von irgendeiner Gesellschaft-Schwäche nicht anzeigend. Wir erwarten R&D Aufwendungen von $5.3 Million, entlang von $7.7 Million in vor dem Jahr Periode und auf bilden Sie die $5.1 Million, die im zweiten Viertel berichtet wird, in regelmäßiger Folge. Wir setzen Sie fort, zu glauben, daß der Anteil-Preis von Immuner Antwort nicht widerspiegelt, das potentiell von Remune für die Behandlung von HIV, und ignoriert ganz das Gesellschaft Plattform-Impfstoff-Technologien für autoimmune-Krankheit und Onkologie Anwendungen. Wir erwarten das nah-Begriff Katalysator für die Anteile zu sein das Vortrag von virological-Fakten vom europäischen entscheidenden Versuch der wir erwarten Sie, in November vorzukommen. Wir wiederholen unsere 1-1 Klasse auf Immuner Antwort Firma mit Ziel-Preisen von $21 und $24 ins dazwischenliegend-und lang-Begriff beziehungsweise.
und hier der Englische Orginaltext
gruntal report
by: inflammablematerial (34/M/Bethesda, Maryland) 10/17/00 4:19 pm
Msg: 22023 of 22047
Immune Response Corp. (IMNR-NASDAQ, $5.38, rated 1-1) We expect Immune
Response to report third quarter revenues of $200,000 versus $3.8 million in
the year-ago period. The quarterly variations arise from timing of milestone
payments and research support from Pfizer (PFE-NYSE, $43.50, rated 1-1) and
are not indicative of any company weakness. We are anticipating R&D expenses
of $5.3 million, down from $7.7 million in the year ago period and up
sequentially form the $5.1 million reported in the second quarter. We
continue to believe that Immune Response`s share price does not reflect the
potential of Remune for the treatment of HIV, and completely disregard the
company`s platform vaccine technologies for autoimmune disease and oncology
applications. We expect the near-term catalyst for the shares to be the
presentation of virological data from the European pivotal trial which we
expect to occur in November. We reiterate our 1-1 rating on Immune Response
Corporation with target prices of $21 and $24 in the intermediate- and
long-term, respectively.
Hallo zusammen
habe einen interessanten link gefunden
wo man die pipeline verschiedener firmen unter anderem auch von imnr abfragen kann
und wenn ich das richtig sehe hat imnr 3 medikamente in der phase III
und weiter 14 in den verschieden anderen phasen
der link
www.recap.com
dann auf clinicals und den namen der firma eingeben
grüsse
K.
habe einen interessanten link gefunden
wo man die pipeline verschiedener firmen unter anderem auch von imnr abfragen kann
und wenn ich das richtig sehe hat imnr 3 medikamente in der phase III
und weiter 14 in den verschieden anderen phasen
der link
www.recap.com
dann auf clinicals und den namen der firma eingeben
grüsse
K.
An alle die Immune Response noch nicht aufgegeben haben :
Aktuell 17,89% im Plus; damit wäre der Abwärtstrend signifikant
durchbrochen. Da muss was im Busch sein.Wenn`s so ist, hat das
Kotzen endlich ein Ende!
Aktuell 17,89% im Plus; damit wäre der Abwärtstrend signifikant
durchbrochen. Da muss was im Busch sein.Wenn`s so ist, hat das
Kotzen endlich ein Ende!
im Yahoo Board haben 2 Leute geschrieben, das im WSJ (WallStreetJournal) und in der Business Week allgemein über Aids je ein Artikel drinstand. nicht über IMNR hier der Link ==> http://messages.yahoo.com/?action=q&board=IMNR (Englisches Board) Übersetzungshilfe gibt es z.B. hier ==> 
und zwar Posting 22119 und 22118
das ist vermutlich die Erklärung für den Kurssprung
ps. es wurden nicht die Artikel ins Netz gestellt,> Quellenangabe nur falls mir keiner glaubt
übrigens, findet man dort eher erklärungen für einen Kurssprung wenn es keine News gegeben hat, weil dort einige User mehr Posten als hier
einziger Nachteil, die Sache ist halt auf Englisch
@Kipferl
die Pipeline ist in diesem Thread im allerersten Posting bzw. auf der IMNR Homepage www.imnr.com
kannst ja mal die Angaben von recap hier posten
MFG
RCZ
und zwar Posting 22119 und 22118
das ist vermutlich die Erklärung für den Kurssprung
ps. es wurden nicht die Artikel ins Netz gestellt,> Quellenangabe nur falls mir keiner glaubt
übrigens, findet man dort eher erklärungen für einen Kurssprung wenn es keine News gegeben hat, weil dort einige User mehr Posten als hier
einziger Nachteil, die Sache ist halt auf Englisch
@Kipferl
die Pipeline ist in diesem Thread im allerersten Posting bzw. auf der IMNR Homepage www.imnr.com
kannst ja mal die Angaben von recap hier posten
MFG
RCZ
@ rcz
hab die adresse gepostet damit sich jeder ein bild von imnr und gegebenenfalls auch von anderen bio´s machen kann
also ist doch nicht zuviel verlangt wenn jeder selber nachsieht
K.
hab die adresse gepostet damit sich jeder ein bild von imnr und gegebenenfalls auch von anderen bio´s machen kann
also ist doch nicht zuviel verlangt wenn jeder selber nachsieht
K.
habe den Link falsch gepostethttp://translate.lycos.com/
hier eine neue meldung auf yahoo gekommen
The Immune Response Corporation Announces Arbitration Proceedings And
Dispute Over Exclusion of Clinical Investigators and Sponsor Comments In
The Publication of Clinical Trial Data Of REMUNE(TM) (HIV-1 Immunogen)
CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it had initiated binding
arbitration proceedings in a disagreement with the University of California San Francisco (UCSF) and a member of its faculty, Dr. James Kahn. The principle basis
for the arbitration is over the public disclosure of clinical data by Dr. Kahn, which the Company believes is subject to customary confidentiality under the terms of a
Research Agreement and an Investigational Site Agreement. The Company also contests that Dr. Kahn excluded clinical investigators and sponsor comments in the
publication of clinical trial data of REMUNE(TM) (HIV-1 Immunogen) from Study 806, which ended and was reported in May 1999. The Company decided that
involvement of a third party arbitrator under the terms of a Research Agreement and an Investigational Site Agreement was a necessary measure to ensure that
confidential clinical trial data from Study 806 of REMUNE would not be published until all parties, including all of the clinical investigators, had an opportunity to
review and agree upon a manuscript to be submitted for publication.
``The Immune Response Corporation is an ardent supporter of publication of clinical trial data,`` said Ronald B. Moss, M.D., Vice President, Medical and Scientific
Affairs of The Immune Response Corporation and Assistant Clinical Professor of Medicine, University of California San Diego School of Medicine. ``The Company
has a strong commitment to publishing clinical trial data. This year alone, we have 11 articles regarding various research with REMUNE that have been either
published in or accepted by peer-reviewed scientific journals.``
As was previously announced by the Company on May 17, 1999, Study 806, a 2500-patient, placebo-controlled Phase III clinical trial of REMUNE, was
concluded based on the recommendation of an independent Data Safety Monitoring Board (DSMB). The trial was concluded because differences in clinical
endpoints were not observed between treatment groups and because extending the trial would have been unlikely to provide sufficient additional clinical endpoints to
permit statistically significant differences between treatment groups to be observed in the near term. Before the study began, the predicted clinical endpoint event rate
was 6% progression per year, meaning that 6% of 2,500 patients would progress to an AIDS defining condition or death each year. However, when the study was
stopped, only 0.73% per year progressed using the original Centers for Disease Control AIDS-defining conditions.
``What is at issue here is that while an effect of REMUNE on `clinical` endpoints was not demonstrated in Study 806, we still gained very important insight from data
concerning the effects of REMUNE on viral load (the amount of HIV in the bloodstream). This viral load information has helped us to design subsequent clinical trials
of REMUNE,`` said Dr. Moss. ``These data were presented to the other clinical trial investigators. We feel that there was a general consensus from the investigators
that these data should be presented in detail in the manuscript.``
Before Study 806 began, a substudy was planned to examine more closely the effects of REMUNE on immune responses and viral load. Data from a random,
pre-selected subset of 252 patients suggested that viral load was significantly lower (p<0.05) at multiple timepoints (Weeks 36, 48, 60, 84, 96 and 120) in
REMUNE treated patients compared to the control group. The reduction in virus correlated with the induction of cell-mediated responses (T cell help) against the
virus. Dr. Moss gave an oral presentation on these subset data at the Royal College of Physicians in London, England, on November 3, 1999 (Company press
release).
``In the subset study, we observed that patients treated with REMUNE had lower viral loads and increased T cell help compared to the placebo group. This is
important because these characteristics are typical for people with HIV that do not progress in their disease,`` said Dr. Moss. ``We had tried to come to an
agreement with Dr. Kahn to publish all the data and to let the clinical investigators have a chance to review the manuscript. However, the authors decided to submit a
manuscript to a scientific journal without input from their colleagues who participated in the study. We felt that involvement of a third party through arbitration was the
only way to ensure that all parties, including the clinical trial investigators, would have input on what would be published.``
``As the top patient-enrolling clinical investigator in Study 806, I am extremely disappointed that neither I nor the other investigators were given the opportunity to
review the manuscript of this very important clinical trial before it was submitted for publication. This omission was particularly surprising given that I have worked
with these authors on several projects in the past,`` said John L. Turner, M.D., at Graduate Hospital, Philadelphia, Pennsylvania. ``The Company has informed me
that the details of the virological substudy will not be included in the manuscript to be submitted for publication, and I find this to be an egregious omission.``
Prompt notification of the ending of Study 806 was provided to the patients and the public. The investigational sites were informed within 24 hours of the Company`s
decision to end the trial in May 1999. With this notification, the clinical trial investigators were instructed to notify the study volunteers at their respective sites and
schedule termination visits. In addition, the Company sponsored several meetings with the clinical investigators, including one at the conclusion of the trial in which
Dr. Kahn, Dr. Stephen Lagakos, Professor of Biostatistics, School of Public Health, Harvard University and the Company presented complete data for review. This
meeting was held in June 1999 and was attended by the majority of the clinical investigators or their designated representatives.
The public was informed of the results of Study 806 through wide dissemination of the Company press release dated May 17, 1999 and Company 8-Ks dated May
14 and 17, 1999 and filed with the Securities & Exchange Commission.
Before the beginning of the clinical trial, the Company entered into customary agreements with the study team, which included Dr. Kahn, as well as the other clinical
investigators. These agreements provided for confidentiality of certain clinical data. When Dr. Kahn informed the Company of his intent to publish data from Study
806 without incorporating a pre-planned substudy analysis, which other clinical investigators and the Company deemed essential for completeness, this reinforced the
Company`s decision to enter into arbitration.
At the time Study 806 began, clinical endpoints were the only measures of efficacy that were accepted by the FDA for approval of REMUNE. Since then, the FDA
now allows viral load markers for licensure of biological products such as REMUNE. A Phase III pivotal trial of REMUNE was initiated in September 1999 that is
testing endpoints based on viral load instead of progression to AIDS and death (clinical endpoints).
NOTE: The Immune Response Corporation will conduct a conference call with the investment community and other interested parties at 4:00 p.m. ET (1:00 p.m.
PT) on Wednesday, November 1, 2000. Interested parties can access this call at www.vcall.com. No access code is required to listen to the call. If you are not able
to listen to the live call, a replay at www.vcall.com will be available for 90 days following the conference call.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune
responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene
therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific
release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company
information can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not
limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year
ended December 31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these
forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
REMUNE(TM) is a trademark of The Immune Response Corporation.
SOURCE: The Immune Response Corporation
grüsse
K.
The Immune Response Corporation Announces Arbitration Proceedings And
Dispute Over Exclusion of Clinical Investigators and Sponsor Comments In
The Publication of Clinical Trial Data Of REMUNE(TM) (HIV-1 Immunogen)
CARLSBAD, Calif., Oct. 31 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it had initiated binding
arbitration proceedings in a disagreement with the University of California San Francisco (UCSF) and a member of its faculty, Dr. James Kahn. The principle basis
for the arbitration is over the public disclosure of clinical data by Dr. Kahn, which the Company believes is subject to customary confidentiality under the terms of a
Research Agreement and an Investigational Site Agreement. The Company also contests that Dr. Kahn excluded clinical investigators and sponsor comments in the
publication of clinical trial data of REMUNE(TM) (HIV-1 Immunogen) from Study 806, which ended and was reported in May 1999. The Company decided that
involvement of a third party arbitrator under the terms of a Research Agreement and an Investigational Site Agreement was a necessary measure to ensure that
confidential clinical trial data from Study 806 of REMUNE would not be published until all parties, including all of the clinical investigators, had an opportunity to
review and agree upon a manuscript to be submitted for publication.
``The Immune Response Corporation is an ardent supporter of publication of clinical trial data,`` said Ronald B. Moss, M.D., Vice President, Medical and Scientific
Affairs of The Immune Response Corporation and Assistant Clinical Professor of Medicine, University of California San Diego School of Medicine. ``The Company
has a strong commitment to publishing clinical trial data. This year alone, we have 11 articles regarding various research with REMUNE that have been either
published in or accepted by peer-reviewed scientific journals.``
As was previously announced by the Company on May 17, 1999, Study 806, a 2500-patient, placebo-controlled Phase III clinical trial of REMUNE, was
concluded based on the recommendation of an independent Data Safety Monitoring Board (DSMB). The trial was concluded because differences in clinical
endpoints were not observed between treatment groups and because extending the trial would have been unlikely to provide sufficient additional clinical endpoints to
permit statistically significant differences between treatment groups to be observed in the near term. Before the study began, the predicted clinical endpoint event rate
was 6% progression per year, meaning that 6% of 2,500 patients would progress to an AIDS defining condition or death each year. However, when the study was
stopped, only 0.73% per year progressed using the original Centers for Disease Control AIDS-defining conditions.
``What is at issue here is that while an effect of REMUNE on `clinical` endpoints was not demonstrated in Study 806, we still gained very important insight from data
concerning the effects of REMUNE on viral load (the amount of HIV in the bloodstream). This viral load information has helped us to design subsequent clinical trials
of REMUNE,`` said Dr. Moss. ``These data were presented to the other clinical trial investigators. We feel that there was a general consensus from the investigators
that these data should be presented in detail in the manuscript.``
Before Study 806 began, a substudy was planned to examine more closely the effects of REMUNE on immune responses and viral load. Data from a random,
pre-selected subset of 252 patients suggested that viral load was significantly lower (p<0.05) at multiple timepoints (Weeks 36, 48, 60, 84, 96 and 120) in
REMUNE treated patients compared to the control group. The reduction in virus correlated with the induction of cell-mediated responses (T cell help) against the
virus. Dr. Moss gave an oral presentation on these subset data at the Royal College of Physicians in London, England, on November 3, 1999 (Company press
release).
``In the subset study, we observed that patients treated with REMUNE had lower viral loads and increased T cell help compared to the placebo group. This is
important because these characteristics are typical for people with HIV that do not progress in their disease,`` said Dr. Moss. ``We had tried to come to an
agreement with Dr. Kahn to publish all the data and to let the clinical investigators have a chance to review the manuscript. However, the authors decided to submit a
manuscript to a scientific journal without input from their colleagues who participated in the study. We felt that involvement of a third party through arbitration was the
only way to ensure that all parties, including the clinical trial investigators, would have input on what would be published.``
``As the top patient-enrolling clinical investigator in Study 806, I am extremely disappointed that neither I nor the other investigators were given the opportunity to
review the manuscript of this very important clinical trial before it was submitted for publication. This omission was particularly surprising given that I have worked
with these authors on several projects in the past,`` said John L. Turner, M.D., at Graduate Hospital, Philadelphia, Pennsylvania. ``The Company has informed me
that the details of the virological substudy will not be included in the manuscript to be submitted for publication, and I find this to be an egregious omission.``
Prompt notification of the ending of Study 806 was provided to the patients and the public. The investigational sites were informed within 24 hours of the Company`s
decision to end the trial in May 1999. With this notification, the clinical trial investigators were instructed to notify the study volunteers at their respective sites and
schedule termination visits. In addition, the Company sponsored several meetings with the clinical investigators, including one at the conclusion of the trial in which
Dr. Kahn, Dr. Stephen Lagakos, Professor of Biostatistics, School of Public Health, Harvard University and the Company presented complete data for review. This
meeting was held in June 1999 and was attended by the majority of the clinical investigators or their designated representatives.
The public was informed of the results of Study 806 through wide dissemination of the Company press release dated May 17, 1999 and Company 8-Ks dated May
14 and 17, 1999 and filed with the Securities & Exchange Commission.
Before the beginning of the clinical trial, the Company entered into customary agreements with the study team, which included Dr. Kahn, as well as the other clinical
investigators. These agreements provided for confidentiality of certain clinical data. When Dr. Kahn informed the Company of his intent to publish data from Study
806 without incorporating a pre-planned substudy analysis, which other clinical investigators and the Company deemed essential for completeness, this reinforced the
Company`s decision to enter into arbitration.
At the time Study 806 began, clinical endpoints were the only measures of efficacy that were accepted by the FDA for approval of REMUNE. Since then, the FDA
now allows viral load markers for licensure of biological products such as REMUNE. A Phase III pivotal trial of REMUNE was initiated in September 1999 that is
testing endpoints based on viral load instead of progression to AIDS and death (clinical endpoints).
NOTE: The Immune Response Corporation will conduct a conference call with the investment community and other interested parties at 4:00 p.m. ET (1:00 p.m.
PT) on Wednesday, November 1, 2000. Interested parties can access this call at www.vcall.com. No access code is required to listen to the call. If you are not able
to listen to the live call, a replay at www.vcall.com will be available for 90 days following the conference call.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune
responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene
therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific
release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company
information can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not
limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year
ended December 31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these
forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
REMUNE(TM) is a trademark of The Immune Response Corporation.
SOURCE: The Immune Response Corporation
grüsse
K.
Wenn ich den Bericht richtig verstanden habe, gibt Immune Response morgen eine Stellungnahme ab.
NOTE: The Immune Response Corporation will conduct a conference call with the investment community and other interested parties at 4:00 p.m. ET (1:00 p.m.
PT) on Wednesday, November 1, 2000. Interested parties can access this call at www.vcall.com. No access code is required to listen to the call. If you are not able
to listen to the live call, a replay at www.vcall.com will be available for 90 days following the conference call.
Weiss jemand etwas näheres?
NOTE: The Immune Response Corporation will conduct a conference call with the investment community and other interested parties at 4:00 p.m. ET (1:00 p.m.
PT) on Wednesday, November 1, 2000. Interested parties can access this call at www.vcall.com. No access code is required to listen to the call. If you are not able
to listen to the live call, a replay at www.vcall.com will be available for 90 days following the conference call.
Weiss jemand etwas näheres?
Nachbörslich in US bei 4,96875 $.
Sieht nicht gut aus.
Sieht nicht gut aus.
@lanzelotte
Wie kommst Du darauf, IMNR hat mit 6 1/16 geschlossen + 2%
Wie kommst Du darauf, IMNR hat mit 6 1/16 geschlossen + 2%
Geschlossen ja. Aber im nachbörslichen Handel gabs kräftig
auf die Mütze.
Oder warum meinst Du wird in Deitschland zur Zeit nur 6,20 €
gezahlt ???
auf die Mütze.
Oder warum meinst Du wird in Deitschland zur Zeit nur 6,20 €
gezahlt ???
AIDS "vaccine" fails to boost immunity in US study
CHICAGO, Oct 31 (Reuters) - A deactivated form of the AIDS virus designed like a vaccine to boost the immune systems of HIV-infected people failed to slow the deadly disease in a trial, and the study was aborted, researchers said on Tuesday.
In earlier testing, HIV-1 Immunogen, made under the brand name Remune by Carlsbad, California-based Immune Response Corp. (NasdaqNM:IMNR - news), had shown promise by increasing the supply of immune system CD4 cells that are targeted by the virus.
But study monitors halted the study last year, several months before the scheduled end of the largest-ever trial with Remune, because the drug failed to slow the disease`s progress.
``They recommended that the study, in fact, be halted, and that the patients released from the study so they could find other ways to receive treatment,`` said study author James Kahn of the University of California at San Francisco.
HIV-1 Immunogen, a so-called therapeutic vaccine, is an inactive form of an AIDS virus stripped of its protein envelope.
The report was published in this week`s Journal of the American Medical Association.
Three-quarters of the 2,527 men participating in the study also were receiving some type of antiretroviral therapy, a cocktail of drugs proven to stave off the immune system breakdown that is the signature of AIDS.
Half the subjects received HIV-1 Immunogen, while the other half took a placebo. Over the three years of the study, 23 subjects taking the drug died, while 19 taking the harmless placebo died.
The hope of the researchers was that the drug would stimulate the immune systems of people already infected with the virus, according to the study.
``Oftentimes the immune system becomes lax in its ability to mount an effective immune response to control the virus,`` Kahn said. ``Therefore, if you were to give it small amounts of HIV proteins, you would either reawaken or restimulate the immune system, so that it`s able to mount a more effective response in controlling the person`s native viral infection.``
CHICAGO, Oct 31 (Reuters) - A deactivated form of the AIDS virus designed like a vaccine to boost the immune systems of HIV-infected people failed to slow the deadly disease in a trial, and the study was aborted, researchers said on Tuesday.
In earlier testing, HIV-1 Immunogen, made under the brand name Remune by Carlsbad, California-based Immune Response Corp. (NasdaqNM:IMNR - news), had shown promise by increasing the supply of immune system CD4 cells that are targeted by the virus.
But study monitors halted the study last year, several months before the scheduled end of the largest-ever trial with Remune, because the drug failed to slow the disease`s progress.
``They recommended that the study, in fact, be halted, and that the patients released from the study so they could find other ways to receive treatment,`` said study author James Kahn of the University of California at San Francisco.
HIV-1 Immunogen, a so-called therapeutic vaccine, is an inactive form of an AIDS virus stripped of its protein envelope.
The report was published in this week`s Journal of the American Medical Association.
Three-quarters of the 2,527 men participating in the study also were receiving some type of antiretroviral therapy, a cocktail of drugs proven to stave off the immune system breakdown that is the signature of AIDS.
Half the subjects received HIV-1 Immunogen, while the other half took a placebo. Over the three years of the study, 23 subjects taking the drug died, while 19 taking the harmless placebo died.
The hope of the researchers was that the drug would stimulate the immune systems of people already infected with the virus, according to the study.
``Oftentimes the immune system becomes lax in its ability to mount an effective immune response to control the virus,`` Kahn said. ``Therefore, if you were to give it small amounts of HIV proteins, you would either reawaken or restimulate the immune system, so that it`s able to mount a more effective response in controlling the person`s native viral infection.``
Weiß jemand was da los ist? So schlecht war die Nachricht gestern doch gar nicht.
Bin bei 12 eingestiegen und warte auf die Zulassung in Thailand, habe aber den Glauben daran verloren. Lieber jetzt raus bevor man den Gigabelleffect hat.
Was ist denn da bloß los...? IMNR auf 5,80...????
Mein Einstiegskurs war 18, im März....
@pillewurm, wir müssen wohl noch eine Weile weiterkotzen....
Mein Einstiegskurs war 18, im März....
@pillewurm, wir müssen wohl noch eine Weile weiterkotzen....
Es sieht wirklich nicht gut aus, bei L&S im Moment
für 5.09
Wer weiss was neues???
für 5.09
Wer weiss was neues???
AIDS "vaccine" fails to boost immunity in US study
CHICAGO, Oct 31 (Reuters) - A deactivated form of the AIDS virus designed like a vaccine to boost the immune systems of HIV-infected people failed to slow the deadly disease in a trial, and the study was aborted, researchers said on Tuesday.
In earlier testing, HIV-1 Immunogen, made under the brand name Remune by Carlsbad, California-based Immune Response Corp. <IMNR.O>, had shown promise by increasing the supply of immune system CD4 cells that are targeted by the virus.
But study monitors halted the study last year, several months before the scheduled end of the largest-ever trial with Remune, because the drug failed to slow the disease`s progress.
"They recommended that the study, in fact, be halted, and that the patients released from the study so they could find other ways to receive treatment," said study author James Kahn of the University of California at San Francisco.
HIV-1 Immunogen, a so-called therapeutic vaccine, is an inactive form of an AIDS virus stripped of its protein envelope.
The report was published in this week`s Journal of the American Medical Association.
Three-quarters of the 2,527 men participating in the study also were receiving some type of antiretroviral therapy, a cocktail of drugs proven to stave off the immune system breakdown that is the signature of AIDS.
Half the subjects received HIV-1 Immunogen, while the other half took a placebo. Over the three years of the study, 23 subjects taking the drug died, while 19 taking the harmless placebo died.
The hope of the researchers was that the drug would stimulate the immune systems of people already infected with the virus, according to the study.
"Oftentimes the immune system becomes lax in its ability to mount an effective immune response to control the virus," Kahn said. "Therefore, if you were to give it small amounts of HIV proteins, you would either reawaken or restimulate the immune system, so that it`s able to mount a more effective response in controlling the person`s native viral infection."
Kahn said that other promising medications may provide the needed boost to the immune system that is ultimately destroyed by AIDS.
((Chicago Newsroom, 312-408-8730, andrew.stern@reuters.com))
REUTERS
Rtr 17:48 10-31-00
CHICAGO, Oct 31 (Reuters) - A deactivated form of the AIDS virus designed like a vaccine to boost the immune systems of HIV-infected people failed to slow the deadly disease in a trial, and the study was aborted, researchers said on Tuesday.
In earlier testing, HIV-1 Immunogen, made under the brand name Remune by Carlsbad, California-based Immune Response Corp. <IMNR.O>, had shown promise by increasing the supply of immune system CD4 cells that are targeted by the virus.
But study monitors halted the study last year, several months before the scheduled end of the largest-ever trial with Remune, because the drug failed to slow the disease`s progress.
"They recommended that the study, in fact, be halted, and that the patients released from the study so they could find other ways to receive treatment," said study author James Kahn of the University of California at San Francisco.
HIV-1 Immunogen, a so-called therapeutic vaccine, is an inactive form of an AIDS virus stripped of its protein envelope.
The report was published in this week`s Journal of the American Medical Association.
Three-quarters of the 2,527 men participating in the study also were receiving some type of antiretroviral therapy, a cocktail of drugs proven to stave off the immune system breakdown that is the signature of AIDS.
Half the subjects received HIV-1 Immunogen, while the other half took a placebo. Over the three years of the study, 23 subjects taking the drug died, while 19 taking the harmless placebo died.
The hope of the researchers was that the drug would stimulate the immune systems of people already infected with the virus, according to the study.
"Oftentimes the immune system becomes lax in its ability to mount an effective immune response to control the virus," Kahn said. "Therefore, if you were to give it small amounts of HIV proteins, you would either reawaken or restimulate the immune system, so that it`s able to mount a more effective response in controlling the person`s native viral infection."
Kahn said that other promising medications may provide the needed boost to the immune system that is ultimately destroyed by AIDS.
((Chicago Newsroom, 312-408-8730, andrew.stern@reuters.com))
REUTERS
Rtr 17:48 10-31-00
Das heißt auf gut deutsch: Das Mittel wirkt in keinster Weise!
Na dann müssen wir die Kursziele neu überdenken!!??
Gruß Stone
Na dann müssen wir die Kursziele neu überdenken!!??
Gruß Stone
Hi,Stone
Vielen Dank für die kurze und schnelle Übersetzung.
Jetzt sieht meine Überlegung zwecks Nachkauf doch nicht mehr
so gut aus .
Gruss Carri
Vielen Dank für die kurze und schnelle Übersetzung.
Jetzt sieht meine Überlegung zwecks Nachkauf doch nicht mehr
so gut aus .
Gruss Carri
19 Personen die den Placebo eingenommen haben sind gestorben
23 mit dem Medikament von IMNR
wenn die Attrappe besser ist als das Medikament, dann heißt das wirklich nichts gutes.
wenn IMNR die Zulassung in Thailand bekommen sollte, dann wird dies wohl nicht der Blockbuster wie ich mir das vorgestellt habe.
und wenn doch, dann kann man immer noch kaufen, dann sind es halt nicht mehr 1000 % gewinn sondern "nur noch" 300 %
deswegen habe ich heute IMNR verkauft,
wer noch welche hat, der sollte nicht vergessen in die Kirche zu gehen und zu beten
die bessere Alternative scheint wohl zu sein, wenn man in einen Biotechfonds umschichtet.
23 mit dem Medikament von IMNR
wenn die Attrappe besser ist als das Medikament, dann heißt das wirklich nichts gutes.
wenn IMNR die Zulassung in Thailand bekommen sollte, dann wird dies wohl nicht der Blockbuster wie ich mir das vorgestellt habe.
und wenn doch, dann kann man immer noch kaufen, dann sind es halt nicht mehr 1000 % gewinn sondern "nur noch" 300 %
deswegen habe ich heute IMNR verkauft,
wer noch welche hat, der sollte nicht vergessen in die Kirche zu gehen und zu beten
die bessere Alternative scheint wohl zu sein, wenn man in einen Biotechfonds umschichtet.
Immune Response kommt nach Studie ins Wanken
Die Aktien der Immune Response Corp. verloren heute über ein drittel ihres Wertes, nach dem eine Studie ergab, dass das Hauptprodukt des Unternehmens, die HIV Impfung Remune, das Fortschreiten des Virus nicht verhindern konnte.
Die Ergebnisse, die in der Mittwochsausgabe des Journals der "American Medical Association" veröffentlichrt wurden, zeigten, dass das Medikament die Anzahl der Patienten bei denen kein Fortschreiten zu beobachten war, nicht erhöhen konnte. Die Studie wurde von Immune Response und der Universität von Kalifornien in San Francisco geleitet.
Immune Response Aktien fielen $2.06 oder über 34 Prozent, auf $4 im frühen Handel.
Die Aktien der Immune Response Corp. verloren heute über ein drittel ihres Wertes, nach dem eine Studie ergab, dass das Hauptprodukt des Unternehmens, die HIV Impfung Remune, das Fortschreiten des Virus nicht verhindern konnte.
Die Ergebnisse, die in der Mittwochsausgabe des Journals der "American Medical Association" veröffentlichrt wurden, zeigten, dass das Medikament die Anzahl der Patienten bei denen kein Fortschreiten zu beobachten war, nicht erhöhen konnte. Die Studie wurde von Immune Response und der Universität von Kalifornien in San Francisco geleitet.
Immune Response Aktien fielen $2.06 oder über 34 Prozent, auf $4 im frühen Handel.
@ community,
ich verstehe den kursverlauf von imr zur zeit nicht. erwartungsgemäss hätte sich die nachricht von gestern auch heute negativ auf den kurs auswirken müssen. stattdessen stagniert der kurs, als ob noch etwas kommen müsste.
hat jemand eine erklärung?
ich verstehe den kursverlauf von imr zur zeit nicht. erwartungsgemäss hätte sich die nachricht von gestern auch heute negativ auf den kurs auswirken müssen. stattdessen stagniert der kurs, als ob noch etwas kommen müsste.
hat jemand eine erklärung?
Wenn ich das genau interpretiere, dann ist die neg. Einschätzung von dem Herrn Kahn *Prof der Uni San Fransico*.
Der war schon immer gegen IMNR, hat aber keinen Einblick in alle Daten. Der Artikel ist auch ein älterer Artikel.
Die Pressekonferenz war erst vor kurzem. Die gibt es im Internet unter imnr.com bzw. vcall.com zu hören. Vielleicht kann einer mal der gut Englsich kann da reinhören und es übersetzen.
Irgendwie ist da doch Hoffnung da, denn sonst wären keine Kaufaufträge in BRD heuet vormittag und Mittag.
Am liebsten würde ich ja rausgehen und die 35% Verlust hinnehmen, aber die Kaufaufträge....
Aber ich denke das geht schon ein, zwei Jahre so. Aber wenn Remune wirklich nicht wirken würde, dann hätten die wohl schon vorher aufgehört zu froschen.....
Schreibt ruhig mehr zum Thema Immune Response.....
Der war schon immer gegen IMNR, hat aber keinen Einblick in alle Daten. Der Artikel ist auch ein älterer Artikel.
Die Pressekonferenz war erst vor kurzem. Die gibt es im Internet unter imnr.com bzw. vcall.com zu hören. Vielleicht kann einer mal der gut Englsich kann da reinhören und es übersetzen.
Irgendwie ist da doch Hoffnung da, denn sonst wären keine Kaufaufträge in BRD heuet vormittag und Mittag.
Am liebsten würde ich ja rausgehen und die 35% Verlust hinnehmen, aber die Kaufaufträge....
Aber ich denke das geht schon ein, zwei Jahre so. Aber wenn Remune wirklich nicht wirken würde, dann hätten die wohl schon vorher aufgehört zu froschen.....
Schreibt ruhig mehr zum Thema Immune Response.....
Sieht doch gar nicht so schlecht aus im Ami-Land (+3,38%). Weiss jemand etwas genaueres über die Veröffnetlichung von IMNR???
Hab das bei individual.com gefunden:
B] Remune study published over Immune Response objections
--------------------------------------------------------------------------------
By BridgeNews
New York--Nov. 01--A study suggesting an AIDS drug made by Immune Response Corp. doesn`t work was published Wednesday despite legal action taken by the company against a researcher.
* * *
The three-year Phase 3 trial concluded that based on clinical endpoints, patients taking Remune fared no better than those who didn`t. It was published in the Journal of the American Medical Association.
Immune Response claims the study omits key information about the drug`s effect on the amount of virus in the bloodstream, and in any event shouldn`t have been published because of a confidentiality pact.
"In the subset study, we observed that patients treated with Remune had lower viral loads and increased T cell help compared to the placebo group," the company said in a press release.
The company has initiated an arbitration proceeding against the University of California and a professor there, James O. Kahn, over disclosure of the study`s results.
"When Dr. Kahn informed the company of his intent to publish data from (the study) without incorporating a pre-planned substudy analysis, which other clinical investigators and the company deemed essential for completeness, this reinforced the company`s decision to enter into arbitration," Immune Response said.
Kahn told the Wall Street Journal: "Companies are frantic to get out positive results, but not neutral or negative results. It`s very hard to publish a study that`s either neutral or negative on a commercial product."
The company`s share price was hammered on May 19, 1999, when news of the study`s curtailment was disclosed. In September 1999, another Phase 3 trial was begun to examine Remune`s effect on viral load, the company said.
Bridge News, Tel: (212) 372-7161
Send comments to: bridge@bridge.com
Also, wenn ich das richtig deute, wurde Remune von Kahn niedergeredet, und im Wallstreet Journal veröffentlicht.
Er greift wohl auch allgemein Biotechfirmen an, weil die nur die positiven Ergebnisse von Test veröffentlichen, nicht aber neutrale oder negative.
Der umsatzstarke positive Trend heute deutet eigentlich darauf hin, dass
1. entweder Remune sowieso schlechte Chancen gegeben werden auf dem Markt zu kommen, und deswegen schon vorher eingepreisst war.
oder dass
2. die Meinung von Kahn nur ein Gerücht ist, dass mit der Zeit immer mehr ignoriert wird
Noch ein paar Gedanken:
Firmen zahlen IMNR Meilensteinzahlungen in Höhe von Mio.$.
Diese schmeissen doch das Geld nicht zum Fenster raus und müssten doch über den aktuellen Stand im Detail informiert sein.
Allerdings kam heute im Fernsehen, dass in D 1999 bis zu 9.2Mrd. DM für unnütze Medikamente ausgegeben wurden (welche, die keinen Effekt hatten)
Auch zur Statistik mit den gestorbenen 19 Placebo-Patienten und 23 Remune-Patienten muss man vorsichtig sein.
Die Patienten könnten ja auch von vornherein andere AiDS- und HIV-Entwicklungsstufen gehabt haben.
Alles in allem besteht wohl noch ein Funken Hoffnung, der mit der Thailand-Zulassung weiter genährt würde. Man kann mit den derzeitigen Infos über Remune leider nicht viel anfangen.
Da ich mit der Forschungslandschaft zu tun habe (aber anderes Gebiet), weiss ich, dass, weil IMNR eine nichtöffentliche Einrichtung ist, nicht damit gerechnet werden kann, dass die wichtigen detailierten Ergebnisse veröffentlicht werden.
Allerdings dürften Gönner ziemlich genau in bestimmten Zeiträumen informiert sein. (weiß jemand ob noch Meilensteinzahlungen erfolgen (werden)?)
Wir werden sehen.
B] Remune study published over Immune Response objections
--------------------------------------------------------------------------------
By BridgeNews
New York--Nov. 01--A study suggesting an AIDS drug made by Immune Response Corp. doesn`t work was published Wednesday despite legal action taken by the company against a researcher.
* * *
The three-year Phase 3 trial concluded that based on clinical endpoints, patients taking Remune fared no better than those who didn`t. It was published in the Journal of the American Medical Association.
Immune Response claims the study omits key information about the drug`s effect on the amount of virus in the bloodstream, and in any event shouldn`t have been published because of a confidentiality pact.
"In the subset study, we observed that patients treated with Remune had lower viral loads and increased T cell help compared to the placebo group," the company said in a press release.
The company has initiated an arbitration proceeding against the University of California and a professor there, James O. Kahn, over disclosure of the study`s results.
"When Dr. Kahn informed the company of his intent to publish data from (the study) without incorporating a pre-planned substudy analysis, which other clinical investigators and the company deemed essential for completeness, this reinforced the company`s decision to enter into arbitration," Immune Response said.
Kahn told the Wall Street Journal: "Companies are frantic to get out positive results, but not neutral or negative results. It`s very hard to publish a study that`s either neutral or negative on a commercial product."
The company`s share price was hammered on May 19, 1999, when news of the study`s curtailment was disclosed. In September 1999, another Phase 3 trial was begun to examine Remune`s effect on viral load, the company said.
Bridge News, Tel: (212) 372-7161
Send comments to: bridge@bridge.com
Also, wenn ich das richtig deute, wurde Remune von Kahn niedergeredet, und im Wallstreet Journal veröffentlicht.
Er greift wohl auch allgemein Biotechfirmen an, weil die nur die positiven Ergebnisse von Test veröffentlichen, nicht aber neutrale oder negative.
Der umsatzstarke positive Trend heute deutet eigentlich darauf hin, dass
1. entweder Remune sowieso schlechte Chancen gegeben werden auf dem Markt zu kommen, und deswegen schon vorher eingepreisst war.
oder dass
2. die Meinung von Kahn nur ein Gerücht ist, dass mit der Zeit immer mehr ignoriert wird
Noch ein paar Gedanken:
Firmen zahlen IMNR Meilensteinzahlungen in Höhe von Mio.$.
Diese schmeissen doch das Geld nicht zum Fenster raus und müssten doch über den aktuellen Stand im Detail informiert sein.
Allerdings kam heute im Fernsehen, dass in D 1999 bis zu 9.2Mrd. DM für unnütze Medikamente ausgegeben wurden (welche, die keinen Effekt hatten)
Auch zur Statistik mit den gestorbenen 19 Placebo-Patienten und 23 Remune-Patienten muss man vorsichtig sein.
Die Patienten könnten ja auch von vornherein andere AiDS- und HIV-Entwicklungsstufen gehabt haben.
Alles in allem besteht wohl noch ein Funken Hoffnung, der mit der Thailand-Zulassung weiter genährt würde. Man kann mit den derzeitigen Infos über Remune leider nicht viel anfangen.
Da ich mit der Forschungslandschaft zu tun habe (aber anderes Gebiet), weiss ich, dass, weil IMNR eine nichtöffentliche Einrichtung ist, nicht damit gerechnet werden kann, dass die wichtigen detailierten Ergebnisse veröffentlicht werden.
Allerdings dürften Gönner ziemlich genau in bestimmten Zeiträumen informiert sein. (weiß jemand ob noch Meilensteinzahlungen erfolgen (werden)?)
Wir werden sehen.
Hier noch ein Artikel, gefunden bei dowjones.work.com:
A recent JAMA study depicts the battle between IMNR and researchers who say the company tried to censor their findings suggesting that its vaccine related AIDS treatment is ineffective
(Es soll Differenzen zwischen Forschern und IMNR geben, da IMNR diese zensiert)
und:
Medical Association Study Questions Effectiveness of Immune Response`s HIV Drug
(11/1/00 5:48:11 AM PT)
Dow Jones Business News
CHICAGO -- The Journal of the American Medical Association has published articles, studies and editorials that drug companies have a growing and sometimes unseemly influence on doctors.
One JAMA study outlines the dispute between Immune Response Corp. (IMNR) and researchers who say the company tried to squelch their findings suggesting that its vaccine-like AIDS treatment is ineffective.
From freebies for medical students to research funding that can taint study results to the growing practice of marketing prescription medicine directly to consumers, JAMA said drug companies` influence is on the rise.
The JAMA study about Immune Response`s HIV-1 Immunogen, which has the brand name Remune, echoes doubts that were expressed several years ago by advisers to the Food and Drug Administration, according to the Associated Press. JAMA`s results suggest that when added to the drug regimen for HIV-infected patients, HIV-1 Immunogen failed to reduce the risk of developing full-blown AIDS.
Dr. Ronald Moss, Immune Response`s vice president of medical and scientific affairs, told the AP that the company entered a fairly common arbitration process during which it tried to produce `a more balanced manuscript.`
Instead, the researchers violated their contractual agreement and published incomplete findings, he said, adding, `It seems like tabloid journalism that JAMA would not investigate this further` before publishing.
Dr. James Kahn of the University of California at San Francisco, the study`s lead author, told the AP that Immune Response withheld important data and then tried to suppress publication.
The company denies both claims. In an arbitration complaint last month, Immune Response also demanded $7 million to $10 million from Dr. Kahn and the university, claiming dissemination of the negative findings caused it financial harm, university attorney Christopher Patti told the AP.
The JAMA study of 2,527 patients in the U.S. found that Remune boosted levels of infection-fighting white blood cells, but the authors questioned whether the effect was clinically significant.
The university contends Dr. Kahn was allowed to publish the results.
JAMA editor Dr. Catherine DeAngelis defended the journal`s decision to publish. `This study stands on its own scientific merit,` she said, according to the AP. `It was peer-reviewed as such.`
In a JAMA editorial, Dr. DeAngelis said the dispute illustrates what can happen when disagreement erupts between researchers and a funding sponsor who `has a proprietary interest in the findings.`
The relationship between research and industry appears to be under growing scrutiny, the AP said. The editor of the New England Journal of Medicine wrote an extraordinary critique in May, saying science is being compromised by the growing influence of industry money.
That same month, the Harvard Medical School said it wouldn`t ease its conflict of interest standards, considered the toughest in the nation, and Dean Joseph B. Martin called for a national dialogue on the issue.
Most experts agree that research needs industry dollars, according to the AP. The top 10 pharmaceutical companies spent nearly $23 billion on clinical research last year, compared with the nearly $18 billion provided by the National Institutes of Health, said Dr. DeAngelis.
The problem is when researchers have financial interests in companies funding their work, the AP reported. Dr. DeAngelis said such research is lower in quality and more likely to report findings favorable to the company.
Another JAMA study found that 7.6% of the faculty researchers at the University of California at San Francisco had personal financial ties to their drug-company sponsors last year. Most of the researchers had short-term speaking engagements or consulting agreements with minimal payments, the AP said.
State and federal guidelines require researchers to disclose certain financial ties, and a UCSF policy prohibits faculty involved in industry-sponsored research from receiving any compensation from the company during the study.
Elizabeth Boyd and Lisa Bero, with UCSF`s Institute for Health Policy Studies, told the AP that a campus committee `worked to accommodate all but the most overtly conflicting relationships in the interest of encouraging its faculty, and, presumably, encouraging future outside investment in the university.`
The authors of the JAMA reports suggested that financial ties may be more prevalent at other universities with less stringent policies.
A 1998-2000 study of 89 major universities found that 17% to 19% had specific limits or prohibitions on relationships with industry. While most had conflict of interest policies, they weren`t as effective because they don`t spell out what is prohibited, the authors said.
Dr. Jerome Kassirer, a former JAMA editor, told the AP that many doctors begin to feel entitled to pharmaceutical manufacturers` largesse in medical school and suggested that school administrators address the problem by refusing drug company support of any events.
Dr. Jordan Cohen, president of the Association of American Medical Colleges, announced last weekend that the group is forming a task force to investigate conflicts of interest and reach a consensus on what types of relationships with drug companies should be allowed.
Copyright (c) 2000 Dow Jones & Company, Inc.
Back to top
bin nicht besonders in Englisch, versuche mal was möglich ist:
-Behauptung: IMNR will von Kahn und der Uni 7 bis 10 Mio.$, wenn diese negative Remuneschädigende Aussagen machen. IMNR weist das zurück.
- (wichtig ist der Satz mit den 2527 Patienten, kann den jemand 100% übersetzen?) meine Variante: Remune fördert die Bekämpfung von AIDS-befallenen Zellen, Wissenschaftler sind sich aber über medizinische Bedeutung im unklaren
- Differenzen zwischen Geldgebern und Forschern: Geldgeber wollen Projekt unbedingt kommerzialisieren
- Behauptung: Ergebnisse würden so gut es geht so gedreht, wie es der Geldgeber will, da es ein nichtstaatliches Projekt ist - die Qualität der (veröffentlichten) Ergebnisse läßt zu wünschen übrig ((ist auch allgemein zu sehen)) Forscher stehen unter Erfolgsdruck wegen erhoffter Finanzierung des Projektes von Dritten und verschönen deswegen die Ergebnisse um weitere Zahlungen zu erhalten
-interessant (bitte um genaue Übersetzung):
7,6% der Forscher von der Uni Kalifornien hatten 1999 Anteile an IMNR
oder an anderen AGs???
- 17 bis 19 % der Unis sollen von Auftragsfirmen in ihren Ergebnissen zensiert werden
A recent JAMA study depicts the battle between IMNR and researchers who say the company tried to censor their findings suggesting that its vaccine related AIDS treatment is ineffective
(Es soll Differenzen zwischen Forschern und IMNR geben, da IMNR diese zensiert)
und:
Medical Association Study Questions Effectiveness of Immune Response`s HIV Drug
(11/1/00 5:48:11 AM PT)
Dow Jones Business News
CHICAGO -- The Journal of the American Medical Association has published articles, studies and editorials that drug companies have a growing and sometimes unseemly influence on doctors.
One JAMA study outlines the dispute between Immune Response Corp. (IMNR) and researchers who say the company tried to squelch their findings suggesting that its vaccine-like AIDS treatment is ineffective.
From freebies for medical students to research funding that can taint study results to the growing practice of marketing prescription medicine directly to consumers, JAMA said drug companies` influence is on the rise.
The JAMA study about Immune Response`s HIV-1 Immunogen, which has the brand name Remune, echoes doubts that were expressed several years ago by advisers to the Food and Drug Administration, according to the Associated Press. JAMA`s results suggest that when added to the drug regimen for HIV-infected patients, HIV-1 Immunogen failed to reduce the risk of developing full-blown AIDS.
Dr. Ronald Moss, Immune Response`s vice president of medical and scientific affairs, told the AP that the company entered a fairly common arbitration process during which it tried to produce `a more balanced manuscript.`
Instead, the researchers violated their contractual agreement and published incomplete findings, he said, adding, `It seems like tabloid journalism that JAMA would not investigate this further` before publishing.
Dr. James Kahn of the University of California at San Francisco, the study`s lead author, told the AP that Immune Response withheld important data and then tried to suppress publication.
The company denies both claims. In an arbitration complaint last month, Immune Response also demanded $7 million to $10 million from Dr. Kahn and the university, claiming dissemination of the negative findings caused it financial harm, university attorney Christopher Patti told the AP.
The JAMA study of 2,527 patients in the U.S. found that Remune boosted levels of infection-fighting white blood cells, but the authors questioned whether the effect was clinically significant.
The university contends Dr. Kahn was allowed to publish the results.
JAMA editor Dr. Catherine DeAngelis defended the journal`s decision to publish. `This study stands on its own scientific merit,` she said, according to the AP. `It was peer-reviewed as such.`
In a JAMA editorial, Dr. DeAngelis said the dispute illustrates what can happen when disagreement erupts between researchers and a funding sponsor who `has a proprietary interest in the findings.`
The relationship between research and industry appears to be under growing scrutiny, the AP said. The editor of the New England Journal of Medicine wrote an extraordinary critique in May, saying science is being compromised by the growing influence of industry money.
That same month, the Harvard Medical School said it wouldn`t ease its conflict of interest standards, considered the toughest in the nation, and Dean Joseph B. Martin called for a national dialogue on the issue.
Most experts agree that research needs industry dollars, according to the AP. The top 10 pharmaceutical companies spent nearly $23 billion on clinical research last year, compared with the nearly $18 billion provided by the National Institutes of Health, said Dr. DeAngelis.
The problem is when researchers have financial interests in companies funding their work, the AP reported. Dr. DeAngelis said such research is lower in quality and more likely to report findings favorable to the company.
Another JAMA study found that 7.6% of the faculty researchers at the University of California at San Francisco had personal financial ties to their drug-company sponsors last year. Most of the researchers had short-term speaking engagements or consulting agreements with minimal payments, the AP said.
State and federal guidelines require researchers to disclose certain financial ties, and a UCSF policy prohibits faculty involved in industry-sponsored research from receiving any compensation from the company during the study.
Elizabeth Boyd and Lisa Bero, with UCSF`s Institute for Health Policy Studies, told the AP that a campus committee `worked to accommodate all but the most overtly conflicting relationships in the interest of encouraging its faculty, and, presumably, encouraging future outside investment in the university.`
The authors of the JAMA reports suggested that financial ties may be more prevalent at other universities with less stringent policies.
A 1998-2000 study of 89 major universities found that 17% to 19% had specific limits or prohibitions on relationships with industry. While most had conflict of interest policies, they weren`t as effective because they don`t spell out what is prohibited, the authors said.
Dr. Jerome Kassirer, a former JAMA editor, told the AP that many doctors begin to feel entitled to pharmaceutical manufacturers` largesse in medical school and suggested that school administrators address the problem by refusing drug company support of any events.
Dr. Jordan Cohen, president of the Association of American Medical Colleges, announced last weekend that the group is forming a task force to investigate conflicts of interest and reach a consensus on what types of relationships with drug companies should be allowed.
Copyright (c) 2000 Dow Jones & Company, Inc.
Back to top
bin nicht besonders in Englisch, versuche mal was möglich ist:
-Behauptung: IMNR will von Kahn und der Uni 7 bis 10 Mio.$, wenn diese negative Remuneschädigende Aussagen machen. IMNR weist das zurück.
- (wichtig ist der Satz mit den 2527 Patienten, kann den jemand 100% übersetzen?) meine Variante: Remune fördert die Bekämpfung von AIDS-befallenen Zellen, Wissenschaftler sind sich aber über medizinische Bedeutung im unklaren
- Differenzen zwischen Geldgebern und Forschern: Geldgeber wollen Projekt unbedingt kommerzialisieren
- Behauptung: Ergebnisse würden so gut es geht so gedreht, wie es der Geldgeber will, da es ein nichtstaatliches Projekt ist - die Qualität der (veröffentlichten) Ergebnisse läßt zu wünschen übrig ((ist auch allgemein zu sehen)) Forscher stehen unter Erfolgsdruck wegen erhoffter Finanzierung des Projektes von Dritten und verschönen deswegen die Ergebnisse um weitere Zahlungen zu erhalten
-interessant (bitte um genaue Übersetzung):
7,6% der Forscher von der Uni Kalifornien hatten 1999 Anteile an IMNR
oder an anderen AGs???
- 17 bis 19 % der Unis sollen von Auftragsfirmen in ihren Ergebnissen zensiert werden
Littlelock: danke für Deinen Kommetar. So deute ich das auch....Aber leider ist mein Englisch nicht so gut.....
Ich denke so geht das aber schon 2,3 Jahre mit IMNR.
Für diei Aktie *und für uns* ist das aber nicht gut.
Aber Forschung dauert und eine Kleinigkeit genmäßig, kann aus einem wirkungslosen Präparat ein Blockbuster machen. Was mich positiv an der Aktie stimmt, ist daß der Prof. von ich glaube Abbot Laboratieries, die Remune unterstützen, jetzt die Forschung bei IMNR übernommen hat.
Das ist ein sehr gutes Zeichen. Schlecht ist halt der Kahn *bezeichnender Name*
Ich hatte noch nie so einen Zwiespalt für eine Aktie wie für diese......
Wait and see.
Ich denke so geht das aber schon 2,3 Jahre mit IMNR.
Für diei Aktie *und für uns* ist das aber nicht gut.
Aber Forschung dauert und eine Kleinigkeit genmäßig, kann aus einem wirkungslosen Präparat ein Blockbuster machen. Was mich positiv an der Aktie stimmt, ist daß der Prof. von ich glaube Abbot Laboratieries, die Remune unterstützen, jetzt die Forschung bei IMNR übernommen hat.
Das ist ein sehr gutes Zeichen. Schlecht ist halt der Kahn *bezeichnender Name*
Ich hatte noch nie so einen Zwiespalt für eine Aktie wie für diese......
Wait and see.
Habe ich es doch gewußt, siehe mein Kommentar vom 30.09.00 Alle bisherigen Meldungen kamen von IMNR selber um den Kurs zu pushen, und hier bei hohen Schwankungen abzusahnen. Den müßte der Prozeß gemacht werden wegen falscher Adhoc Meldungen. Mir kann doch keiner erzählen daß nur einer von den Bossen der IMNR an die Zulassung in Thailand geglaubt hat. Die sind satt und der Kleinanleger hat das Nachsehen.Was lernen wir daraus? Lass die Finger von solch künstlichen hochgezüchtigten Aktien. Den nächsten Knall gibts bei Antisoma, die kannste dann für 0´5 Euro einsammeln.
Hallo,
ich weiß nicht, ob das hier schon einer reingeschrieben hat:
Global Biotech Invest meint, daß der starke Kurssturz vor ein Paar Tagen nicht gerechtfertigt war. Da gab es nämlich eine Meldung, daß ein AIDS-Impfstoff keine Wirkung hat. Diese Meldung ist laut GBI aber schon Jahre alt und hat nichts mit derzeitigen Studien oder Entwicklungen zu tun. Immune Response will das Blatt, das den Bericht veröffentlicht hat (er war auch damals vor ein Paar Jahren schon veröffentlicht) auf ein Paar Mill. Schadenersatz wg. Rufschädigung verklagen.
Gruß,
ricox
ich weiß nicht, ob das hier schon einer reingeschrieben hat:
Global Biotech Invest meint, daß der starke Kurssturz vor ein Paar Tagen nicht gerechtfertigt war. Da gab es nämlich eine Meldung, daß ein AIDS-Impfstoff keine Wirkung hat. Diese Meldung ist laut GBI aber schon Jahre alt und hat nichts mit derzeitigen Studien oder Entwicklungen zu tun. Immune Response will das Blatt, das den Bericht veröffentlicht hat (er war auch damals vor ein Paar Jahren schon veröffentlicht) auf ein Paar Mill. Schadenersatz wg. Rufschädigung verklagen.
Gruß,
ricox
@ricox
stimmt, die kurssturzauslösende Nachricht beruht auf eine fehlgeschlagene Remune-Studie von Mai 1999. Ist also Schnee von gestern.
stimmt, die kurssturzauslösende Nachricht beruht auf eine fehlgeschlagene Remune-Studie von Mai 1999. Ist also Schnee von gestern.
Kann keiner mal *der gut Englisch versteht* bei imnr.com bzw. vcall.com in die Presseerklärung reinhören ?
hallo zusammen
klingt doch gar nicht so schlecht
also wenn wir kein englisch können dann können es die amis doch auch nicht wenn die meldung schon 1 jahr
alt sein soll und die meldung keine relevants hat
außerdem warum sollte imnr ein paar tage zuvor ein abkommen über die vermarktung von remmune abschliessen
wenn sie schon wissen das ihr medikament dreck ist
also ich denke außer warten wird uns wohl nichts anderes übrig bleiben und wir werden hoffentlich bald positiv
überrascht werden mit einer guten meldung aus thailand
grüsse
K.
klingt doch gar nicht so schlecht
also wenn wir kein englisch können dann können es die amis doch auch nicht wenn die meldung schon 1 jahr
alt sein soll und die meldung keine relevants hat
außerdem warum sollte imnr ein paar tage zuvor ein abkommen über die vermarktung von remmune abschliessen
wenn sie schon wissen das ihr medikament dreck ist
also ich denke außer warten wird uns wohl nichts anderes übrig bleiben und wir werden hoffentlich bald positiv
überrascht werden mit einer guten meldung aus thailand
grüsse
K.
Hi ,
Ich denke auch, in diesem harten Fall von IMNR. hilft nur noch abwarten. Die kurzfristigen positiven Meldungen sind zwar schön, aber gehen nur an die Substanz.
Also Ruhe bewahren und geduldig Lauern !!!
Ich denke auch, in diesem harten Fall von IMNR. hilft nur noch abwarten. Die kurzfristigen positiven Meldungen sind zwar schön, aber gehen nur an die Substanz.
Also Ruhe bewahren und geduldig Lauern !!!
Im Yahoo-Board wird derzeit geschrieben, dass Remune eine stagnierende Wirkung auf die Virus Last hat, und dass zur Zeit Versuche mit anderen Medikamenten durchgeführt werden, die angeblich schon äußerst positive Ergebnisse gebracht haben.
Außerdem sollen, wahrscheinlich wegen den schlechten Pressemeldungen, noch diesen Monat aktuelle Ergebnisse aus dem Spanienversuch veröffentlicht werden.
Die Meinung im Yahoo-Board ist nach wie vor geteilt. Beschwert wird sich hauptsächlich über die schlechte PR-Arbeit.
In einiger Zeit wissen wir woran wir sind.
Außerdem sollen, wahrscheinlich wegen den schlechten Pressemeldungen, noch diesen Monat aktuelle Ergebnisse aus dem Spanienversuch veröffentlicht werden.
Die Meinung im Yahoo-Board ist nach wie vor geteilt. Beschwert wird sich hauptsächlich über die schlechte PR-Arbeit.
In einiger Zeit wissen wir woran wir sind.
Habe noch einen dicken Batzen für über 10 Euro. Die sollen wirklich mal eine bessere PR betreiben. Glaube aber nicht mehr an die Zulassung in Thailand. Und wenn doch, wie reagiert der Kurs? Mehr als 10 Euro werden wir auch dann nicht sehen.
Hier die Zahlen vom 3. Quartal:
The Immune Response Corporation Announces Third Quarter 2000 Financial Results
PR Newswire
CARLSBAD, Calif., Nov 13, 2000 /PRNewswire via COMTEX/ -- The Immune Response
Corporation (Nasdaq: IMNR) today announced its financial results for the quarter
ended September 30, 2000. The net loss for the third quarter of 2000 was $6.4
million, or $0.22 per share, compared to a net loss of $5.1 million, or a loss
of $0.21 per share, reported in the third quarter of 1999. For the nine months
ended September 30, 2000, the Company reported a net loss of $12.1 million, or
$0.44 per share, compared to a net loss of $13.6 million, or $0.56 per share
reported for the nine months ended September 30, 1999.
Research related revenue for the quarter ended September 30, 2000 was $108,000
compared to $3.8 million for the same quarter in 1999. For the nine months ended
September 30, 2000 and 1999, revenues were $3.8 million and $16.9 million,
respectively, of which $3.7 million in 2000 and $15.2 million in 1999 were from
Agouron Pharmaceuticals, Inc. ("Agouron"), a wholly-owned subsidiary of Pfizer
Inc. The decrease in research related revenue was primarily attributed to a $5.0
million milestone payment and three quarterly payments of $3.0 million from
Agouron in 1999 versus the final quarterly payment of $3.0 million in the first
quarter of 2000.
In addition to research related revenue, the Company received non-research
revenue from investment and other income of $4.1 million for the nine months
ended September 30, 2000 versus $1.0 million for the same period in 1999. During
the nine months ended September 30, 2000, $3.2 million of other revenue was
primarily due to sales of an equity security that was acquired through the
licensing of technology and from the sale of undeveloped property.
Operating expenses for the three and nine months ended September 30, 2000 of
$6.9 million and $19.2 million, respectively, decreased from $9.0 million and
$30.8 million during the same periods in 1999. The decrease in operating
expenses was primarily the result of a decrease in clinical and regulatory
expenses.
Cash, cash equivalents and short-term investments were $35.4 million at
September 30, 2000 compared with $23.1 million at the end of 1999. In August
2000, the Company completed a public offering of 2,760,000 shares of its common
stock at a price of $6.00 per share through First Security Van Kasper and
Gruntal & Co., L.L.C.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases, and cancer. In
addition, the Company is developing a targeted non-viral delivery technology for
gene therapy, which is designed to enable the delivery of genes directly to the
liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On- Call fax
service. For a menu of available news releases or to retrieve a specific release
made by The Immune Response Corporation, please call 800-758-5804, extension
434675. Please retain these numbers for future reference. Company information
can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary
materially from those expected due to a variety of risk factors, including the
uncertainty of successful completion of clinical trials, and those risks set
forth from time to time in The Immune Response Corporation`s SEC filings,
including but not limited to its report on Form 10-K for the year ended December
31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to
publicly release the result of any revisions to these forward-looking
statements, which may be made to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SELECTED FINANCIAL DATA ATTACHED
The Immune Response Corporation
Condensed Consolidated Statements of Operations
(Amount in thousands, except share data)
(unaudited)
Three months ended Nine months ended
September 30, September 30,
2000 1999 2000 1999
Research revenue $108 $3,827 $3,753 $16,927
Expenses:
Research and
development 5,649 7,692 15,841 26,129
General and
administrative 1,207 1,288 3,361 4,023
Restructuring costs -- -- -- 650
6,856 8,980 19,202 30,802
Other revenue:
Investment income 611 304 3,400 1,007
Other income -- -- 736 --
Net loss (6,137) (4,849) (11,313) (12,868)
Accretion of preferred
stock (70) (70) (210) (210)
Dividends on preferred
stock (188) (189) (561) (561)
Net loss applicable to
common stockholders $(6,395) $(5,108) $(12,084) $(13,639)
Net loss per share -
basic and diluted $(0.22) $(0.21) $(0.44) $(0.56)
Weighted average number
of shares
outstanding 28,912,001 24,852,510 27,734,937 24,502,843
The Immune Response Corporation
Condensed Consolidated Balance Sheets
(Dollars in thousands)
September 30, December 31,
2000 1999
(unaudited)
Assets
Cash, cash equivalents and short-term
investments $35,352 $23,087
Other current assets 422 202
35,774 23,289
Property and equipment, net 8,908 10,760
Licensed technology 4,415 4,945
Other assets 847 1,003
Total assets $49,944 $39,997
Liabilities and stockholders` equity
Current liabilities $3,933 $8,603
Long-term deferred revenue 138 --
Equipment notes payable 1,988 1,221
Redeemable convertible preferred stock 9,837 9,627
Stockholders` equity 34,048 20,546
Total liabilities and stockholders` equity $49,944 $39,997
SOURCE The Immune Response Corporation
CONTACT: Howard Sampson, Vice President, Finance, Chief Financial
Officer and Treasurer of The Immune Response Corporation, 760-431-7080
/Company News On-Call: http://www.prnewswire.com/comp/434675.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/434675.html or fax,
800-758-5804, ext. 434675
URL: http://www.imnr.com
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: California
INDUSTRY KEYWORD: MTC
HEA
SUBJECT CODE: ERN
The Immune Response Corporation Announces Third Quarter 2000 Financial Results
PR Newswire
CARLSBAD, Calif., Nov 13, 2000 /PRNewswire via COMTEX/ -- The Immune Response
Corporation (Nasdaq: IMNR) today announced its financial results for the quarter
ended September 30, 2000. The net loss for the third quarter of 2000 was $6.4
million, or $0.22 per share, compared to a net loss of $5.1 million, or a loss
of $0.21 per share, reported in the third quarter of 1999. For the nine months
ended September 30, 2000, the Company reported a net loss of $12.1 million, or
$0.44 per share, compared to a net loss of $13.6 million, or $0.56 per share
reported for the nine months ended September 30, 1999.
Research related revenue for the quarter ended September 30, 2000 was $108,000
compared to $3.8 million for the same quarter in 1999. For the nine months ended
September 30, 2000 and 1999, revenues were $3.8 million and $16.9 million,
respectively, of which $3.7 million in 2000 and $15.2 million in 1999 were from
Agouron Pharmaceuticals, Inc. ("Agouron"), a wholly-owned subsidiary of Pfizer
Inc. The decrease in research related revenue was primarily attributed to a $5.0
million milestone payment and three quarterly payments of $3.0 million from
Agouron in 1999 versus the final quarterly payment of $3.0 million in the first
quarter of 2000.
In addition to research related revenue, the Company received non-research
revenue from investment and other income of $4.1 million for the nine months
ended September 30, 2000 versus $1.0 million for the same period in 1999. During
the nine months ended September 30, 2000, $3.2 million of other revenue was
primarily due to sales of an equity security that was acquired through the
licensing of technology and from the sale of undeveloped property.
Operating expenses for the three and nine months ended September 30, 2000 of
$6.9 million and $19.2 million, respectively, decreased from $9.0 million and
$30.8 million during the same periods in 1999. The decrease in operating
expenses was primarily the result of a decrease in clinical and regulatory
expenses.
Cash, cash equivalents and short-term investments were $35.4 million at
September 30, 2000 compared with $23.1 million at the end of 1999. In August
2000, the Company completed a public offering of 2,760,000 shares of its common
stock at a price of $6.00 per share through First Security Van Kasper and
Gruntal & Co., L.L.C.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases, and cancer. In
addition, the Company is developing a targeted non-viral delivery technology for
gene therapy, which is designed to enable the delivery of genes directly to the
liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On- Call fax
service. For a menu of available news releases or to retrieve a specific release
made by The Immune Response Corporation, please call 800-758-5804, extension
434675. Please retain these numbers for future reference. Company information
can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary
materially from those expected due to a variety of risk factors, including the
uncertainty of successful completion of clinical trials, and those risks set
forth from time to time in The Immune Response Corporation`s SEC filings,
including but not limited to its report on Form 10-K for the year ended December
31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to
publicly release the result of any revisions to these forward-looking
statements, which may be made to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SELECTED FINANCIAL DATA ATTACHED
The Immune Response Corporation
Condensed Consolidated Statements of Operations
(Amount in thousands, except share data)
(unaudited)
Three months ended Nine months ended
September 30, September 30,
2000 1999 2000 1999
Research revenue $108 $3,827 $3,753 $16,927
Expenses:
Research and
development 5,649 7,692 15,841 26,129
General and
administrative 1,207 1,288 3,361 4,023
Restructuring costs -- -- -- 650
6,856 8,980 19,202 30,802
Other revenue:
Investment income 611 304 3,400 1,007
Other income -- -- 736 --
Net loss (6,137) (4,849) (11,313) (12,868)
Accretion of preferred
stock (70) (70) (210) (210)
Dividends on preferred
stock (188) (189) (561) (561)
Net loss applicable to
common stockholders $(6,395) $(5,108) $(12,084) $(13,639)
Net loss per share -
basic and diluted $(0.22) $(0.21) $(0.44) $(0.56)
Weighted average number
of shares
outstanding 28,912,001 24,852,510 27,734,937 24,502,843
The Immune Response Corporation
Condensed Consolidated Balance Sheets
(Dollars in thousands)
September 30, December 31,
2000 1999
(unaudited)
Assets
Cash, cash equivalents and short-term
investments $35,352 $23,087
Other current assets 422 202
35,774 23,289
Property and equipment, net 8,908 10,760
Licensed technology 4,415 4,945
Other assets 847 1,003
Total assets $49,944 $39,997
Liabilities and stockholders` equity
Current liabilities $3,933 $8,603
Long-term deferred revenue 138 --
Equipment notes payable 1,988 1,221
Redeemable convertible preferred stock 9,837 9,627
Stockholders` equity 34,048 20,546
Total liabilities and stockholders` equity $49,944 $39,997
SOURCE The Immune Response Corporation
CONTACT: Howard Sampson, Vice President, Finance, Chief Financial
Officer and Treasurer of The Immune Response Corporation, 760-431-7080
/Company News On-Call: http://www.prnewswire.com/comp/434675.html" target="_blank" rel="nofollow ugc noopener">http://www.prnewswire.com/comp/434675.html or fax,
800-758-5804, ext. 434675
URL: http://www.imnr.com
http://www.prnewswire.com
(C) 2000 PR Newswire. All rights reserved.
-0-
KEYWORD: California
INDUSTRY KEYWORD: MTC
HEA
SUBJECT CODE: ERN
Ich hab hier eine Seite die ich auch oft benutze (gerade bei IMNR)
Das ist eine Übersetzungsseite. Schaut sie euch einfach mal an.
http://translator.go.com/cb/trans_entry?lo=ge&
Vom Computer erstellte Übersetzungen sind Annäherungen an den Ausgangstext. Sie
sind nicht als genaue Übersetzung zu verstehen.
Das ist eine Übersetzungsseite. Schaut sie euch einfach mal an.
http://translator.go.com/cb/trans_entry?lo=ge&
Vom Computer erstellte Übersetzungen sind Annäherungen an den Ausgangstext. Sie
sind nicht als genaue Übersetzung zu verstehen.
Im Focus, Nr. 46, v.13.11.00 ist ein Bericht über IMNR enthalten. Zusammengefaßt geht es darum, daß nach Meinung von James Kahn die Testsubstanz keinerlei Wirkung zeige (veröffentlichte eine Studie in der Fachzeitschrift JAMA). IMNR fordert nun Schadensersatz, da unvollständige und falsch interpretierte Daten veröffentlicht wurden. Diese Projekt ist das umfangreichste der HIV Forschung der 90er Jahre.
Sundrade:Immune Response - fallen angel
Eine sehr einseitige Studie brachte den Wert ins Trudeln...
Immune Response ist ein Biotechunternehmen, das schwerpunktmäßig Immuntherapien entwickelt, die spezielle T-Zellen induzieren, um Krankheiten wie HIV, Autoimmunerkrankungen und entgegenzuwirken.
Das Unternehmen besitzt eine sehr aussichtsreich Produktpipeline, die insbesondere im Kampf gegen den Aids-Virus große Fortschritte gemacht hat. Für Furore konnte man am 23.3. diesen Jahres sorgen, als bekannt wurde, daß das Hauptprodukt Remune in Thailand erfolgreich getestet wurde. Über einen Zeitraum von 40 Wochen erprobte man das Medikament bei 297 HIV-Patienten auch in Verbindung mit den notwendigen Placeboverabreichungen. Die Zahl der CD4-T-Helferzellen war bei den mit Remune behandelten Patienten im Endeffekt wesentlich höher, wodurch eine Immunität gegen Aids immer größer wird. Beim Verlauf der Krankheit werden diese Zellen vollendes zerstört vom Virus, so daß es auf diesem Wege zum Versagen des gesamten Immunsystems kommt und der Patient auf diesem Wege stirbt. Diese Ergebnisse wurden sowohl in Bangkik als auch auf der Bio2000 in Boston präsentiert und konnten eine Vielzahl von interessierten Investoren auf das Unternehmen aufmerksam machen. Die Phase III ist beendet, die Freigabe seitens der Behörden genehmigt, das Medikament in seiner Beschaffenheit einzigartig auf dem Markt, nun beginnt die kommerzielle Vermarktungsphase seitens des Unternehmens. Mit diesem Medikament kann Immune der Durchbruch gelingen und zum Blockbuster in der Welt avancieren.
Autoimmunerkrankungen stellen immer noch eine recht unbekannte Art von Erkrankungen dar. Hier nutzt das Unternehmen seine Erfahrungen und versucht mit seinen Techniken T-Zellen so zu stimulieren, daß sie diese Art der Krankheit nicht auslösen können. Die Behandlung zur Bekämpfung von Arthritis und Schuppenflechte befinden in klinischen Tests. Auch wird momentan eine Therapie zur Bekämpfung multipler Sklerose entwickelt. Desweiteren entwickelt das Unternehmen Methoden zur Reproduktion beschädigter Gene, insbesondere Hepatitis wird hier zunehmends bekämpft. Im Bereich der Krebsbekämpfung entwickelt das Unternehmen Möglichkeiten, Krebszellen erkennen zu können und auf diesem Wege eine Ausbreitung verhindern zu können.
Konkurrenten von Immune Response sind derzeit u.a. Abgenix, Amgen und Genentech.
Die Marktkapitalisierung des Wertes ist mit 113 Mio. US$ als sehr gering zu erachten, jedoch befinden sich momentan noch knapp 21% der ausstehenden Aktien im Besitz von Shortsellern sind.
Momentan steht der Wert bei 4,125 US$, was als äußerst gering zu erachten ist. Noch ist der Abwärtstrend intakt, der Wert scheint einen Doppelboden bei 3 US$ bilden zu wollen in den kommenden Handelstagen, was einem klaren Kauf gleichkommt. Mittelfristig sind Kurse im Bereich von 15 US$ möglich sein, sofern die Zulassungsbehörden entsprechend mitspielen.
Momentan gibt es Unstimmigkeiten bei Immune, die den Wert auch am 1.11. knapp 25% seines Wertes verlieren ließen. Eine Studie gab bekannt, daß Remune angeblich keine längere Überlebensdauer von Patienten bedeuten würde. Diese Studie wurde nicht nur von seitens Immune sondern auch von University of California finanziert. Nun droht der Universität ein Gerichtsverfahren seitens Immune`s, auf Grund der nicht zugestimmten Freigabe der angeblichen Ergebnisse. Auch sollen laut Immune angeblich positive Daten der Studie nicht veröffentlicht worden sein.
Das Unternehmen ist m.E. ein interessantes, vielversprechendes und zu stark verprügeltes Investment, sollten die einzelnen Länder alle eine Genehmigung des Medikamentes Remune vollziehen. Sowohl der technologische als auch der zeitliche Vorsprung sprechen klar für ein Invest, gegen ein Invest spricht die momentan unklare Studie und das schwebende Gerichtsverfahren gegen die Universität.
Diese Analyse wurde verfasst von Michel LeRoi (Paraglider) am: 11.11.2000
Eine sehr einseitige Studie brachte den Wert ins Trudeln...
Immune Response ist ein Biotechunternehmen, das schwerpunktmäßig Immuntherapien entwickelt, die spezielle T-Zellen induzieren, um Krankheiten wie HIV, Autoimmunerkrankungen und entgegenzuwirken.
Das Unternehmen besitzt eine sehr aussichtsreich Produktpipeline, die insbesondere im Kampf gegen den Aids-Virus große Fortschritte gemacht hat. Für Furore konnte man am 23.3. diesen Jahres sorgen, als bekannt wurde, daß das Hauptprodukt Remune in Thailand erfolgreich getestet wurde. Über einen Zeitraum von 40 Wochen erprobte man das Medikament bei 297 HIV-Patienten auch in Verbindung mit den notwendigen Placeboverabreichungen. Die Zahl der CD4-T-Helferzellen war bei den mit Remune behandelten Patienten im Endeffekt wesentlich höher, wodurch eine Immunität gegen Aids immer größer wird. Beim Verlauf der Krankheit werden diese Zellen vollendes zerstört vom Virus, so daß es auf diesem Wege zum Versagen des gesamten Immunsystems kommt und der Patient auf diesem Wege stirbt. Diese Ergebnisse wurden sowohl in Bangkik als auch auf der Bio2000 in Boston präsentiert und konnten eine Vielzahl von interessierten Investoren auf das Unternehmen aufmerksam machen. Die Phase III ist beendet, die Freigabe seitens der Behörden genehmigt, das Medikament in seiner Beschaffenheit einzigartig auf dem Markt, nun beginnt die kommerzielle Vermarktungsphase seitens des Unternehmens. Mit diesem Medikament kann Immune der Durchbruch gelingen und zum Blockbuster in der Welt avancieren.
Autoimmunerkrankungen stellen immer noch eine recht unbekannte Art von Erkrankungen dar. Hier nutzt das Unternehmen seine Erfahrungen und versucht mit seinen Techniken T-Zellen so zu stimulieren, daß sie diese Art der Krankheit nicht auslösen können. Die Behandlung zur Bekämpfung von Arthritis und Schuppenflechte befinden in klinischen Tests. Auch wird momentan eine Therapie zur Bekämpfung multipler Sklerose entwickelt. Desweiteren entwickelt das Unternehmen Methoden zur Reproduktion beschädigter Gene, insbesondere Hepatitis wird hier zunehmends bekämpft. Im Bereich der Krebsbekämpfung entwickelt das Unternehmen Möglichkeiten, Krebszellen erkennen zu können und auf diesem Wege eine Ausbreitung verhindern zu können.
Konkurrenten von Immune Response sind derzeit u.a. Abgenix, Amgen und Genentech.
Die Marktkapitalisierung des Wertes ist mit 113 Mio. US$ als sehr gering zu erachten, jedoch befinden sich momentan noch knapp 21% der ausstehenden Aktien im Besitz von Shortsellern sind.
Momentan steht der Wert bei 4,125 US$, was als äußerst gering zu erachten ist. Noch ist der Abwärtstrend intakt, der Wert scheint einen Doppelboden bei 3 US$ bilden zu wollen in den kommenden Handelstagen, was einem klaren Kauf gleichkommt. Mittelfristig sind Kurse im Bereich von 15 US$ möglich sein, sofern die Zulassungsbehörden entsprechend mitspielen.
Momentan gibt es Unstimmigkeiten bei Immune, die den Wert auch am 1.11. knapp 25% seines Wertes verlieren ließen. Eine Studie gab bekannt, daß Remune angeblich keine längere Überlebensdauer von Patienten bedeuten würde. Diese Studie wurde nicht nur von seitens Immune sondern auch von University of California finanziert. Nun droht der Universität ein Gerichtsverfahren seitens Immune`s, auf Grund der nicht zugestimmten Freigabe der angeblichen Ergebnisse. Auch sollen laut Immune angeblich positive Daten der Studie nicht veröffentlicht worden sein.
Das Unternehmen ist m.E. ein interessantes, vielversprechendes und zu stark verprügeltes Investment, sollten die einzelnen Länder alle eine Genehmigung des Medikamentes Remune vollziehen. Sowohl der technologische als auch der zeitliche Vorsprung sprechen klar für ein Invest, gegen ein Invest spricht die momentan unklare Studie und das schwebende Gerichtsverfahren gegen die Universität.
Diese Analyse wurde verfasst von Michel LeRoi (Paraglider) am: 11.11.2000
Hier etwas mehr Unternehmensinformationen zum Thailandprojekt:
Euer
TTT
Trinity Medical Group USA Announces Public Availability of REMUNE(TM) Treatment in Thailand
SAN RAFAEL, Calif., Nov. 15 /PRNewswire/ -- The first open label availability in Southeast Asia of Immune Based Therapy (IBT) for humans infected with HIV has been approved by the government of Thailand. Up to 10,000 individuals in this program may receive treatment with REMUNE provided they have certain levels of immune system cells (CD4+) and viral loads. Each patient will be analyzed before and during the course of treatment according to a Thai government accepted scientific program known as M903. The open ended program has the potential to gather the most extensive body of data available on the effect of REMUNE used as the only anti-viral therapy and used in combination with other drugs. The ultimate goal of the program is to identify the most beneficial and cost-effective regimen of REMUNE as a treatment for HIV.
Results of this program are not required by the Thai FDA in their consideration of REMUNE for full commercialization and are independent of the Protocol 2101B announced by the Company on November 13, 2000.
"From our previous work, we have seen indications that successful treatment of HIV using REMUNE requires tailoring the course of treatment to the patient`s immune system status. While a great many patients respond to the standard treatment dose of REMUNE alone (1 ml. injection once per quarter), others may require additional doses of REMUNE or fortification with other drugs and treatments. We requested, and were granted approval, to have the ability to study the first wave of general public patients in a precise way for the benefit of future recipients of REMUNE," says Dr. Vina Churdboonchart, the Principal Investigator of this program. "We expect the program will be enrolled very quickly."
REMUNE is the leading IBT product in human clinical studies around the world for the treatment of HIV. IBT relies upon the infected individual`s own immune system to ward off progression of the disease as opposed to conventional drug therapy which may have adverse side effects and may become less effective due to viral mutation. REMUNE is a result of the scientific collaboration between the late Dr. Jonas Salk, the renowned creator of the world`s first Polio vaccine, and The Immune Response Corporation which licenses and manufactures REMUNE.
The program was approved by two national committees of the Thai government, The Technical Subcommittee on AIDS Vaccine Development and the National Ethical Committee, Ministry of Public Health.
The program will be coordinated through Mahidol University of Bangkok in cooperation with several other University and government operated hospitals. REMUNE will be exclusively manufactured for the Company by The Immune Response Corporation. Trinity Medical Group USA, Inc., the licensee of REMUNE in Thailand and nine other Southeast Asian Countries, will be the supplier of REMUNE to Mahidol University.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
For more information on the Company, visit the web site at http://www.trinitymg.com. Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is listed on the National Quotation Services Pink Sheets under the symbol TMGU. The Company`s first product in development is an Immune Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further testing in Thailand.
REMUNE is a trademark of The Immune Response Corporation, a Carlsbad California company (Nasdaq: IMNR.)
Euer
TTT
Trinity Medical Group USA Announces Public Availability of REMUNE(TM) Treatment in Thailand
SAN RAFAEL, Calif., Nov. 15 /PRNewswire/ -- The first open label availability in Southeast Asia of Immune Based Therapy (IBT) for humans infected with HIV has been approved by the government of Thailand. Up to 10,000 individuals in this program may receive treatment with REMUNE provided they have certain levels of immune system cells (CD4+) and viral loads. Each patient will be analyzed before and during the course of treatment according to a Thai government accepted scientific program known as M903. The open ended program has the potential to gather the most extensive body of data available on the effect of REMUNE used as the only anti-viral therapy and used in combination with other drugs. The ultimate goal of the program is to identify the most beneficial and cost-effective regimen of REMUNE as a treatment for HIV.
Results of this program are not required by the Thai FDA in their consideration of REMUNE for full commercialization and are independent of the Protocol 2101B announced by the Company on November 13, 2000.
"From our previous work, we have seen indications that successful treatment of HIV using REMUNE requires tailoring the course of treatment to the patient`s immune system status. While a great many patients respond to the standard treatment dose of REMUNE alone (1 ml. injection once per quarter), others may require additional doses of REMUNE or fortification with other drugs and treatments. We requested, and were granted approval, to have the ability to study the first wave of general public patients in a precise way for the benefit of future recipients of REMUNE," says Dr. Vina Churdboonchart, the Principal Investigator of this program. "We expect the program will be enrolled very quickly."
REMUNE is the leading IBT product in human clinical studies around the world for the treatment of HIV. IBT relies upon the infected individual`s own immune system to ward off progression of the disease as opposed to conventional drug therapy which may have adverse side effects and may become less effective due to viral mutation. REMUNE is a result of the scientific collaboration between the late Dr. Jonas Salk, the renowned creator of the world`s first Polio vaccine, and The Immune Response Corporation which licenses and manufactures REMUNE.
The program was approved by two national committees of the Thai government, The Technical Subcommittee on AIDS Vaccine Development and the National Ethical Committee, Ministry of Public Health.
The program will be coordinated through Mahidol University of Bangkok in cooperation with several other University and government operated hospitals. REMUNE will be exclusively manufactured for the Company by The Immune Response Corporation. Trinity Medical Group USA, Inc., the licensee of REMUNE in Thailand and nine other Southeast Asian Countries, will be the supplier of REMUNE to Mahidol University.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized.
For more information on the Company, visit the web site at http://www.trinitymg.com. Trinity Medical Group USA, Inc. is a developmental stage company. The Company`s common stock is listed on the National Quotation Services Pink Sheets under the symbol TMGU. The Company`s first product in development is an Immune Based Therapy for the treatment of Human Immunodeficiency Virus (HIV) that has completed Phase II clinical trials and is undergoing further testing in Thailand.
REMUNE is a trademark of The Immune Response Corporation, a Carlsbad California company (Nasdaq: IMNR.)
Hier mal ein paar news aus Spanien:
Independent HIV Expert Committee Recommends Completion of Study of REMUNE(TM) Plus Antiretroviral Drugs in Order to Solidify the Findings
DSMB Satisfied With Conduct and Analysis of Spanish Trial (STIR-2102 Study) With REMUNE (HIV-1 Immunogen)
CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the trial in Spain of REMUNE(TM) plus antiretroviral drugs in patients infected with HIV continue to its conclusion in May 2001. This decision followed review of efficacy data from the trial concerning viral load (the amount of HIV detected in the blood) and CD4 T cell counts (immune cells selectively destroyed by HIV).
The DSMB issued a statement regarding their recommendation: ``The DSMB is satisfied with the conduct and analysis of the study.`` ``Based on the results so far, the DSMB feels that the study might yield pivotal information for the (future) development of and application of immunotherapy in HIV-1 infection.`` The DSMB also indicated that the immunological plausibility of the findings strengthen the data.
The DSMB decided that, ``In the interest of solidifying the findings, the DSMB recommends to continue the study, as protocolled, for another 6 months.`` The DSMB for the Phase II Spain trial is composed of European and U.S. scientists who are experts in HIV/AIDS.
Dr. Eduardo Fernandez-Cruz, Professor of Clinical Immunology at the University General Hospital of Madrid, the Principal Investigator for the trial, commented on the DSMB`s recommendation. ``The DSMB has reviewed the efficacy data so far in Study STIR-2102 and has recommended completing the study in order to solidify the current findings.`` In addition, Dr. Cruz stated, ``I am hopeful that the significant immunological results observed in STIR-2102, that were previously reported, among other places, at the 13th International AIDS Conference, will confirm the hypothesis that it is possible by immunization with REMUNE (HIV-1 Immunogen) to achieve long term control of HIV-1 virus. These immunological markers include T helper responses, cytokine and chemokine production, and killer T cell activity (CTL).``
The REMUNE study in Spain is a double blind, placebo-controlled trial with 243 patients enrolled with chronic HIV infection. This is the first prospective study to examine the effect of Remune on viral load and CD4 T cells. The efficacy of REMUNE, administered in combination with antiretroviral therapy (ART), will be assessed by comparing the time to increases in viral load and decreases in CD4 T cell counts between patient groups that received ART plus REMUNE or ART plus placebo. Several immunological markers of HIV disease progression, such as T cell helper activity, chemokine and cytokine production (molecules of the immune system which play an antiviral role) and killer T cells (cells that kill infected T cells), are also being monitored to better understand the mechanism of action of REMUNE. The trial is being conducted at 13 major clinical centers throughout Spain.
REMUNE is an immune-based therapy under development that is designed to be used alone or in combination with existing antiviral drug therapies for HIV and is intended to treat HIV-infected individuals and prevent or delay the progression to Acquired Immune Deficiency Syndrome (AIDS). REMUNE is the subject of investigation in several clinical trials with Agouron Pharmaceuticals, Inc. (a Pfizer company), the Company`s partner for development and commercialization of REMUNE.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Independent HIV Expert Committee Recommends Completion of Study of REMUNE(TM) Plus Antiretroviral Drugs in Order to Solidify the Findings
DSMB Satisfied With Conduct and Analysis of Spanish Trial (STIR-2102 Study) With REMUNE (HIV-1 Immunogen)
CARLSBAD, Calif., Nov. 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced that an independent Data Safety Monitoring Board (DSMB) recommended that the trial in Spain of REMUNE(TM) plus antiretroviral drugs in patients infected with HIV continue to its conclusion in May 2001. This decision followed review of efficacy data from the trial concerning viral load (the amount of HIV detected in the blood) and CD4 T cell counts (immune cells selectively destroyed by HIV).
The DSMB issued a statement regarding their recommendation: ``The DSMB is satisfied with the conduct and analysis of the study.`` ``Based on the results so far, the DSMB feels that the study might yield pivotal information for the (future) development of and application of immunotherapy in HIV-1 infection.`` The DSMB also indicated that the immunological plausibility of the findings strengthen the data.
The DSMB decided that, ``In the interest of solidifying the findings, the DSMB recommends to continue the study, as protocolled, for another 6 months.`` The DSMB for the Phase II Spain trial is composed of European and U.S. scientists who are experts in HIV/AIDS.
Dr. Eduardo Fernandez-Cruz, Professor of Clinical Immunology at the University General Hospital of Madrid, the Principal Investigator for the trial, commented on the DSMB`s recommendation. ``The DSMB has reviewed the efficacy data so far in Study STIR-2102 and has recommended completing the study in order to solidify the current findings.`` In addition, Dr. Cruz stated, ``I am hopeful that the significant immunological results observed in STIR-2102, that were previously reported, among other places, at the 13th International AIDS Conference, will confirm the hypothesis that it is possible by immunization with REMUNE (HIV-1 Immunogen) to achieve long term control of HIV-1 virus. These immunological markers include T helper responses, cytokine and chemokine production, and killer T cell activity (CTL).``
The REMUNE study in Spain is a double blind, placebo-controlled trial with 243 patients enrolled with chronic HIV infection. This is the first prospective study to examine the effect of Remune on viral load and CD4 T cells. The efficacy of REMUNE, administered in combination with antiretroviral therapy (ART), will be assessed by comparing the time to increases in viral load and decreases in CD4 T cell counts between patient groups that received ART plus REMUNE or ART plus placebo. Several immunological markers of HIV disease progression, such as T cell helper activity, chemokine and cytokine production (molecules of the immune system which play an antiviral role) and killer T cells (cells that kill infected T cells), are also being monitored to better understand the mechanism of action of REMUNE. The trial is being conducted at 13 major clinical centers throughout Spain.
REMUNE is an immune-based therapy under development that is designed to be used alone or in combination with existing antiviral drug therapies for HIV and is intended to treat HIV-infected individuals and prevent or delay the progression to Acquired Immune Deficiency Syndrome (AIDS). REMUNE is the subject of investigation in several clinical trials with Agouron Pharmaceuticals, Inc. (a Pfizer company), the Company`s partner for development and commercialization of REMUNE.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether REMUNE will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1999 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
jetzt gehts hoffentlich aufwärts
Tja,
im Moment geht es ja ziemlich abwärts, denn egal ob die
Nasdaq positiv oder negativ schliesst, imnr ist immer bei
Verlierern.
Gibt es denn keine News oder arbeitet imnr jetzt im
verborgenen um dann mal wieder positive Ergebnisse zu
veröffentlichen?
im Moment geht es ja ziemlich abwärts, denn egal ob die
Nasdaq positiv oder negativ schliesst, imnr ist immer bei
Verlierern.
Gibt es denn keine News oder arbeitet imnr jetzt im
verborgenen um dann mal wieder positive Ergebnisse zu
veröffentlichen?
Hi Nussel!
Ich bin bei einem Durchschnittskurs von knapp über 12Euro rein. Das ist `ne lustige Sache. Irgendwie hab ich keinen
Bock nachzukaufen und irgendwie auch kein Geld dafür.
Ich lass sie einfach liegen.Wir werden hier wohl noch eine Menge Geduld haben müssen.
Weitergeholfen wird Dir das jetzt zwar auch nicht haben aber irgendwie hab ich mich berufen gefühlt hier
noch etwas für Leben zu sorgen. Hier ist ja scheinbar niemand mehr dabei... außer uns, wie`s aussieht.
Was solls, lieber ne schlechte Aktie als gar keine Aktie!
Das klingt zwar auch unlogisch, vielleicht sogar ausgesprochen dumm, aber wenn man sich das 24h am Tag
sagt glaubt man`s irgendwann... Hoffe ich!!!
Ich bin bei einem Durchschnittskurs von knapp über 12Euro rein. Das ist `ne lustige Sache. Irgendwie hab ich keinen
Bock nachzukaufen und irgendwie auch kein Geld dafür.
Ich lass sie einfach liegen.Wir werden hier wohl noch eine Menge Geduld haben müssen.
Weitergeholfen wird Dir das jetzt zwar auch nicht haben aber irgendwie hab ich mich berufen gefühlt hier
noch etwas für Leben zu sorgen. Hier ist ja scheinbar niemand mehr dabei... außer uns, wie`s aussieht.
Was solls, lieber ne schlechte Aktie als gar keine Aktie!
Das klingt zwar auch unlogisch, vielleicht sogar ausgesprochen dumm, aber wenn man sich das 24h am Tag
sagt glaubt man`s irgendwann... Hoffe ich!!!
hi,
es sind noch andere dabei. habe gestern nochmal 500 nachgelauft bei dem aktuellen spottpreis konnte ich einfach nicht wiederstehen.
die kommen schon noch und wenn remmune wirkt, dann braucht eigentlich jeder hiv-positive das zeug.
also weiter dabei bleiben,
marcXIX
es sind noch andere dabei. habe gestern nochmal 500 nachgelauft bei dem aktuellen spottpreis konnte ich einfach nicht wiederstehen.
die kommen schon noch und wenn remmune wirkt, dann braucht eigentlich jeder hiv-positive das zeug.
also weiter dabei bleiben,
marcXIX
Das Zeug wirkt leider nicht....
Ich hab mich verabschiedet..
Ich hab mich verabschiedet..
hat jemand news?
sie läuft nicht schlecht.
sie läuft nicht schlecht.
Hallo zusammen,
ist heute irgend etwas zu erwarten in Amiland steht die Aktie nach Börsenschluß mit 6,50 USD im Ask????
Nussel
ist heute irgend etwas zu erwarten in Amiland steht die Aktie nach Börsenschluß mit 6,50 USD im Ask????
Nussel
Hallo IMNR-Fans (?)
Gruntal & Co. hat IMNR auf "outperformer" gestuft.
Widerstandsmarke wurde durchbrochen. IMNR was reiterated
short-term "outperform". Kursziel $ 21 - $ 24.
Nach langer Durststrecke endlich eine gute Nachricht.
Gruß
Ceres
Gruntal & Co. hat IMNR auf "outperformer" gestuft.
Widerstandsmarke wurde durchbrochen. IMNR was reiterated
short-term "outperform". Kursziel $ 21 - $ 24.
Nach langer Durststrecke endlich eine gute Nachricht.
Gruß
Ceres
Hallo ceres,
wirklich eine gute Nachricht, nur wo kann man die nachlesen,
vielleicht kannst Du mal die Quelle angeben, denn das Kursziel ist doch ziemlich hoch gegriffen, gerade weil im
Moment die 5 Dollarmarke getestet wird.
Gruß
Nussel
wirklich eine gute Nachricht, nur wo kann man die nachlesen,
vielleicht kannst Du mal die Quelle angeben, denn das Kursziel ist doch ziemlich hoch gegriffen, gerade weil im
Moment die 5 Dollarmarke getestet wird.
Gruß
Nussel
Hallo Nussel,
Infos unter www.Bloomberg.com zu bekommen.
Kursziel hat mich selbst überrascht u. mit Vorsicht zu
genießen. IMNR-Kurs war ja in letzter Zeit nicht gerade der
Hit.
Aber Cutting.Edge ( Informationsdienst für spekulative
Anleger ) ist wieder auf IMNR aufmerksam geworden.
Allerdings warten die noch ab und haben den Titel zunächst
nur auf der Watchlist.
Wenn ich mehr weiß, gibt es weitere Infos.
Bis bald
Gruß Ceres
Infos unter www.Bloomberg.com zu bekommen.
Kursziel hat mich selbst überrascht u. mit Vorsicht zu
genießen. IMNR-Kurs war ja in letzter Zeit nicht gerade der
Hit.
Aber Cutting.Edge ( Informationsdienst für spekulative
Anleger ) ist wieder auf IMNR aufmerksam geworden.
Allerdings warten die noch ab und haben den Titel zunächst
nur auf der Watchlist.
Wenn ich mehr weiß, gibt es weitere Infos.
Bis bald
Gruß Ceres
Hallo zusammen,habe jetzt fast 1 Jahr imnr aktien, aber glaubt mir eins imnr arbeiten garnicht mehr an dem HIV Mittel, sie haben wohl selbst festgestellt, daß es keinem weiterhilft, zwar haben die noch eine Menge in der Pipeline, aber allae ohne Fantasie, d.h. ich kann noch Dekaden auf meinen Einstand von 12 Euro warten.
Weiss hier einer etwas über die Gerüchte das Pfizer die
Immune Response Corp. aufkaufen will? Angeblich für das
doppelte des aktuellen (ca. 20. Januar) Kurses...
Oder hab` ich wieder das Dementi verpennt?
Gruß, randomizer
Immune Response Corp. aufkaufen will? Angeblich für das
doppelte des aktuellen (ca. 20. Januar) Kurses...
Oder hab` ich wieder das Dementi verpennt?
Gruß, randomizer
Hallo zusammen,
die Diskussionen um Immune Response sind hier echt
eingeschlafen, leider ist der Kursverlauf der letzten
Tage auch nicht gerade berauschend sondern eher
beängstigend hat denn jemand Infos?
Gruß Nussel
die Diskussionen um Immune Response sind hier echt
eingeschlafen, leider ist der Kursverlauf der letzten
Tage auch nicht gerade berauschend sondern eher
beängstigend hat denn jemand Infos?
Gruß Nussel
Hallo !
IMNR Reterated Near-Term ` Outperform ` at Gruntal & Co. vom
5.3.2001. Kursziel $ 14 - $ 17. Hab` keine Ahnung, woher die
ihren Optimismus nehmen. Am 22.1.2001 haben die noch ein
Kursziel von $ 21 - $ 24 avisiert. Aufgrund der momentanen
Entwicklung und der nicht überzeugenden vergangenen Monate
verkneif` ich mir einen Zukauf und warte lieber ab.
Oder weiß jemand mehr ?
Gruß
Ceres
IMNR Reterated Near-Term ` Outperform ` at Gruntal & Co. vom
5.3.2001. Kursziel $ 14 - $ 17. Hab` keine Ahnung, woher die
ihren Optimismus nehmen. Am 22.1.2001 haben die noch ein
Kursziel von $ 21 - $ 24 avisiert. Aufgrund der momentanen
Entwicklung und der nicht überzeugenden vergangenen Monate
verkneif` ich mir einen Zukauf und warte lieber ab.
Oder weiß jemand mehr ?
Gruß
Ceres
Press Release Issued March 13, 2001 7:05:00 AM ET
The Immune Response Corporation Scientists Report Preliminary Results Of Structured Treatment Interruption Study in HIV-Positive Individuals...
wen es interessiert:
http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=no&T…
gruß aus hh
The Immune Response Corporation Scientists Report Preliminary Results Of Structured Treatment Interruption Study in HIV-Positive Individuals...
wen es interessiert:
http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=no&T…
gruß aus hh
aus Aktiencheck vom 12.03.2001
Immune Response kaufen
Global Biotech Investing
Zu einer Investition in Aktien der Immune Response Corporation (WKN 879428) empfehlen die Experten des Börsenbriefes Global Biotech Investing.
Mehrere US-Investmenthäuser stünden dem Papier sehr optimistisch gegenüber und billigten der Aktie ein Kurspotential von mehreren hundert Prozent auf mittelfristige Sicht zu.
Das AIDS-Mittel Remune sei das Hauptprodukt des Unternehmens, welches sich momentan in Phase 3III der klinischen Tests befinde und im nächsten Jahr auf den Markt kommen solle.
Die Umsatzerlöse sollen sich in den kommenden Jahr vervielfachen. In diesem Jahr werde ein Gewinn je Aktie in Höhe von 47 US-Cents angestrebt, welcher bis zum Jahre 2003 auf 1,34 USD gesteigert werden solle.
Aktien kaufen und 2 Jahre liegen lassen, so laute der Ratschlag der Analysten.
Copyright © 1998 - 2001 aktiencheck.de AG
Immune Response kaufen
Global Biotech Investing
Zu einer Investition in Aktien der Immune Response Corporation (WKN 879428) empfehlen die Experten des Börsenbriefes Global Biotech Investing.
Mehrere US-Investmenthäuser stünden dem Papier sehr optimistisch gegenüber und billigten der Aktie ein Kurspotential von mehreren hundert Prozent auf mittelfristige Sicht zu.
Das AIDS-Mittel Remune sei das Hauptprodukt des Unternehmens, welches sich momentan in Phase 3III der klinischen Tests befinde und im nächsten Jahr auf den Markt kommen solle.
Die Umsatzerlöse sollen sich in den kommenden Jahr vervielfachen. In diesem Jahr werde ein Gewinn je Aktie in Höhe von 47 US-Cents angestrebt, welcher bis zum Jahre 2003 auf 1,34 USD gesteigert werden solle.
Aktien kaufen und 2 Jahre liegen lassen, so laute der Ratschlag der Analysten.
Copyright © 1998 - 2001 aktiencheck.de AG
March 29, 2001
IMMUNE RESPONSE CORP (IMNR)
Annual Report (SEC form 10-K)
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion contains forward-looking statements concerning our operating results and timing of anticipated revenues and expenditures. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include those discussed under "Risk Factors", as well as those discussed elsewhere in this Form 10-K. The following should be read in conjunction with the Consolidated Financial Statements and Notes thereto included elsewhere in this Form 10-K. These forward-looking statements speak only as of the date hereof. We undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
OVERVIEW
We are a biopharmaceutical company developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, we are developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
In January 2000, we received a $5.0 million payment from Pfizer consisting of a $3.0 million payment for research and development and a $2.0 million payment for the purchase of 266,667 shares of unregistered common stock priced at a $333,000 premium to the market, which was recognized as deferred revenue. This was the final payment in a series of six quarterly payments made by Pfizer to fund research and development and to purchase unregistered common stock under our binding letter of intent with Pfizer. Under the agreement, we agreed to exclusively license REMUNE, our immune-based therapy under development for the treatment of HIV infection, to Pfizer. Under the terms of the agreement, we will manufacture commercial supplies of REMUNE, and Pfizer will have exclusive rights to market REMUNE in North America, Europe and certain other countries. Pfizer and we will share profits from the commercialization on a 50/50 basis, if regulatory approvals are received. Pfizer will make additional payments upon achievement of certain milestones. To date, we have received $47.0 million in payments under the agreement. In September 2000, we filed a registration statement with the Securities and Exchange Commission covering the resale of 1,317,609 shares of common stock that Pfizer owns through Agouron.
In May 2000, we utilized the remaining $1.4 million of available credit under a $3.0 million equipment line of credit as reimbursement for capital expenditures.
In August 2000, we raised $14.9 million, net of expenses, from a public offering of 2,760,000 shares of our common stock at a price of $6.00.
During 2000, we sold for cash $5.7 million of equity securities held for sale.
We have not been profitable since inception and had an accumulated deficit of $211.0 million as of December 31, 2000. To date, we have not recorded any revenues from the sale of products. Revenues recorded through December 31, 2000 were primarily received from contract research, licensing of technology, milestone achievement payments and investment income. We expect our operating losses to continue, as well as to have quarter-to-quarter fluctuations, some of which could be significant, due to research, development and clinical trial activities. There can be no assurance that we will be able to generate sufficient product revenue to become profitable at all or on a sustained basis.
In December 1999, the SEC issued SAB 101, "Revenue Recognition in Financial Statements". We implemented SAB 101 in the fourth quarter of 2000 by adjusting the first, second and third quarters of our 2000 financial statements. Our statement of operations reflects a one-time charge to earnings of $13.2 million for the cumulative effect of the change in accounting principle as of January 1, 2000.
Deferred revenue recognized, to reflect the application of the SAB 101 adjustment, was approximately $960,000 for each quarter of 2000. The balance of $9.7 million of deferred revenue from this adjustment will be recognized as revenue over the expected development period, which is estimated to be through June 2003. See Footnote 2 to the Consolidated Financial Statements.
RESULTS OF OPERATIONS
We recorded revenues of $7.4 million in 2000 as compared to $20.8 million in 1999 and $17.7 million in 1998. Revenues for each year were derived primarily from our agreement with Pfizer, which includes license fees, milestone payments and research and development payments. The decrease in revenues from 1999 to 2000 was primarily related to the timing of revenues received under our agreement with Pfizer. Revenues for 2000 included the final payment in a series of six quarterly payments of approximately $3.3 million to fund research and development as compared to 1999, which included four quarterly payments and a milestone payment of $5.0 million. Revenues for 2000 also included an adjustment due to the implementation of SAB 101, which recognized $3.5 million of the $13.2 million deferred under SAB101. The change in revenues from 1998 to 1999 was also related to the timing of revenues received under the Pfizer agreement. The $13.2 million of deferred revenue from the SAB 101 adjustment was associated with 1998 and 1999 revenues recognized under the Pfizer agreement, leaving the remaining deferred revenues of $9.7 million is expected to be fully recognized by June 30, 2003. As a result, we expect no additional revenues, with the exception of deferred revenue under SAB 101, unless it is earned through existing corporate collaborations or new research and development agreements, if any. We have not received any revenues from the commercial sale of products and do not expect to derive revenue from the sale of products for the foreseeable future.
Our research and development costs totaled $21.9 million for 2000 as compared to $31.2 million for 1999 and $33.2 million for 1998. The decrease in costs from 1999 to 2000 was due primarily to reduced spending on clinical and regulatory expenses of $8.0 million and to a lesser degree, reduced spending on our autoimmune, gene therapy and cancer programs of $1.1 million. The decrease in costs in 1999 over 1998 was due primarily to reduced spending on clinical and regulatory expenses of $3.1 million and to a lesser degree, reduced spending on our autoimmune, gene therapy and cancer programs of $1.7 million. This decrease in 1999 over 1998 was somewhat offset by an increase in spending on the scale-up of the manufacturing process of REMUNE of $2.8 million. The decrease in clinical and regulatory expenses for both years was primarily related to the discontinuation of a 2,500 patient, Phase 3 clinical trial of REMUNE in May 1999 and the decreased spending on our autoimmune, gene therapy and cancer programs related to the workforce reduction in June 1999.
Future spending associated with our scale-up of the manufacturing process for REMUNE and the cost of producing clinical supplies for ongoing and future REMUNE studies is expected to increase in the foreseeable future. Our expenses associated with the REMUNE HIV clinical trials are expected to remain level with 2000 spending, but less than 1999. This is due to Pfizer conducting and funding a REMUNE U.S. pivotal study that began in the second half of 1999 and which is still ongoing. Future research and development expenditures are expected to increase slightly in the coming year unless additional collaborations are entered into, at which time additional spending could occur. There can be no assurance that we will enter into any collaborations, that existing collaborations will not end, or that we will be able to obtain other financing needed to continue our research and development efforts.
General and administrative expenses totaled $4.4 million for 2000 as compared to $5.2 million for 1999 and $4.2 million for 1998. The decrease in spending from 1999 to 2000 was primarily attributed to our work force reduction in 1999 and somewhat lower professional fees and office related expenses. The increase in spending in 1999 over 1998 was attributable to higher support costs associated with our research and development effort, increase in public company activities and changes associated with the restructuring. General and administrative expenses for 2001 are expected to remain somewhat constant to 2000 levels.
Restructuring costs of $650,000 for the year ended December 1999 were associated with our restructuring plan implemented in June 1999 and completed in October 1999, which reduced the work force by approximately 30%. Employee severance, health benefits, placement services and other implementation costs were included in the restructuring costs. As of December 1999, there was approximately $100,000 of accrued restructuring costs remaining to provide for severance costs for salaries. These amounts were paid out in the first quarter of 2000.
Investment income increased to $7.2 million for 2000 from $1.4 million for 1999 and $1.7 million for 1998. The increase in investment income in 2000 compared to 1999 was due primarily to the sale of $5.7 million of equity securities held for sale that were acquired through licensing of our technology. Also contributing to the 2000 increase was more investment income due to higher average cash and short-term investment balances during the year. The decrease from 1998 to 1999 was the result of lower investment income on lower average cash and short-term investment balances.
Interest expense, generated from interest on equipment notes payable used to finance manufacturing and research laboratory equipment, increased to $308,000 in 2000 from $45,000 in 1999. The equipment financed under the note increased from $1.6 million in 1999 to $3.0 million in 2000.
Other income of $736,000 was primarily attributable to the gain recognized from the sale in March 2000 of undeveloped property adjacent to our headquarters facility in Carlsbad, California for approximately $2.0 million
The cumulative effect of accounting change of $13.2 million for the year ended December 31, 2000 was the result of adopting SAB 101 and is associated with revenues recognized primarily in 1998 and 1999. See Footnote 2 to the Consolidated Financial Statements.
LIQUIDITY AND CAPITAL RESOURCES
Since our inception through December 31, 2000, we have financed our activities primarily from public and private sales of equity, funding from collaborations with corporate partners and investment income. At December 31, 2000, we had working capital of $20.6 million, including $28.4 million of cash, cash equivalents and marketable securities. This compares with working capital at December 31, 1999 of $14.7 million, including $23.1 million of cash, cash equivalents and marketable securities. Working capital increased in 2000 as a result of the sale of common stock to institutional investors for $14.9 million, net of expenses, the exercise of $3.9 million of stock options and the sales of $5.7 million of equity securities held for sale and approximately $2.0 million of undeveloped property.
We will need to raise additional funds to conduct research and development, preclinical studies and clinical trials necessary to bring potential products to market and to establish manufacturing and marketing capabilities. We anticipate that for the foreseeable future, the scale-up of the manufacturing process for REMUNE and the cost of producing clinical supplies for ongoing and future REMUNE studies will continue to represent a significant portion of our overall expenditures. Overall, future research and development expenditures are expected to increase slightly from current levels. However, future spending for research and development may see a greater increase if we enter into additional collaborations, but there can be no assurance that we will enter into any such collaborations. We anticipate additional capital improvements of approximately $3.0 million for 2001 related to the scale-up of the manufacturing process; some of which we anticipate will be funded with debt financing, if available. Other anticipated costs with respect to REMUNE, including investment in inventory, will depend on many factors including the results of clinical trials, the continuation of our collaboration with Pfizer and other factors which will influence our determination of the appropriate continued investment of our financial resources in this program.
Our future capital requirements will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of preclinical studies and
clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patent claims, competing technological and market developments, the cost of manufacturing scale-up and inventories, effective commercialization activities and arrangements and other factors not within our control. We intend to seek additional funding through additional research and development agreements with suitable corporate collaborators, extensions of existing corporate collaborations and through public or private financings, if available. However, there can be no assurance that such collaboration arrangements or any public or private financings will be available on acceptable terms, if at all. If funds are raised through equity arrangements, further dilution to stockholders may result. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs, or take other measures to cut costs, which could have a material adverse effect on us. We estimate that our existing capital resources will be sufficient to fund our current and planned operations through 2001. There can be no assurance, however, that changes in our research and development plans or other changes affecting our operating expenses may result in the expenditure of such resources before such time. In any event, we will need to raise substantial additional capital to fund our operations in future periods.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We invest our excess cash primarily in U.S. government securities and money market accounts. These instruments have maturities of two years or less when acquired. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions. Accordingly, we believe that, while the instruments we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements and supplementary data of the Company required by this item are set forth at the pages indicated in Item 14(a)(1).
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Not applicable
IMMUNE RESPONSE CORP (IMNR)
Annual Report (SEC form 10-K)
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion contains forward-looking statements concerning our operating results and timing of anticipated revenues and expenditures. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include those discussed under "Risk Factors", as well as those discussed elsewhere in this Form 10-K. The following should be read in conjunction with the Consolidated Financial Statements and Notes thereto included elsewhere in this Form 10-K. These forward-looking statements speak only as of the date hereof. We undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
OVERVIEW
We are a biopharmaceutical company developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, we are developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
In January 2000, we received a $5.0 million payment from Pfizer consisting of a $3.0 million payment for research and development and a $2.0 million payment for the purchase of 266,667 shares of unregistered common stock priced at a $333,000 premium to the market, which was recognized as deferred revenue. This was the final payment in a series of six quarterly payments made by Pfizer to fund research and development and to purchase unregistered common stock under our binding letter of intent with Pfizer. Under the agreement, we agreed to exclusively license REMUNE, our immune-based therapy under development for the treatment of HIV infection, to Pfizer. Under the terms of the agreement, we will manufacture commercial supplies of REMUNE, and Pfizer will have exclusive rights to market REMUNE in North America, Europe and certain other countries. Pfizer and we will share profits from the commercialization on a 50/50 basis, if regulatory approvals are received. Pfizer will make additional payments upon achievement of certain milestones. To date, we have received $47.0 million in payments under the agreement. In September 2000, we filed a registration statement with the Securities and Exchange Commission covering the resale of 1,317,609 shares of common stock that Pfizer owns through Agouron.
In May 2000, we utilized the remaining $1.4 million of available credit under a $3.0 million equipment line of credit as reimbursement for capital expenditures.
In August 2000, we raised $14.9 million, net of expenses, from a public offering of 2,760,000 shares of our common stock at a price of $6.00.
During 2000, we sold for cash $5.7 million of equity securities held for sale.
We have not been profitable since inception and had an accumulated deficit of $211.0 million as of December 31, 2000. To date, we have not recorded any revenues from the sale of products. Revenues recorded through December 31, 2000 were primarily received from contract research, licensing of technology, milestone achievement payments and investment income. We expect our operating losses to continue, as well as to have quarter-to-quarter fluctuations, some of which could be significant, due to research, development and clinical trial activities. There can be no assurance that we will be able to generate sufficient product revenue to become profitable at all or on a sustained basis.
In December 1999, the SEC issued SAB 101, "Revenue Recognition in Financial Statements". We implemented SAB 101 in the fourth quarter of 2000 by adjusting the first, second and third quarters of our 2000 financial statements. Our statement of operations reflects a one-time charge to earnings of $13.2 million for the cumulative effect of the change in accounting principle as of January 1, 2000.
Deferred revenue recognized, to reflect the application of the SAB 101 adjustment, was approximately $960,000 for each quarter of 2000. The balance of $9.7 million of deferred revenue from this adjustment will be recognized as revenue over the expected development period, which is estimated to be through June 2003. See Footnote 2 to the Consolidated Financial Statements.
RESULTS OF OPERATIONS
We recorded revenues of $7.4 million in 2000 as compared to $20.8 million in 1999 and $17.7 million in 1998. Revenues for each year were derived primarily from our agreement with Pfizer, which includes license fees, milestone payments and research and development payments. The decrease in revenues from 1999 to 2000 was primarily related to the timing of revenues received under our agreement with Pfizer. Revenues for 2000 included the final payment in a series of six quarterly payments of approximately $3.3 million to fund research and development as compared to 1999, which included four quarterly payments and a milestone payment of $5.0 million. Revenues for 2000 also included an adjustment due to the implementation of SAB 101, which recognized $3.5 million of the $13.2 million deferred under SAB101. The change in revenues from 1998 to 1999 was also related to the timing of revenues received under the Pfizer agreement. The $13.2 million of deferred revenue from the SAB 101 adjustment was associated with 1998 and 1999 revenues recognized under the Pfizer agreement, leaving the remaining deferred revenues of $9.7 million is expected to be fully recognized by June 30, 2003. As a result, we expect no additional revenues, with the exception of deferred revenue under SAB 101, unless it is earned through existing corporate collaborations or new research and development agreements, if any. We have not received any revenues from the commercial sale of products and do not expect to derive revenue from the sale of products for the foreseeable future.
Our research and development costs totaled $21.9 million for 2000 as compared to $31.2 million for 1999 and $33.2 million for 1998. The decrease in costs from 1999 to 2000 was due primarily to reduced spending on clinical and regulatory expenses of $8.0 million and to a lesser degree, reduced spending on our autoimmune, gene therapy and cancer programs of $1.1 million. The decrease in costs in 1999 over 1998 was due primarily to reduced spending on clinical and regulatory expenses of $3.1 million and to a lesser degree, reduced spending on our autoimmune, gene therapy and cancer programs of $1.7 million. This decrease in 1999 over 1998 was somewhat offset by an increase in spending on the scale-up of the manufacturing process of REMUNE of $2.8 million. The decrease in clinical and regulatory expenses for both years was primarily related to the discontinuation of a 2,500 patient, Phase 3 clinical trial of REMUNE in May 1999 and the decreased spending on our autoimmune, gene therapy and cancer programs related to the workforce reduction in June 1999.
Future spending associated with our scale-up of the manufacturing process for REMUNE and the cost of producing clinical supplies for ongoing and future REMUNE studies is expected to increase in the foreseeable future. Our expenses associated with the REMUNE HIV clinical trials are expected to remain level with 2000 spending, but less than 1999. This is due to Pfizer conducting and funding a REMUNE U.S. pivotal study that began in the second half of 1999 and which is still ongoing. Future research and development expenditures are expected to increase slightly in the coming year unless additional collaborations are entered into, at which time additional spending could occur. There can be no assurance that we will enter into any collaborations, that existing collaborations will not end, or that we will be able to obtain other financing needed to continue our research and development efforts.
General and administrative expenses totaled $4.4 million for 2000 as compared to $5.2 million for 1999 and $4.2 million for 1998. The decrease in spending from 1999 to 2000 was primarily attributed to our work force reduction in 1999 and somewhat lower professional fees and office related expenses. The increase in spending in 1999 over 1998 was attributable to higher support costs associated with our research and development effort, increase in public company activities and changes associated with the restructuring. General and administrative expenses for 2001 are expected to remain somewhat constant to 2000 levels.
Restructuring costs of $650,000 for the year ended December 1999 were associated with our restructuring plan implemented in June 1999 and completed in October 1999, which reduced the work force by approximately 30%. Employee severance, health benefits, placement services and other implementation costs were included in the restructuring costs. As of December 1999, there was approximately $100,000 of accrued restructuring costs remaining to provide for severance costs for salaries. These amounts were paid out in the first quarter of 2000.
Investment income increased to $7.2 million for 2000 from $1.4 million for 1999 and $1.7 million for 1998. The increase in investment income in 2000 compared to 1999 was due primarily to the sale of $5.7 million of equity securities held for sale that were acquired through licensing of our technology. Also contributing to the 2000 increase was more investment income due to higher average cash and short-term investment balances during the year. The decrease from 1998 to 1999 was the result of lower investment income on lower average cash and short-term investment balances.
Interest expense, generated from interest on equipment notes payable used to finance manufacturing and research laboratory equipment, increased to $308,000 in 2000 from $45,000 in 1999. The equipment financed under the note increased from $1.6 million in 1999 to $3.0 million in 2000.
Other income of $736,000 was primarily attributable to the gain recognized from the sale in March 2000 of undeveloped property adjacent to our headquarters facility in Carlsbad, California for approximately $2.0 million
The cumulative effect of accounting change of $13.2 million for the year ended December 31, 2000 was the result of adopting SAB 101 and is associated with revenues recognized primarily in 1998 and 1999. See Footnote 2 to the Consolidated Financial Statements.
LIQUIDITY AND CAPITAL RESOURCES
Since our inception through December 31, 2000, we have financed our activities primarily from public and private sales of equity, funding from collaborations with corporate partners and investment income. At December 31, 2000, we had working capital of $20.6 million, including $28.4 million of cash, cash equivalents and marketable securities. This compares with working capital at December 31, 1999 of $14.7 million, including $23.1 million of cash, cash equivalents and marketable securities. Working capital increased in 2000 as a result of the sale of common stock to institutional investors for $14.9 million, net of expenses, the exercise of $3.9 million of stock options and the sales of $5.7 million of equity securities held for sale and approximately $2.0 million of undeveloped property.
We will need to raise additional funds to conduct research and development, preclinical studies and clinical trials necessary to bring potential products to market and to establish manufacturing and marketing capabilities. We anticipate that for the foreseeable future, the scale-up of the manufacturing process for REMUNE and the cost of producing clinical supplies for ongoing and future REMUNE studies will continue to represent a significant portion of our overall expenditures. Overall, future research and development expenditures are expected to increase slightly from current levels. However, future spending for research and development may see a greater increase if we enter into additional collaborations, but there can be no assurance that we will enter into any such collaborations. We anticipate additional capital improvements of approximately $3.0 million for 2001 related to the scale-up of the manufacturing process; some of which we anticipate will be funded with debt financing, if available. Other anticipated costs with respect to REMUNE, including investment in inventory, will depend on many factors including the results of clinical trials, the continuation of our collaboration with Pfizer and other factors which will influence our determination of the appropriate continued investment of our financial resources in this program.
Our future capital requirements will depend on many factors, including continued scientific progress in our research and development programs, the scope and results of preclinical studies and
clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in filing, prosecuting and enforcing patent claims, competing technological and market developments, the cost of manufacturing scale-up and inventories, effective commercialization activities and arrangements and other factors not within our control. We intend to seek additional funding through additional research and development agreements with suitable corporate collaborators, extensions of existing corporate collaborations and through public or private financings, if available. However, there can be no assurance that such collaboration arrangements or any public or private financings will be available on acceptable terms, if at all. If funds are raised through equity arrangements, further dilution to stockholders may result. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs, or take other measures to cut costs, which could have a material adverse effect on us. We estimate that our existing capital resources will be sufficient to fund our current and planned operations through 2001. There can be no assurance, however, that changes in our research and development plans or other changes affecting our operating expenses may result in the expenditure of such resources before such time. In any event, we will need to raise substantial additional capital to fund our operations in future periods.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We invest our excess cash primarily in U.S. government securities and money market accounts. These instruments have maturities of two years or less when acquired. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions. Accordingly, we believe that, while the instruments we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements and supplementary data of the Company required by this item are set forth at the pages indicated in Item 14(a)(1).
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Not applicable
Friday March 30, 7:00 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Is Granted U.S. Patent for DNA Vaccine Technology Related to Rheumatoid Arthritis
CARLSBAD, Calif., March 30 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it has received United States Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, RAVAX(TM). The recently issued patent has specific claims covering immunization utilizing DNA vaccines that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key ``superantigen`` protein sequences from the Vbeta 3, Vbeta 14 and Vbeta 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis. The Company believes that vaccination with RAVAX may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease.
``This recent issuance is a key patent in that it extends previous coverage related to the delivery and composition of RAVAX to now include DNA vaccines in addition to peptide vaccines,`` said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. ``DNA vaccination is proving to be an effective method of inducing immunity against a number of human diseases. The issuance of this patent to include DNA vaccination for our peptide vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research.`` The Company previously announced that it was issued U.S. patent number 6,090,387 for vaccinating with T cell receptor peptides on August 9, 2000.
Several autoimmune disorders, including rheumatoid arthritis, psoriasis and multiple sclerosis, are thought to result in part from the proliferation of ``autoreactive pathogenic T cells,`` immune cells that incorrectly identify the body`s own cells as foreign and destroy them.
The Immune Response Corporation has completed two Phase II clinical trials in rheumatoid arthritis using their proprietary immune-based therapy based on TCR peptide vaccines. In a phase IIb trial of 340 rheumatoid arthritis patients, RAVAX demonstrated safety and tolerability, and suggested a statistically significant treatment effect at one time point after the third injection using criteria established by the American College of Rheumatology (ACR 20). The ACR 20 criteria require an improvement in tender and swollen joint counts of at least 20% from baseline, along with improvement in three of five other disease-related criteria. To date, no clinical studies have been initiated utilizing the DNA vaccination approach.
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Is Granted U.S. Patent for DNA Vaccine Technology Related to Rheumatoid Arthritis
CARLSBAD, Calif., March 30 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today that it has received United States Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, RAVAX(TM). The recently issued patent has specific claims covering immunization utilizing DNA vaccines that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key ``superantigen`` protein sequences from the Vbeta 3, Vbeta 14 and Vbeta 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis. The Company believes that vaccination with RAVAX may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease.
``This recent issuance is a key patent in that it extends previous coverage related to the delivery and composition of RAVAX to now include DNA vaccines in addition to peptide vaccines,`` said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. ``DNA vaccination is proving to be an effective method of inducing immunity against a number of human diseases. The issuance of this patent to include DNA vaccination for our peptide vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research.`` The Company previously announced that it was issued U.S. patent number 6,090,387 for vaccinating with T cell receptor peptides on August 9, 2000.
Several autoimmune disorders, including rheumatoid arthritis, psoriasis and multiple sclerosis, are thought to result in part from the proliferation of ``autoreactive pathogenic T cells,`` immune cells that incorrectly identify the body`s own cells as foreign and destroy them.
The Immune Response Corporation has completed two Phase II clinical trials in rheumatoid arthritis using their proprietary immune-based therapy based on TCR peptide vaccines. In a phase IIb trial of 340 rheumatoid arthritis patients, RAVAX demonstrated safety and tolerability, and suggested a statistically significant treatment effect at one time point after the third injection using criteria established by the American College of Rheumatology (ACR 20). The ACR 20 criteria require an improvement in tender and swollen joint counts of at least 20% from baseline, along with improvement in three of five other disease-related criteria. To date, no clinical studies have been initiated utilizing the DNA vaccination approach.
Hallo !
Letzte Nachricht vom 12.4.2001 bei Bloomberg nachgelesen:
Webb (Del) Corp. will replace IMNR in the S & P SmallCap 600
Index. IMNR will be removed. Gilt ab Börsenschluß in New
York am 16.4.2001.
Kurz und knapp. IMNR wurde ersetzt und fliegt aus den
SmallCap 600 Index.
Nach der letzten Kursentwicklung u. mageren Nachrichten war
nichts anderes zu erwarten.
Gebe den Wert aber trotzdem " noch " nicht auf.
Gruß Ceres
Letzte Nachricht vom 12.4.2001 bei Bloomberg nachgelesen:
Webb (Del) Corp. will replace IMNR in the S & P SmallCap 600
Index. IMNR will be removed. Gilt ab Börsenschluß in New
York am 16.4.2001.
Kurz und knapp. IMNR wurde ersetzt und fliegt aus den
SmallCap 600 Index.
Nach der letzten Kursentwicklung u. mageren Nachrichten war
nichts anderes zu erwarten.
Gebe den Wert aber trotzdem " noch " nicht auf.
Gruß Ceres
in den letzten Tagen/Wochen hat es einige Meldungen gegeben, für Spekulativ eingestellte Investoren könnte sich ein Blick lohnen, Vorbörslich bei 3,02
--------------------------------------------------------
Global Biotech Investing
Immune Response kaufen Datum: 12.03.2001
Zu einer Investition in Aktien der Immune Response Corporation (WKN 879428) empfehlen die Experten des Börsenbriefes Global Biotech Investing. Mehrere US-Investmenthäuser stünden dem Papier sehr optimistisch gegenüber und billigten der Aktie ein Kurspotential von mehreren hundert Prozent auf mittelfristige Sicht zu. Das AIDS-Mittel Remune sei das Hauptprodukt des Unternehmens, welches sich momentan in Phase 3III der klinischen Tests befinde und im nächsten Jahr auf den Markt kommen solle. Die Umsatzerlöse sollen sich in den kommenden Jahr vervielfachen. In diesem Jahr werde ein Gewinn je Aktie in Höhe von 47 US-Cents angestrebt, welcher bis zum Jahre 2003 auf 1,34 USD gesteigert werden solle. Aktien kaufen und 2 Jahre liegen lassen, so laute der Ratschlag der Analysten.
Quelle: AktienCheck
----------------------------------------------------
Global Biotech Investing
Immune Response interessant Datum: 30.04.2001
Bei Kursen unter 2 USD Aktien der United Therapeutics Corporation (WKN 879428) nachkaufen, so lautet die Empfehlung von Analysten des Börsenbriefes Global Biotech Investing. Aufgrund der Meldung, dass das Aids-Medikament Remune in einer Studie von 1996 bis 1999 nun doch positive Ergebnisse gebracht habe, sei die Aktie um 100% in die Höhe geschnellt. Eine erste Auswertung habe an der Effektivität des Medikaments zweifeln lassen. Nun werde mit Spannung auf die Ergebnisse einer in Spanien laufenden Phase II-Studie gewartet, die für das dritte Quartal erwartet würden sowie auf den Ausgang einer Phase III-Studie in den USA, bei der Remune in Kombination mit traditionellen Aids-Medikamenten getestet werde. Als Einproduktunternehmen werde die Aktie natürlich mit einem deutlichen Abschlag gehandelt. Sollte die Markteinführung gelingen, seien auf langfristige Sicht hin 1.000% schon möglich. Bei Kursen unter 2 USD auf jeden Fall nachlaufen, so die Expertenmeinung.
Quelle: AktienCheck
-------------------------------------------------------
Börse-Online Info: IMNR berichtet positive Ergebnisse der
Testphase III für Remune-HIV-Therapie. Die Therapie stärkt
bei HIV-infizierten Personen das Immunsystem und kann die
Ausbreitung des Virus reduzieren.
------------------------------------------------------
ich würde vorschlagen diesen Thread beizubehalten, da hier die meisten News, Analysen etc. drinstehen.
habe jetzt aber keine Lust die Letzten Meldungen hier reinzustellen, auf www.imnr.com kann man sowieso alle Meldungen lesen
--------------------------------------------------------
Global Biotech Investing
Immune Response kaufen Datum: 12.03.2001
Zu einer Investition in Aktien der Immune Response Corporation (WKN 879428) empfehlen die Experten des Börsenbriefes Global Biotech Investing. Mehrere US-Investmenthäuser stünden dem Papier sehr optimistisch gegenüber und billigten der Aktie ein Kurspotential von mehreren hundert Prozent auf mittelfristige Sicht zu. Das AIDS-Mittel Remune sei das Hauptprodukt des Unternehmens, welches sich momentan in Phase 3III der klinischen Tests befinde und im nächsten Jahr auf den Markt kommen solle. Die Umsatzerlöse sollen sich in den kommenden Jahr vervielfachen. In diesem Jahr werde ein Gewinn je Aktie in Höhe von 47 US-Cents angestrebt, welcher bis zum Jahre 2003 auf 1,34 USD gesteigert werden solle. Aktien kaufen und 2 Jahre liegen lassen, so laute der Ratschlag der Analysten.
Quelle: AktienCheck
----------------------------------------------------
Global Biotech Investing
Immune Response interessant Datum: 30.04.2001
Bei Kursen unter 2 USD Aktien der United Therapeutics Corporation (WKN 879428) nachkaufen, so lautet die Empfehlung von Analysten des Börsenbriefes Global Biotech Investing. Aufgrund der Meldung, dass das Aids-Medikament Remune in einer Studie von 1996 bis 1999 nun doch positive Ergebnisse gebracht habe, sei die Aktie um 100% in die Höhe geschnellt. Eine erste Auswertung habe an der Effektivität des Medikaments zweifeln lassen. Nun werde mit Spannung auf die Ergebnisse einer in Spanien laufenden Phase II-Studie gewartet, die für das dritte Quartal erwartet würden sowie auf den Ausgang einer Phase III-Studie in den USA, bei der Remune in Kombination mit traditionellen Aids-Medikamenten getestet werde. Als Einproduktunternehmen werde die Aktie natürlich mit einem deutlichen Abschlag gehandelt. Sollte die Markteinführung gelingen, seien auf langfristige Sicht hin 1.000% schon möglich. Bei Kursen unter 2 USD auf jeden Fall nachlaufen, so die Expertenmeinung.
Quelle: AktienCheck
-------------------------------------------------------
Börse-Online Info: IMNR berichtet positive Ergebnisse der
Testphase III für Remune-HIV-Therapie. Die Therapie stärkt
bei HIV-infizierten Personen das Immunsystem und kann die
Ausbreitung des Virus reduzieren.
------------------------------------------------------
ich würde vorschlagen diesen Thread beizubehalten, da hier die meisten News, Analysen etc. drinstehen.
habe jetzt aber keine Lust die Letzten Meldungen hier reinzustellen, auf www.imnr.com kann man sowieso alle Meldungen lesen
nächster Wiederstand 3,5 $
Tuesday May 8, 7:01 am Eastern Time
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces First Quarter 2001 Financial Results
CARLSBAD, Calif., May 8 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced its financial results for the quarter ended March 31, 2001. The net loss for the first quarter of 2001 was $4.9 million or $.16 per share, compared to a net loss of $12.2 million or a loss of $.45 per share, reported in the first quarter of 2000. The results for the quarter ended March 31, 2000 reflect the implementation of the Staff Accounting Bulletin No. 101, ``Revenue Recognition in Financial Statements,`` (SAB 101), which the SEC issued in December 1999.
Research related revenue for the quarter ended March 31, 2001 was $1.0 million compared to $4.0 million for the same quarter in 2000. The decrease in research revenue in 2001 was primarily related to the timing of revenues received under our agreement with Agouron Pharmaceuticals, Inc., a Pfizer Inc. company, entered into in June 1998 along with the effects of implementing SAB 101.
The Company implemented SAB 101 in the fourth quarter of 2000 by restating the first, second and third quarters of its 2000 financial statements. The statement of operations reflects a one-time charge to earnings of $13.2 million for the cumulative effect of the change in accounting principle as of January 1, 2000. Accordingly, revenue for the first quarter of 2000 was increased by $0.9 million to reflect the recognition of the deferred license revenue arising from the SAB 101 adjustment. The balance of $9.7 million of deferred revenue from the adjustment is being recognized as revenue over the expected development period, including $968,000 recognized in the first quarter of 2001.
In addition to research related revenue, the Company received non-research revenue from investment and other income of $644,000 for the first quarter of 2001 versus $3.3 million for the same period in 2000. This decrease in investment and other income in 2001 was due primarily to less sales in 2001 of equity securities acquired through the licensing of technology and from the sale of undeveloped property in 2000.
Operating expenses increased to $6.6 million for the quarter ended March 31, 2001 from $6.2 million in the first quarter of 2000. The increase in operating expenses was due primarily to spending on the scale-up of the manufacturing process of REMUNE and higher professional fees for general and administrative expenses in the quarter ended March 31, 2001.
Cash, cash equivalents and short-term investments were $21.2 million at March 31, 2001 compared with $28.4 million at the end of 2000.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted, non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On- Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2000. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
The Immune Response Corporation
Condensed Consolidated Statements of Operations
(Amounts in thousands, except share data)
(unaudited)
Three Months Ended
March 31,
2001 2000
(Restated)
Research revenue $1,032 $3,960
Expenses:
Research and development 5,333 5,061
General and administrative 1,227 1,106
6,560 6,167
Other revenue:
Investment income, net 644 2,523
Other income, net -- 732
Income (loss) before cumulative effect
of accounting change (4,884) 1,048
Cumulative effect of accounting change -- (13,212)
Net loss (4,884) (12,164)
Preferred stock items (255) (256)
Net loss applicable to common stockholders $(5,139) $(12,420)
Net loss per share - basic and diluted $(0.17) $(0.46)
Weighted average number of
shares outstanding 30,809,984 26,955,087
The Immune Response Corporation
Condensed Consolidated Balance Sheets
(Amounts in thousands)
March 31, December 31,
2001 2000
(unaudited)
Assets
Cash, cash equivalents and
short-term investments $21,183 $28,356
Other current assets 1,015 607
22,198 28,963
Property and equipment, net 8,909 8,554
Licensed technology 4,062 4,238
Investment in MicroGenomics, Inc. 3,000 3,000
Other assets 848 848
Total assets $39,017 $45,603
Liabilities and stockholders` equity
Current liabilities $8,278 $8,409
Long-term liabilities 6,624 7,765
Redeemable, convertible preferred stock 9,977 9,907
Stockholders` equity 14,138 19,522
Total liabilities and
stockholders` equity $39,017 $45,603
Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces First Quarter 2001 Financial Results
CARLSBAD, Calif., May 8 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced its financial results for the quarter ended March 31, 2001. The net loss for the first quarter of 2001 was $4.9 million or $.16 per share, compared to a net loss of $12.2 million or a loss of $.45 per share, reported in the first quarter of 2000. The results for the quarter ended March 31, 2000 reflect the implementation of the Staff Accounting Bulletin No. 101, ``Revenue Recognition in Financial Statements,`` (SAB 101), which the SEC issued in December 1999.
Research related revenue for the quarter ended March 31, 2001 was $1.0 million compared to $4.0 million for the same quarter in 2000. The decrease in research revenue in 2001 was primarily related to the timing of revenues received under our agreement with Agouron Pharmaceuticals, Inc., a Pfizer Inc. company, entered into in June 1998 along with the effects of implementing SAB 101.
The Company implemented SAB 101 in the fourth quarter of 2000 by restating the first, second and third quarters of its 2000 financial statements. The statement of operations reflects a one-time charge to earnings of $13.2 million for the cumulative effect of the change in accounting principle as of January 1, 2000. Accordingly, revenue for the first quarter of 2000 was increased by $0.9 million to reflect the recognition of the deferred license revenue arising from the SAB 101 adjustment. The balance of $9.7 million of deferred revenue from the adjustment is being recognized as revenue over the expected development period, including $968,000 recognized in the first quarter of 2001.
In addition to research related revenue, the Company received non-research revenue from investment and other income of $644,000 for the first quarter of 2001 versus $3.3 million for the same period in 2000. This decrease in investment and other income in 2001 was due primarily to less sales in 2001 of equity securities acquired through the licensing of technology and from the sale of undeveloped property in 2000.
Operating expenses increased to $6.6 million for the quarter ended March 31, 2001 from $6.2 million in the first quarter of 2000. The increase in operating expenses was due primarily to spending on the scale-up of the manufacturing process of REMUNE and higher professional fees for general and administrative expenses in the quarter ended March 31, 2001.
Cash, cash equivalents and short-term investments were $21.2 million at March 31, 2001 compared with $28.4 million at the end of 2000.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted, non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On- Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 2000. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
The Immune Response Corporation
Condensed Consolidated Statements of Operations
(Amounts in thousands, except share data)
(unaudited)
Three Months Ended
March 31,
2001 2000
(Restated)
Research revenue $1,032 $3,960
Expenses:
Research and development 5,333 5,061
General and administrative 1,227 1,106
6,560 6,167
Other revenue:
Investment income, net 644 2,523
Other income, net -- 732
Income (loss) before cumulative effect
of accounting change (4,884) 1,048
Cumulative effect of accounting change -- (13,212)
Net loss (4,884) (12,164)
Preferred stock items (255) (256)
Net loss applicable to common stockholders $(5,139) $(12,420)
Net loss per share - basic and diluted $(0.17) $(0.46)
Weighted average number of
shares outstanding 30,809,984 26,955,087
The Immune Response Corporation
Condensed Consolidated Balance Sheets
(Amounts in thousands)
March 31, December 31,
2001 2000
(unaudited)
Assets
Cash, cash equivalents and
short-term investments $21,183 $28,356
Other current assets 1,015 607
22,198 28,963
Property and equipment, net 8,909 8,554
Licensed technology 4,062 4,238
Investment in MicroGenomics, Inc. 3,000 3,000
Other assets 848 848
Total assets $39,017 $45,603
Liabilities and stockholders` equity
Current liabilities $8,278 $8,409
Long-term liabilities 6,624 7,765
Redeemable, convertible preferred stock 9,977 9,907
Stockholders` equity 14,138 19,522
Total liabilities and
stockholders` equity $39,017 $45,603
und das heißt ???????????
das die zahlen 1 cent besser waren als erwartet, bzw. das sie die erwartungen erfüllt haben.
und der Kurs zieht an: 3.66...
ich erwarte morgen die 3.70$ und mehr... :-)
ich erwarte morgen die 3.70$ und mehr... :-)
Na, wer sagts denn? :-)
heute über 4 Dollar!!!
und steigt und steigt.... :-)
schöne woche...
heute über 4 Dollar!!!
und steigt und steigt.... :-)
schöne woche...
bei 4,60$ verläuft die 200 tage linie, wenn sie dich auch noch packen, versteh ich die welt nicht mehr
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,36 | |
| -0,93 | |
| -0,11 | |
| +0,02 | |
| -1,95 | |
| +0,52 | |
| -1,19 | |
| +1,23 | |
| +0,59 | |
| -0,21 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 204 | ||
| 116 | ||
| 61 | ||
| 47 | ||
| 45 | ||
| 42 | ||
| 35 | ||
| 30 | ||
| 29 | ||
| 28 |
The Immune Response Corp. (IMNR)
